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ABSTRACT

ROBYN GRAYSON LOTTES. Alveolar Epithelial Type II Cell Metabolism in
Health, Hypoxia and Disease. (Under the direction of JOHN E BAATZ, PhD).

Alveolar epithelial type II (ATII) cells constitute 50% of cells composing the
alveolar epithelium and are essential to proper lung function. They are the
primary producers of pulmonary surfactant, serve as progenitors capable of rapid
self-renewal and differentiation, and play roles in immunity and fluid homeostasis,
all of which require considerable energy investment. Given their many ATPdemanding functions, ATII cells are expected to be highly metabolically active;
however, little is known about the fundamental metabolism of this critical cell
type.
ATII cells are normally exposed to uniquely high oxygen concentrations.
However, numerous lung diseases including idiopathic pulmonary fibrosis (IPF)
lead to pulmonary hypoxia. The role of hypoxia has been extensively investigated
in pathologies like cancer and heart disease but has received far less attention in
pulmonary disease. Recent findings of lactic acid build-up in IPF lung suggest a
role for altered cell metabolism, potentially related to hypoxia.
We investigate the hypothesis that hypoxia alters ATII metabolism, and
that similar metabolic change occurs in IPF lung. ATII metabolism was
characterized under ambient versus 1.5% O2. Additionally, to understand
possible contributions of ATII to lactic acid build-up in disease, the ability of
xvi

healthy cells to both produce and consume lactate was assessed. Extracellular
flux analysis was performed to measure glycolytic and mitochondrial metabolism
in a model cell line and ATII isolated from mouse and human lungs, and flux
experiments were correlated with metabolite measurements and gene and
protein expression.
This work demonstrates that ATII cells are highly metabolic and
dependent on mitochondrial metabolism. Hypoxia suppresses ATII mitochondrial
metabolism without concurrent change in glycolysis, despite enhanced enzyme
expression. Similarly, ATII from IPF patient lung showed low mitochondrial
function compared to control, while glycolytic output occurred at near-control
rates or higher, generating a highly glycolytic phenotype. In both hypoxia-treated
and

IPF-derived

ATII,

reserve

mitochondrial

capacity

was

maintained.

Additionally, we demonstrate that ATII consume lactate and that this ability is
limited by hypoxia. Based on our findings, we propose a hypothetical model by
which metabolic cooperation between ATII and other cell types is altered in IPF
to favor enhanced lactic acid generation and reduced consumption.

xvii

CHAPTER 1. GENERAL INTRODUCTION

The cells that compose the pulmonary epithelium reside in a specialized
physiological environment with significant implications for cellular metabolism.
First, the lung is the best-oxygenated organ in the mammalian body, with healthy
adult pulmonary tissue subjected to relatively oxygen concentrations of
approximately 13% (or an alveolar pO2 of approximately 104 mm Hg). Oxygen is
a critical substrate for mitochondrial metabolism which is often an important
factor determining cellular metabolic function, yet pulmonary cells have more
oxygen readily accessible than cells of any other tissue. Second, the lung is the
only organ apart from the heart itself that receives the full cardiac output on every
circuit through the body. The full volume of the circulatory system passes through
the lungs before being divided amongst the other organs, thus cells of the
pulmonary tissue receive the full complement of circulating metabolic substrates
from the heart. This creates a situation in which the local metabolic function of
the lung has potential to globally influence circulating substrate and metabolite
concentrations to which the rest of the body is exposed. Additionally, as the thin
barrier between the external and internal environments across which gaseous
substrate and waste are continuously exchanged, the cells of the pulmonary
epithelium serve a number of energy-demanding functions that are absolutely

critical to the function and survival of the organism. Thus, a steady supply of
cellular ATP must be available in order for pulmonary functions to be maintained.
From this viewpoint, it is clear that cell metabolism is likely an important factor in
determining lung function and potentially influences whole-body homeostasis.
However, little is understood about the influence of pulmonary cellular
metabolism in health and disease.

1.1 The pulmonary alveolar epithelium
In mammals, exchange of gases between the body and the environment is
mediated by the lung and conducting airways, as well as muscoelastic structures
of the thorax that physically move air through the respiratory passages. Each
portion of the mammalian respiratory system serves a distinct function. The
upper airways including the nasal passages and larynx serve primarily to filter
incoming air of particulates and infectious agents; the trachea, bronchi and
bronchioles conduct air to the heavily branched distal lung; and the alveolar
ducts and saccular alveoli facilitate gas exchange between the blood and
alveolar airspace. The pulmonary epithelium forms a specialized physiological
barrier between the inside of the mammalian body and the external environment,
and just as each anatomical region of the lung serves a distinct purpose, each
region is lined by a distinct epithelial layer that facilitates specific function.
The alveolar epithelium forms the layer across which oxygen and waste
gases are exchanged (Figure 1.1). Two distinct epithelial cell types compose the
alveolar epithelium. Large, squamous alveolar epithelial type I (ATI) cells make
19

up approximately 50% of the cell population but 95% of the epithelial surface
area, and serve as the primary mediators of gas exchange across the epithelial
barrier. The other 50% of cells composing the alveolar epithelium are alveolar
epithelial type II (ATII) cells, which do not play a direct role in gas exchange but
instead serve many vital roles in lung function as the primary producers of
pulmonary surfactant.
In addition to alveolar epithelial cells (AEC), fibroblasts and macrophages
are major cell types composing the distal lung tissue. Pulmonary fibroblasts are
found in the alveolar parenchyma, residing in the interstitial space outside of the
alveolar sacs. Resident macrophages are present in the lung parenchyma in
close association with the alveolar epithelium, where their function is to scavenge
foreign material that makes it through the respiratory tract and into the alveoli,
and to regulate local inflammatory responses.

20

Alveolus in Cross Section

Alveolar epithelial
type II cell

Alveolar epithelial
type I cell

Pulmonary
surfactant

Alveolar
airspace

Pulmonary
capillary

Figure 1.1: The alveolar epithelium. The alveolar epithelium is composed of ATI and
ATII cells. The large, window-like ATI cells serve as the passive barrier for gas exchange
between the alveolar space and the fine network of capillaries that surrounds each
alveolus. ATII cells serve a wide variety of supportive functions, including production of
pulmonary surfactant, that are essential for proper lung function (see text). Adapted from
Camelo et al, 2014 (1).
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1.2 Alveolar Epithelial Type II cells
ATII cells are the primary producers of pulmonary surfactant (2), a role
that is absolutely essential in the maintenance of proper lung function. Surfactant
is a mixture of proteins and phospholipid species that lines the alveolar
epithelium. Its primary function is to reduce surface tension of the fluid coating
the alveolar sac, an air-fluid interface which otherwise would collapse upon
expiration and resist re-inflation. Surfactant proteins are synthesized in the ATII
cell endoplasmic reticulum and packaged with phospholipids into intracellular
lamellar bodies. Surfactant secretion is achieved through fusion of the lamellar
body membrane with the apical cell membrane. Initially secreted as large
aggregates from the lamellar body, surfactant in the extracellular space
organizes into a complex, organized structure of tubular myelin and spreads
across the air-fluid interface of the alveolar airspace to form a surface-active,
monolayer film (3). The extremely hydrophobic surfactant proteins SP-B and SPC are incorporated into surfactant and aid biochemically in organization of lipids
into the interfacial monolayer and enhance the surface-active properties of the
lipid mixture. Secreted surfactant is continuously recycled, in that a large portion
of secreted surfactant is internalized and catabolized or re-organized into
lamellar bodies. The processes of surfactant synthesis, transport, packaging,
secretion, and recycling that are crucial for maintenance of homeostasis and
proper lung function collectively require substantial energetic investment by ATII
cells (4). Furthermore, surfactant plays a vital role in protecting the lung from
foreign material such as bacteria. Surfactant proteins, as well as complete
22

surfactant itself, have properties that serve in innate immunity. SP-A and SP-D
act as collectins that bind foreign antigens and promote phagocytosis by alveolar
macrophages, cytokine production, and other innate immune cell responses. SPC has been shown to negatively regulate innate immune response by interacting
with and suppressing Toll-Like Receptors (TLR) in macrophages when engulfed
with other surfactant components (5).
While generation of complete surfactant is perhaps the most characteristic
function of ATII cells, they also have important roles in ion and fluid transport (68). Fluid clearance is particularly important for the alveoli, as accumulation of
fluid in the airspace (pulmonary edema) greatly impairs gas exchange. Fluid
transport is facilitated by ion transport across the epithelium, which in ATII cells is
performed by sodium channels in the apical membrane and Na+/K+ ATPase ion
pumps in the basolateral membrane.
Additionally, ATII cells serve as progenitor cells capable of repopulating
the population of ATI cells following physical damage or stress (9). In this
manner, they play a critical role in wound healing in the alveolar epithelium.
While normal turnover of alveolar epithelial cells is relatively slow, when the
epithelium is injured ATII cells multiply and differentiate rapidly to facilitate wound
healing and re-establish an unbroken epithelial barrier.
Given the many ATP-consuming roles they continuously serve to facilitate
lung function, ATII cells are expected to be highly metabolically active under
normal physiological conditions. Thorough characterization of ATII cell metabolic
function has not been performed.
23

1.3 Metabolic function of the lung
1.3.1 Lung tissue metabolism
Much of what is known about metabolism in the lung comes from tissueand organ-level investigations conducted by providing isotopically-labeled
metabolic substrates (10, 11). This was primarily accomplished by perfusing
media containing labeled substrates through the pulmonary circulation of small
mammals, known as the isolated perfused lung model. Following the innovation
of this model which allowed researchers to quantitatively measure uptake and
output of compounds across pulmonary circulation (12), a slew of investigations
conducted in the 1970s and 1980s reported on the metabolism of glucose and
other substrates by the lung parenchyma. Despite early assumption that the lung
was a relatively passive tissue in terms of metabolic function, as an organ it was
in fact found to be highly metabolic, with rates of glucose oxidation comparable to
those observed in brain and heart (10).
Much of the original work was focused on glucose turnover to lactate, and
multiple reports demonstrated net lactate generation from lung tissue perfused
with glucose-formulated media, demonstrating that anaerobic glycolysis was
performed in the lung under fully-oxygenated conditions (13). In perfusion
studies, 40-50% of glucose-derived carbon ended up as monocarboxylate
species lactate and pyruvate, with lactate production 10-fold higher than pyruvate
(14). This measured rate of lactate generation via glycolysis was higher than
rates measured in other tissues; for example, conversion to lactate accounts for
only 20-25% of glucose consumption in the isolated, perfused heart (15).
24

However, further investigation demonstrated that despite the observation that the
lung generates lactic acid and as a whole does not rapidly consume oxygen,
oxidative metabolism is necessary to maintain energy balance in lung tissue (16),
indicating that mitochondrial metabolism is a critical component of normal lung
function.
Studies of whole lung metabolism expanded beyond glucose metabolism
to investigate the use of other substrates for energy production. In particular,
lactate was shown to be removed from pulmonary circulation and rapidly oxidized
by lung tissues (11, 17, 18). This surprising finding suggested that while lactate is
produced from glucose by the lung, it may also serve as an important metabolic
substrate for lung cells. These observations are discussed in more depth in
Section 1.4.
In addition to lactate and glucose, fatty acids are utilized by lung tissue.
Only approximately 20% of free fatty acid taken up by the lung is oxidized to
CO2, indicating that a small percentage is actually used for mitochondrial energy
production, with the remainder assumed to be used in synthetic reactions (19).
Free fatty acid (i.e. palmitic acid) oxidation generates more ATP per mole than
glucose, thus fatty acids could still be a significant source of energy for oxidative
metabolism in the lung. However, the addition of palmitate to perfusion media in
the perfused lung model was shown to have minimal impact on glucose
oxidization, suggesting minimal contribution to whole lung energy production
under in vivo conditions (20). Alanine, glycerol, and the ketone 3-hydroxybutarate
have also been investigated but were shown to be used sparingly (11).
25

The impact of oxygen availability was a point of particular interest in early
studies of lung metabolism. In a landmark study of pulmonary metabolism,
Longmore and Mourning (21) investigated lung lactate production under ambient
O2 and hypoxic conditions. Similar to previous studies, they observed net lactate
production in 21% O2. Under hypoxic conditions, lactate production increased
two-fold; however, using

14

C-labeled glucose, they showed that the excess

lactate was not a product of anaerobic glucose metabolism, suggesting instead
that lactate was produced by non-glycolytic means, such as amino acid
breakdown, in hypoxia.

1.3.2 ATII cellular metabolism
More than a decade after the many studies examining whole-lung
metabolism of glucose and other substrates, Fox and colleagues performed
similar

14

C-labeled substrate studies, this time performed in isolated and cultured

primary ATII cells from fetal rat lung. Of the measured substrates which included
glucose, lactate, 3-hydroxybutyrate, and glutamine, glucose actually had the
lowest rate of oxidation (22). Lactate was oxidized to carbon dioxide at a rate
more than 20 times that of glucose, while other substrates showed intermediates
rates of oxidation. Furthermore, lactate and glucose were shown to be
metabolized via similar pathways, as reciprocal inhibition of oxidization occurred
between the two when provided simultaneously. This same group investigated
oxidization of these substrates in ATII cells compared to fibroblasts isolated from
fetal lung and showed that ATII cells oxidized all measured substrates more
26

rapidly than fibroblasts (22). This was particularly true for lactate, which was
oxidized twice as fast by ATII cells compared to fibroblasts.
Despite the many critical, energy-consuming functions of ATII cells, ATII
cellular metabolism has not been studied in detail at the functional level.
Estimates based on cellular oxygen consumption indicate that around 15% of
oxygen consumed by ATII cells is dedicated to generating ATP to serve function
of the Na+/K+ ATPase, indicating a substantial energetic commitment to ion and
fluid transport (23) (although previous estimates concerning ATP consumption in
mammalian cells in general were greater, approximately 40%) (24). The demand
of other energy-consuming processes has not been addressed, although
maintenance of surfactant production and homeostasis in particular is assumed
to require considerable ATP in vivo for de novo protein and lipid synthesis and
intracellular shuttling.
Classic Clark electrode studies of rat ATII cells showed that ATII consume
oxygen, and provided rate estimates of approximately 3 pmoles/minute/µg
protein (23). Recently, studies of metabolic flux have been performed using MLE12, an immortalized mouse cell line used as a model for ATII cells. This work
indicated a higher level of metabolic function with relatively rapid oxygen
consumption and significant levels of extracellular acidification under ambient
oxygen conditions. However, similar metabolic flux measurements have not been
performed in primary ATII cells, and thus the usefulness of MLE-12 (and other
MLE cell lines) as a metabolic model for primary cells is unknown (25).

27

1.4 Lactate as a metabolic substrate
1.4.1 Cellular Lactate Consumption
Lactic acid is produced as the end product of anaerobic glycolysis, and
therefore lactate is generally considered as a metabolic waste product.
Approximately 25%-50% of total lactate removal and turnover in the body is
accomplished through gluconeogenesis in the liver, through which lactate is
converted back to glucose. However, a comparatively larger proportion of lactate
is metabolized through oxidation to pyruvate by cells in other tissues and
subsequent use as a metabolic substrate to fuel mitochondrial energy production
(26). Pyruvate generated from lactate oxidation serves as a primary metabolic
substrate for heart muscle, wherein cardiomyocytes consume lactate produced
by distant tissues and delivered via circulation. In brain and muscle tissue, highly
oxidative cell types (neurons and red fibers) directly utilize lactate produced by
neighboring glycolytic cells (astrocytes and white fibers) (27-29). This form of
metabolic cooperation, in which oxidative cells utilize lactate generated as waste
by glycolytic cells, is referred to as “the intercellular lactate shuttle” and plays a
major role in removal of lactate in the body as well as local supply of metabolic
substrate in tissues (Figure 1.2).
Cellular consumption of lactate requires conversion to pyruvate via the
reverse activity of Lactate Dehydrogenase (LDH). Pyruvate is subsequently
shuttled into the mitochondria to fuel tricarboxylic acid (TCA) cycle reactions,
providing reducing equivalents necessary for mitochondrial electron transport
and ATP production. To undertake this process, a cell must have active
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mitochondria, a favorable lactate gradient into the cell, and must express
monocarboxylate transport proteins (MCT) and LDH (26, 30).
Different isoforms of MCT and LDH favor lactate import (versus export)
and oxidation (versus reduction), and these isoforms tend to be more highly
expressed in cell types that can utilize lactate. Concerning MCT expression, the
higher-affinity MCT1 and MCT2 transporters tend to be expressed in cells known
to import lactate including skeletal muscle red fibers, neurons, and liver cells. The
lower-affinity isoform MCT4 is expressed in cells that rely predominantly on
glycolytic metabolism and is therefore more heavily associated with lactate efflux
(31, 32). Likewise, differential expression of LDH isoforms has been found
between cell types. LDH5 is composed entirely of four M subunits (LDH-M,
encoded by the LDHA gene) and strongly favors the forward reaction that
converts pyruvate to lactate. Accordingly, the LDH5 isoenzyme is generally
expressed by highly glycolytic cell types. The other LDH isoforms contain at least
one H subunit (LDH-H, encoded by the LDHB gene). The more H subunits in the
complete LDH protein, the higher the tendency of the isoenzyme to facilitate the
lactate-to-pyruvate conversion necessary for lactate consumption (33).
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Figure 1.2: Intercellular lactate shuttling. In the cell-cell lactate shuttling scheme,
anaerobic glycolysis and mitochondrial respiration are linked in distinct cell types within a
tissue. Highly glycolytic cells meet their energy and charge balance needs via
processing of glucose to lactate, which is extruded from the cell into the extracellular
space. Highly oxidative neighboring cells import the extracellular lactate, and after
conversion to pyruvate, use the monocarboxylate to fuel TCA cycle reactions and
electron transport. Acetyl-coA derived from lactate may also be diverted from the TCA
cycle for use in lipid synthesis.
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1.4.2 Lactate metabolism in the lung
Studies of whole-lung metabolism in the isolated perfused lung indicated
that lactate is oxidized to carbon dioxide in pulmonary tissue, suggesting that it
could be used as substrate for mitochondrial ATP production. Experiments using
labeled substrates demonstrated rapid generation of CO2 from lactate precursor,
even when glucose was provided simultaneously and at higher concentrations
(17, 18). The presence of lactate reduced oxidization of glucose, indicating that,
when available, lactate is utilized as a substrate for mitochondrial metabolism in
lieu of glucose to some degree (17). Altogether, early studies of glucose and
lactate metabolism in the isolated perfused lung model and in tissue slices
indicated that lactate is not only produced by the lung, but is simultaneously
utilized by the lung as metabolic substrate (11).
More recent work by Brooks and colleagues has demonstrated consistent
net lactate removal from pulmonary circulation into lung tissue (30, 34). The cell
type(s) responsible for lactate uptake and oxidation in the lung have yet to be
determined, though experiments following the biochemical fate of labeled lactate
observed preferential incorporation into lipids found in pulmonary surfactant (35,
36), implying a role for ATII cells. Furthermore, when lactate and glucose were
both provided in whole lung perfusate, the acetyl moiety of synthesized lipid was
composed almost exclusively of carbon derived from lactate precursor.
Study of isolated fetal rat alveolar epithelial cells demonstrated rapid
lactate oxidization and reciprocal inhibition of oxidization between lactate and
glucose (22). However, this has not been assessed in mature ATII cells, nor has
31

lactate oxidization been linked directly to pulmonary cell ATP generation. ATII
cells have active mitochondria and a high energy demand, in addition to residing
in an extremely well-oxygenated environment (37). Thus, the metabolism and
physiological location of ATII cells indicate potentially favorable conditions for
lactate oxidation.

1.5 Pulmonary hypoxia
The lung is normally exceptionally well-oxygenated compared to other
body tissues, and the pulmonary parenchyma is unique among tissues in that it
does not require vascular perfusion for oxygen delivery. The alveolar epithelium
where ATII cells reside is estimated to experience oxygen conditions of
approximately 100 mm Hg, or about 13% O2 (38). By comparison, the renal
cortex experiences O2 levels of approximately 7-8% (39) or ~55 mm Hg, and the
environment of the myocardium at rest is approximately 3-4% O2 (40) or ~25 mm
Hg.
While the alveolus is normally exposed to comparatively high oxygen
levels, a variety of pathological conditions lead to decreased oxygen tensions in
pulmonary tissue. Lung diseases that disrupt normal oxygen exposure include
fibrotic diseases in which tissue remodeling limits oxygen permeation to the
alveoli and gas exchange, including idiopathic pulmonary fibrosis (IPF) and cystic
fibrosis (CF); and obstructive diseases that block portions of the lung from
exposure to incoming O2, including chronic obstructive pulmonary disease
(COPD) (38). High altitude pulmonary edema (HAPE) results from travel to high
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altitudes where atmospheric O2 is comparatively low, with edema limiting gas
exchange across the epithelial barrier and leading to reduced oxygen exposure
to the alveolar epithelial cells themselves. In the case of lung cancer, tissue
becomes hypoxic when vascular perfusion is limited within tumor masses.
In addition to pathological conditions associated with disease, the lung is
exposed to low oxygen tensions during development. While in the adult lung a
decrease in oxygen exposure represents hypoxic conditions for the tissue, low
oxygen tensions are normal during development. In utero lung development
occurs in oxygen levels well below those in the adult lung, estimated at
approximately 1-5% (38). For the fetal lung, these low oxygen conditions are
technically “normoxic”. Indeed, normal lung development appears to require this
low oxygen environment, as pre-term exposure to atmospheric oxygen results in
disruption of normal tissue development and is likely causative in the onset of
neonatal lung diseases like bronchopulmonary dysplasia (BPD) and respiratory
distress syndrome (RDS). Hypoxia-related signaling is required for normal
alveolarization and development of the pulmonary surfactant system (41).

1.5.1 Clinical significance of decreased oxygen in pulmonary tissue
Pulmonary hypoxia is a contributing pathological factor in a variety of lung
diseases. The cause of pulmonary hypoxia differs between diseases. In IPF, for
example, onset of pulmonary hypoxia is the result of extensive tissue fibrosis and
remodeling. COPD is also associated with development of pulmonary hypoxia;

33

however, in this case, airways become blocked due to severe inflammation. In
HAPE, hypoxia develops due to pulmonary edema.
In response to pulmonary hypoxia, hypoxic pulmonary vasoconstriction
(HPV) occurs in affected regions of the tissue (42). This decreases blood flow
locally in an effort to conserve the gas exchange efficiency of the organ by
limiting blood flow to poorly ventilated regions and increasing perfusion to
unaffected regions of the lung. However, when disease results in widespread
regions of hypoxia throughout the lung this can lead to severely limited
pulmonary blood flow, poor overall perfusion, and greatly impaired gas
exchange. Extensive vasoconstriction in the pulmonary tissue results in
increased pulmonary arterial pressure. If this effect is severe and prolonged, it
can lead to pulmonary arterial and right ventricular remodeling to accommodate
the high pressure. In both COPD and IPF, patients presenting with pulmonary
hypertension have particularly poor prognoses (43).
There remains debate about the degree to which pulmonary diseases
result in truly hypoxic conditions in the lung tissue, primarily because it is
extremely difficult to directly measure oxygen tension in patient lung tissue.
However, in the case of IPF, stabilization of hypoxia-inducible factor transcription
regulator proteins and downstream signaling has been demonstrated, suggesting
that hypoxia does in fact occur and stimulate cellular hypoxia responses. There
are mechanisms other than, or in addition to, true hypoxia through which HIF can
become stabilized including generation of reactive oxygen species and other
responses to stress, and these cannot be discounted as the cause of HIF
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stabilization in disease. However, as HIF isoforms are currently considered to be
the primary oxygen sensors in the lung and the main drivers of downstream
responses, HIF stabilization indicates a “hypoxic” response at the cellular level,
whether or not the tissue is in a state of true oxygen limitation.

1.5.2 Cellular Response to Hypoxia: General
In most cells, hypoxia causes physiological stress including loss of
bioenergetic

homeostasis

and

insufficient

ATP

levels,

generation

and

accumulation of reactive oxygen species leading to DNA and protein damage,
endoplasmic reticular stress, and even apoptosis. Without appropriate cellular
adaptations to prevent or mediate these stressors, hypoxia can lead to cell death.
Fortunately, cells are able to sense reduced oxygen tensions and respond
accordingly to limit stress and damage. Generally, the response to hypoxia
involves temporary cell cycle arrest, suppressed mitochondrial respiration,
enhanced anaerobic glycolysis with lactic acid generation for ATP production,
and reduction of ATP-consuming processes (44).
Metabolic changes are a fundamental component of the cellular response
to hypoxia. In general, the hypoxic phenotype is characterized by a shift away
from primary reliance on oxidative phosphorylation to enhanced glycolysis for
maintenance of energy homeostasis. However, the typical response varies
significantly by cell type, and depends largely on cell-specific function and energy
demand, as well as the transient or chronic nature of exposure. AMP-activated
kinase (AMPK), mTOR, the unfolded protein response (UPR), and other
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signaling pathways are involved in mediating cellular metabolic homeostasis and
response to stressors including oxygen limitation (45, 46). At the level of oxygensensing and initiation of response pathways, hypoxic responses are currently
considered to be primarily mediated by the family of oxygen-sensitive hypoxiainducible factor (HIF) transcription factor proteins.
The Hypoxia-Inducible Factor (HIF) family of transcriptional regulatory
proteins is primarily responsible for mediating oxygen sensing and initiation of
response pathways throughout the body. HIF transcription factors are
heterodimeric proteins composed of a beta subunit (called HIFβ or ARNT) and
one of three different HIFα subunits, HIF1α, HIF2α, or HIF3α. HIF heterodimers
bind to HIF Response Element (HRE) sequences in DNA to enhance
transcription of hypoxia-inducible genes. Control of HIF is achieved through posttranslational, oxygen-dependent degradation of the alpha subunits. HIFα
subunits are continuously transcribed and translated; however, when oxygen is
available, prolyl-hydroxylase enzymes (PHD) hydroxylates HIFα at conserved
proline residues. Hydroxylation promotes ubiquitination by Von Hippel-Lindau E3
ubiquitin ligase (VHL), which targets the protein for proteasomal degradation
(47). Because oxygen is a substrate for PHD-mediated hydroxylation, PHD
function is inhibited by hypoxia. In addition to this classic view of HIF stabilization
in hypoxia, another mechanism of HIF stabilization involving ROS has been more
recently elucidated. Under hypoxic conditions, mitochondria generate ROS from
complexes of the electron transport chain that migrate to the cytosol where they
inhibit PHD (48). Both mechanisms result in stabilization of HIFα subunits,
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heterodimerization with beta subunits, and localization to the nucleus where they
promote target gene transcription.
Multiple HIF isoforms regulate a wide variety of genes involved in directing
cell energy metabolism under conditions of limited oxygen availability. The
different HIF transcription factors (HIF1, 2, and 3) regulate transcription of
overlapping, but different, sets of target genes containing HRE sequences. While
both HIF1 and HIF2 regulate expression of some hypoxia-inducible genes
including erythropoietin (EPO) and vascular endothelial growth factor (VEGF),
other genes are specific targets of either HIF1 or HIF2. In the regulation of
cellular metabolism in hypoxia, HIF1 and HIF2 play distinct roles (Figure 1.3).
Genes associated with glycolysis and glucose uptake (including glucose
transporters, pyruvate dehydrogenase kinase 1, and LDHA) are HIF1-specific
targets, while HIF2 induces expression of genes associated with lipid storage,
glycogen synthesis, and redox homeostasis. HIF2 also induces expression of
PDK4 which, similar to PDK1, limits mitochondrial substrate availability.
Oxygen sensing and the coordinated response to hypoxia are primarily
mediated by HIF stabilization and transcriptional control, but other pathways also
contribute to hypoxic adaptation. The mTOR kinase signaling pathway controls
cell growth, proliferation, and survival, and transcription and protein synthesis.
The UPR also responds to hypoxia and together, these pathways control
changes in protein translation and cellular metabolism. Transcriptional regulators
besides HIFs induce expression of genes involved in the response to hypoxia.
For example, PGC1α can directly induce expression of VEGF, which is a HIF
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target gene, independently of HIF activation. AMPK is a major modulator of
metabolism that responds to cellular ATP deficit. The kinase is activated in
response to changes in both cellular energy status and intracellular calcium, and
has been shown to become activated in response to production of mitochondrial
ROS in hypoxia (24). Under these conditions, different kinases act on AMPK
resulting in phosphorylation and activation of AMPK. Activated AMPK generally
shifts metabolism to favor glycolysis and contributes to down-regulation of ATPconsuming processes. AMPK activity is responsible for endocytosis of the
Na+/K+ ATPase ion pump protein from the cell membrane under conditions of
energy deficit, effectively conserving ATP by reducing pump activity. This is a
rapid cellular response to conditions that induce energy deficit, including acute
hypoxic exposure.

1.5.3 Cellular Response to Hypoxia: ATII Cells
Unlike the majority of cells in the body, ATII cells strongly express HIF2α
in addition to HIF1α. Upon exposure to hypoxia, both HIF1 and HIF2 are
immediately stabilized and translocate to the cell nucleus to regulate
transcriptional responses. However, HIF1 expression in ATII cells peaks at
approximately 8 hours of exposure, after which the level of HIF1 in the cell
decreases steadily (49, 50). HIF2, on the other hand, remains stabilized and in
the nucleus at a consistent level through 20 hours’ exposure, suggesting that the
long-term adaptation to hypoxia by ATII cells may be potentiated primarily by
HIF2. This temporal difference in expression of the different isoforms has been
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Figure 1.3: HIF1 and HIF2 regulate transcription of genes associated with
overlapping but distinct roles in metabolism. HIF1 target genes include glycolytic
enzymes and glucose transporters, as well as LDH. HIF2 enhances transcription of
glycogenic enzymes and antioxidant enzymes including superoxide dismutase, and
negatively regulates lipid β-oxidation. PDKs, which inhibit entry of pyruvate into the TCA
cycle, are regulated by both HIF1 and HIF2. FFA, free fatty acids. Adapted from
Majmundar, Wong, and Simon, 2010 (46).
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investigated in the context of ATII cells, but may apply to other HIF2-expressing
cell types as well. Previous investigations have detailed several ATII cell
responses to short-term hypoxic exposure. These cellular processes include proangiogenesis signaling, generation of reactive oxygen species and activation of
AMPK (51) and up-regulation of glucose transporters and localization to the cell
membrane (52). Immediate metabolic responses include down-regulation of
Na+/K+ ATPase pump, which normally mediates fluid and ion homeostasis
across the alveolar epithelium. Reduced pump activity is achieved rapidly
following hypoxic exposure by removal of the pump from the cell membrane via
an AMP-kinase dependent mechanism. Despite this being a well-characterized
response to hypoxia, metabolic analyses accounting for ATP allocation to
Na+/K+ ATPase function have questioned the impact of this adaptation on ATP
conservation, indicating that the energy savings achieved through this
mechanism are relatively small (23).
The impacts of longer periods of hypoxia (ie, over 8 hours) are poorly
characterized. Over extended exposure, HIF1 expression declines while HIF2
remains stable. Neither ATP levels (52) nor cell survival (23, 53) appear to be
impacted, indicating robust hypoxia tolerance. Reduced citrate synthase
concentrations following 24 hour exposure suggest decreased mitochondrial
density (23) although these measurements were performed in A549, a cancerderived, highly glycolytic cell line that has not been critically assessed as a model
for metabolism of ATII. More detailed investigation of mitochondrial population
dynamics in hypoxic ATII has not been performed.
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ATII cell surfactant protein expression is reduced at the level of
transcription in a HIF-responsive manner (49, 54). Additionally, findings from our
laboratory and others have conclusively demonstrated that globin protein and
associated globin regulatory proteins are expressed specifically in ATII cells (55,
56) and up-regulated at the level of transcription in response to HIF stabilization
(49). This has been confirmed via immunohistochemical staining of tissue slices
and also in vivo, with globins observed in the lung tissues and bronchoalveolar
lavage fluid (BALF) obtained from long-term hypoxia-exposed rats (57). The
function of hemoglobin in ATII cells under hypoxia has yet to be determined, but
hypotheses include oxygen-sensing, scavenging of reactive oxygen and nitrogen
species, and sequestration of oxygen within the cell.

1.6 Idiopathic Pulmonary Fibrosis
1.6.1 IPF overview
Idiopathic pulmonary fibrosis is a devastating lung disease characterized
by the progressive formation of fibrotic scar tissue in the pulmonary interstitium.
IPF affects up to an estimated 500,000 people in the USA, with approximately
50,000 new cases diagnoses each year. The disease is generally diagnosed in
patients over the age of 50 and is more common in men than woman. IPF has no
cure, with palliative care and lung transplantation being the only non-investigative
courses of treatment, and is ultimately fatal with the median survival time of 3-5
years following diagnosis. In the progression of IPF, extensive fibrosis eventually
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damages bronchioles and alveoli resulting in greatly impaired gas exchange and
chronic oxygen deficiency that ultimately leads to death.
IPF is characterized as an interstitial lung disease, although the alveoli
and peripheral airways are also heavily affected and substantial evidence points
to the alveolar epithelium as the initial point of injury. It is classified as a chronic
fibrosing, idiopathic interstitial pneumonia. Common clinical features include
patient age greater than 50 years old, dry cough, exertional dyspnea, crackles on
auscultation, and evidence of impaired gas exchange in pulmonary function tests
(58). Radiologically, the disease is characterized by reticular and ground-glass
opacities indicating dense fibrosis, and “honeycombing” of the lung where
normal, saccular tissue has been thickened and dilated into large cystic
airspaces. Fibrosis in IPF concentrates in subpleural regions and distal lung
interstitium and alveolar tissue, relatively sparing the proximal, bronchiolar tissue.
Characteristic honeycombing can also be observed histopathologically, in
addition to areas of dense matrix deposition, infiltrating inflammatory cells, and
fibroblastic foci containing proliferating myofibroblasts clustered locally atop the
alveolar epithelium and disrupting the normally thin epithelial layer of the alveolar
septae. The presence of organized fibrotic foci is a defining characteristic of IPF.

Environmental & Genetic Factors
Genetic predispositions including mutations in surfactant proteins A and C
(59, 60), mucin protein 5B (61, 62), and telomerase (63) have been associated
with both familial and non-familial IPF. SPC mutations related to IPF result in
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surfactant proteins that do not fold properly in the ATII cells that produce them.
This leads to activation of the Unfolded Protein Response (UPR) and associated
endoplasmic reticulum stress, which causes mitochondrial dysfunction and ATII
cell apoptosis. MUC5B encodes a mucin protein expressed by bronchial
epithelial cells, and MUC5B polymorphisms have been associated with
development of IPF (61). Telomerase is critical for ATII cell progenitor function,
and mutations in the gene affect the ability of ATII cells to replicate and
differentiate into ATI cells upon epithelial damage. Mutations in hTERT, the gene
encoding telomerase, that impair function of the enzyme are present in a
significant proportion of familial IPF cases.

Pathobiology of IPF
The current consensus is that IPF originates with injury to the alveolar
epithelium. Although the injurious stimulus/stimuli are still unknown, senescence
and/or apoptosis of ATII cells are thought to be the initiating factor (1, 64). ATII
injury, senescence, and apoptosis generate a pro-fibrotic environment by
secretion of factors that stimulate fibroblast conversion into an activated state,
enhance extracellular matrix production, and recruit inflammatory cells to sites of
injury. Additionally, the ability of surviving ATII cells to heal the damaged
epithelium via cell proliferation and differentiation is impaired in IPF, wherein
aberrant replication and differentiation by ATII cells leads to cell hyperplasia, loss
of ATII cell phenotype, a decrease in fully-differentiated ATI cells, and potentially
epithelial-to-mesenchymal transition (EMT) by ATII.
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The cellular pathogenesis of fibrotic disease (as well as the normal
wound-healing

process)

includes

stimulation

of

normal

fibroblasts

and

differentiation into the myofibroblast phenotype. Myofibroblasts are secretory,
contractile mesenchymal cells that express markers of both fibroblasts and
smooth muscle cells (65). Fibroblasts are stimulated by growth factors and
cytokines to differentiate into the myofibroblast phenotype, which rapidly
generates extracellular matrix components including collagen type I and II. The
primary differences between fibroblasts and the differentiated myofibroblast
include expression of alpha-Smooth Muscle Actin (αSMA), enhanced expression
of collagen, increased contractility, and increased connections to the extracellular
matrix and to other myofibroblasts (66). The enhanced secretory function of
myofibroblasts that leads to excessive matrix deposition paired with reduced
degradation makes myofibroblasts key cellular drivers of IPF pathogenesis
downstream of alveolar epithelial injury. There is ongoing debate regarding the
source of myofibroblasts in IPF lung, in that they may be the result of resident
fibroblast differentiation and proliferation, recruitment of fibroblasts to sites of
injury, or even the result of ATII cell EMT and adoption of a fibrogenic phenotype.
Myofibroblasts concentrate into “fibroblastic foci” around sites of epithelial injury
leading to localized areas of intense matrix deposition and tissue remodeling.
The major pro-fibrotic cytokine involved in stimulating recruitment,
proliferation and differentiation of fibroblasts as well as inducing matrix
production and deposition is transforming growth factor beta (TGFβ) (67). TGFβ
is produced by a variety of pulmonary cell types including ATII cells and
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stimulated fibroblasts, and plays an integral role in the development of IPF by
continuously

driving

myofibroblast

differentiation

and

stimulating

matrix

production. TGFβ also affects ATII cell function directly, leading to ATII cell stress
and apoptosis. The driving force of TGFβ is highlighted by observations that the
cytokine is consistently elevated in IPF lung from both human patients and
mouse models, and that inhibition of TGFβ resolves fibrosis in mouse models of
IPF.
While originally thought to be a central component of IPF disease biology,
inflammation is now considered a secondary event to epithelial injury and
myofibroblast proliferation. This is altogether unlike COPD, in which inflammation
is the primary driver of the disease leading to alveolar obstruction and hypoxia
(64). Supporting this updated view of IPF pathogenesis are the observations that
fibrosis is non-responsive to immune suppression including steroid treatment,
and that the onset and clinical course of the disease after diagnosis is not
associated with any major changes in inflammatory processes (68). However,
epithelial damage does stimulate release of cytokines that recruit monocytes and
neutrophils to injured tissue that do contribute to the pro-fibrotic environment.
Inflammatory cells recruited to sites of damaged lung tissue produce ROS,
TGFβ, and cytokines including IL-1, all of which feed back into epithelial cell
damage and myofibroblast stimulation. A feed-forward cycle of progressive,
unresolved epithelial damage driving inappropriate fibrotic response appears to
encapsulate the progression of the disease, but the cause of epithelial damage
and the inability of the epithelial to heal are unknown. Thus, whereas
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considerable progress has been made concerning the role of the fibroblast in
IPF, epithelial dysfunction is still relatively undefined and is thus the focus of
heavy investigation.
Progression of fibrosis leads to local epithelial tissue hypoxia, thickening
of alveolar septae, and disrupted gas exchange. Eventually, when the disease
becomes severe, blood flow to areas of poor gas exchange is reduced by the
HPV response in an effort to improve gas exchange efficiency for the organ as a
whole, which further aggravates the localized hypoxic conditions. The most
common cause of mortality in IPF patients is respiratory failure, although death
related to pulmonary hypertension and cardiac failure is also common.

1.6.2 Alveolar Epithelial Cells in IPF
Injury & Phenotypic Change
Despite the clear and integral role of fibroblasts in the progression of IPF,
it is now widely accepted that the ultimate initiating event is injury to the alveolar
epithelium, specifically ATII cells (1, 69). ATII cell senescence and apoptosis is
increased in the IPF lung (70) and is likely a triggering event for the
immunological and fibroblastic responses that follow. However, despite the
evolution of this hypothesis that puts ATII cell damage at the onset of IPF
pathogenesis, the molecular insult that results in ATII cell death in IPF remains
unknown. Many different possible forms of injury to the alveolar epithelium are
being examined in the initiation of IPF, including ROS generation (71), viral
infections (72) autoimmunity (73), and aspiration of gastric contents (74).
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In addition to senescence and apoptosis, the cellular phenotype of
subpopulations of surviving ATII cells is altered in and around fibrotic foci.
Regions of aggregated cuboidal cells form, indicating ATII cell hyperplasia.
Hyperplastic ATII cells and populations that express ATII cell markers but have
lost morphological characteristics of the ATII phenotype are also seen,
suggested to be transitional phenotypes indicative of impaired differentiation to
ATI cells (68). ATII hyperplasia and aberrant differentiation generates cells that
express a variety of cell phenotype markers and do not effectively heal the
wounded epithelial barrier.
Recent investigation has also demonstrated an EMT-like response by
alveolar epithelial cells in vitro following exposure to TGFβ. In multiple in vitro
studies, exposed cells adopted altered cell morphology, expressed fibroblast
markers and extracellular matrix proteins, and decreased epithelial cell markers
(75, 76). This was later connected to ROS, in that exposure to ROS induces
TGFβ expression and EMT in model ATII cells, while inhibition of TGFβ
prevented ROS-induced EMT (77). Cells expressing both epithelial and
fibroblastic markers have been observed in human tissue from IPF patients (78),
suggesting that transition can occur between the two phenotypes. This evidence
has inspired the hypothesis that both ATII cell loss and the prevalence of
myofibroblasts in IPF tissue may be the result of TGFβ-induced ATII cell EMT.
Accordingly, preventing TGFβ-induced EMT has been a focus of current
research in treatment of IPF (79). However, this EMT hypothesis is heavily
debated in IPF literature, based on inconsistency in histochemical labeling
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studies to show co-localization of ATII and fibroblast markers, as well as labeling
studies that fail to demonstrate myofibroblast generation from labeled ATII.
Surviving ATII cells in IPF lung, particularly those in proximity to
fibroblastic foci, are primary sites of cytokine and growth factor production. IPF
ATIIs produce TGFβ, the main pro-fibrotic cytokine involved in converting
fibroblasts to myofibroblasts and stimulating extracellular matrix deposition. ATII
also play a critical role in activation latent TGFβ stored in the extracellular matrix
via integrin binding. ανβ6 integrins are expressed on the surface of ATII cells,
and their expression is up-regulated in IPF (80). These integrins bind to TGFβ
latency-associated peptides, which are bound to inactive TGFβ in the
extracellular matrix and prevents activation. When contraction of ATII cells is
stimulated by binding of other mediators, the physical pulling of the integrin on
the latency-associated peptide results in TGFβ activation. Other factors released
at sites of alveolar epithelial injury in IPF lung include tumor necrosis factor alpha
(TNFα) and platelet-derived growth factor (PDGF) (68), which contributes to lung
fibrosis by stimulating fibroblast proliferation and synthetic activity (81).
In summary, the epithelium and ATII cells specifically are the primary
target of injury in the initiation of IPF. Following initial injury, aberrant response by
ATII cells results in apoptosis, senescence, and phenotypic change including
altered morphology and gene expression. These cells become important
producers of pro-fibrotic growth factors and cytokines and may possibly
contribute directly to the myofibroblast population through EMT. However, the
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source of initiating injury to ATII cells and the nature of their chronic dysfunction
is unknown.

Fibroblast-AEC interactions
In addition to matrix components, IPF lung fibroblasts produce
extracellular signaling molecules that contribute to disease pathogenesis. TGFβ
is a critical signal for initiating conversion of fibroblasts into the myofibroblast
phenotype, but it is also activated by myofibroblasts themselves (82). In vitro
exposure to active TGFβ has been shown to promote a variety of effects in
alveolar epithelial cells including, epithelial-to-mesenchymal transition in alveolar
epithelial type II cells (83), apoptosis (84), and ATII to ATI differentiation (85).
Thus, TGFβ may be a molecular mediator in both the early events of IPF that
generate myofibroblasts and the prolonged, unresolved epithelial cell injury that
progresses the disease.
Myofibroblasts produce reactive oxygen species, and several studies have
demonstrated elevated ROS in the lungs of IPF patients (86, 87). Production is
dependent on NADPH oxidase 4 (NOX4), which is up-regulated in myofibroblasts
by exposure to TGFβ and is highly expressed at fibroblastic foci (88). NOX4dependent H2O2 generation plays a critical role in disease progression, as
multiple mouse models of IPF showed resolution of fibrosis following NOX4
knockdown; therefore, ROS is a key component of the pro-fibrotic environment.
While the exact contributions of ROS are under investigation, it has been shown
that exposure to hydrogen peroxide induces cell death in alveolar epithelial cells
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and prevents wound closure in vitro (89), demonstrating that exogenous ROS
can cause epithelial injury. In the bleomycin-induced mouse model of IPF, NOX4
knockdown in vivo reduced epithelial cell apoptosis (88) and administration of the
antioxidant enzyme superoxide dismutase suppressed fibrosis (90). Altogether,
this evidence points to an important role for myofibroblast-produced ROS in the
repetitive epithelial injury that characterizes the progression of IPF.

Immune Effector-AEC interactions
Epithelial injury at the initiation of IPF also initiates an immune response
through several mechanisms. Platelets activated in response to wounding of the
alveolar epithelium release TGFβ and other growth factors that contribute directly
to myofibroblast activation and matrix production (1). Injured epithelial cells
themselves produce cytokines that recruit cellular inflammatory mediators,
namely neutrophils and monocytes, which produce ROS. When inflammatory
cells are not effectively cleared from the wounded tissue, as occurs in IPF,
continued ROS production by these cells contributes to further injury (91). While
the role of the innate immune system in IPF is less defined, cytokine secretion
from T cells appears to play a role as well. In particular, IL-13 both directly
stimulates fibroblast hyperproliferation and causes epithelial cell apoptosis (92),
and IL-13 and IL-13 Receptor expression correlate with IPF disease severity
(93).
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1.6.3 Pulmonary cell metabolism in IPF
Despite the range of possible epithelial cell injuries that could conceivably
lead to metabolic adaptation or dysfunction, the contribution of cellular
metabolism to IPF has only relatively recently come under investigation. Recent
work has discovered that lactic acid build-up occurs in IPF lung tissue, and
further investigation demonstrated that an increased level of lactic acid
contributes at the molecular level to the pro-fibrotic environment in IPF lung.
Specifically, the decrease in extracellular pH associated with tissue lactic acid
build-up activates TGFβ from the extracellular milieu of the epithelium (94). TGFβ
is the primary signal leading to conversion of fibroblasts into the myofibroblast
phenotype responsible for increased matrix deposition and fibrogenesis (95, 96).
Therefore, processes that lead to a metabolic shift to enhanced glycolysis and/or
a decrease in lactate removal from the extracellular space have the potential to
drive pulmonary fibrosis via pH-mediated TGFβ activation. The cellular source
and cause(s) of elevated lactic acid in IPF is yet unknown, though TGFβstimulated myofibroblasts have been shown to produce greater amounts of lactic
acid than unstimulated fibroblasts in vitro.
A shift in LDH isoform expression has also been observed in IPF lung
tissue, in conjunction with increased tissue lactate. Enhanced expression of the
LDH5 isoenzyme occurs, localized in the approximate region of the alveolar
epithelial cells near fibrotic foci (94), though the specific cells up-regulating LDH5
expression have not previously been determined. This isoform of the LDH
enzyme most strongly favors the forward, lactate-producing reaction, and is often
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expressed in highly glycolytic cells that favor lactic acid production from pyruvate
over mitochondrial metabolism. In TGFβ-stimulated myofibroblasts, up-regulated
LDH5 expression was demonstrated to be influenced by HIF signaling, as
overexpression of HIF1 lead to enhanced LDH5. This suggests that the localized
hypoxia that occurs in IPF (or other factors that stabilize HIF, like ROS) may
contribute to shifts in metabolic enzymes leading to overproduction of lactic acid.
Follow-up studies to the discovery of elevated lactate generation in IPF lung
tissue demonstrated improvement of fibrosis in mice treated systemically with a
pharmacological LDH-inhibitor, further validating the influence of pulmonary cell
glycolytic metabolism on the pro-fibrotic milieu.
Interestingly, neither lactic acid build-up, tissue acidification, nor LDH5
over-expression were found in tissue from patients with COPD, another hypoxiaassociated lung disease. This indicates that the shift in metabolism and the
insult(s) that initiates it may be unique to IPF, and not simply a consequence of
onset of tissue hypoxia. Though both diseases are associated with pulmonary
hypoxia, there are many differences in the two, most notably the injury to the ATII
cells and subsequent fibrosis in IPF (versus mesenchymal cells and subsequent
inflammation in COPD) (97). Thus, the specific metabolic rearrangements
leading to lactic acid build-up in the lung appear to be somewhat unique to IPF,
and not merely a consequent of pulmonary hypoxia. While elevated lactic acid
has been noted also in lung tissue of patients with cystic fibrosis, this is thought
to be a consequence of neutrophil accumulation and subsequent tissue necrosis
and hypoxia, and not glycolytic change in pulmonary cells themselves (98, 99).
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The contribution of ATII to lactic acid build-up in IPF lung is unknown, and
metabolic function of ATII from IPF lung has never been measured. Several
forms of alveolar cell injury under investigation in IPF could conceivably lead to
mitochondrial impairment and metabolic change in ATII cells, potentially also
leading to enhanced lactic acid generation. Oxidative stress is a possible
underlying cause of fibrosis (100), and there are many different cellular and
molecular mechanisms through which ROS generation and oxidative stress are
thought to be enhanced in IPF. First, as discussed previously, both
myofibroblasts and innate immune cells generate ROS directly, providing
exogenous sources of ROS exposure to the lung epithelium. Second,
intracellular sources of ROS are also likely enhanced in response to the
extracellular conditions in IPF. Of particular interest to ATII cell metabolism, in
vitro TGFβ exposure leads to mitochondrial suppression and ROS generation by
decreasing activity of complex IV of the electron transport chain (101). In this
study, treatment and mitochondrial ROS generation resulted in cell cycle arrest
senescence in a line of lung epithelial cells.
Complimentary to enhanced ROS, depletion of antioxidant defense
enzymes is linked to IPF. Glutathione is reduced in cells composing fibrotic foci in
human IPF lungs (102) and knockout mice for superoxide dismutase have
increased fibrotic response to bleomycin treatment, while administration of
antioxidant enzymes prevents fibrosis in the mouse model (100). Reduced
expression of antioxidant defense enzymes in AEC has been linked in vitro to
TGFβ exposure.
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From previous investigation, it is clear that a number of different conditions
associated with IPF have potential to impact alveolar epithelial cell metabolism in
IPF. This is of chief interest, given that recent study has identified metabolic
changes in fibroblasts in the IPF lung and that the exact nature of epithelial cell
dysfunction in IPF is unknown. Despite the implication based on molecular study
that epithelial metabolism may be impacted in IPF, these observations have not
been correlated to functional changes in overall alveolar epithelial cellular
metabolism in IPF patients.

1.6.4 Need for assessment of human IPF patient samples
There is a critical need for basic science research utilizing human patient
tissue obtained from IPF patients. At this time, there is no animal model available
that faithfully replicates the unique human disease progression in IPF (103). For
years, the most commonly-used animal model has been the bleomycin model of
lung injury in mouse. Using this model, many breakthroughs in the molecular
process of lung fibrosis have been made; however, the pathogenesis of the
bleomycin-induced injury is different in critical aspects from IPF. Histologically,
the models are quite different concerning the main sites of fibrosis: in the mouse
model, fibrosis is often concentrated in the airways, while in human sub-pleural
fibrosis dominates. Honeycombing, characteristic of human IPF, is variable in the
mouse model. The organized pattern of layered myofibroblasts in parallel to the
injured epithelium that is evident in fibroblastic foci in human disease is rarely
observed the mouse, as is ATII cell hyperplasia. A portion of human patients
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experience acute exacerbations of the disease, wherein clinical condition
deteriorates over a matter of weeks; no model has been able to recapitulate this
facet of disease progression. Furthermore, fibrosis self-resolves in mice over
time, while in human spontaneous resolution does not occur. There is also strong
dependency of fibrotic response to bleomycin on the strain of mouse exposed
(104).
Not only is there a need to measure variables in human samples, but also
to assess the metabolic function of ATII cells derived from IPF lung in general.
While, as discussed, many molecular drivers of IPF have potential to alter cellular
metabolism of the target epithelial cells, to our knowledge this has never been
directly measured at the functional level in cells isolated from IPF lung. Recent
work has measured cellular metabolism in myofibroblasts derived from IPF lung
tissue, the first ever to connect previously noted molecular changes with a
functional metabolic response with potential to impact not only the myofibroblasts
themselves, but also the extracellular milieu by way of acidification and
metabolite availability. While fibroblasts are central players in the disease, ATII
cells are the proposed target of much of the injury and subsequent dysfunction in
IPF. Thus, functional metabolic studies of human ATII derived from tissue
samples from IPF lung are a natural, needed step in IPF investigation.
Despite the desperate need for novel research using human IPF patient
samples, the reality is that lung tissue samples from human patients, those with
and without IPF are severely limited. Investigation using patient samples can
yield valuable, immediately translatable, and even highly personalized medical
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findings; however, well-supported and reliable findings in human research will
require assessment of many patient samples. Current efforts in tissue collection,
preservation, and banking have expanded the availability of patient lung tissue
samples, making fundamental cellular biology studies of human lung diseases
feasible without the need to extrapolate from imperfect animal models of the
disease. In the case of IPF, where no animal model to date faithfully recapitulates
either the pathology or progression of the disease, access to human samples is
of critical importance.

1.7 Overall significance and specific aims
Lung disease is a leading cause of death in the United States. Epithelial
damage and cellular dysfunction are major features of lung disease, and in some
cases defines the root cause of the disease, as in IPF. The role of cellular
metabolic dysfunction has begun to be elucidated in many diseases including
cancer, heart failure, ocular diseases, and renal disease; by comparison,
investigation of cellular metabolism in the lung and its contribution to pulmonary
disease pathogenesis is severely lacking.
In particular, idiopathic pulmonary fibrosis is associated with a variety of
factors with the potential to influence cellular metabolism. Current theory
regarding IPF pathogenesis considers ATII cell damage to be a critical initiating
factor, but the role of ATII metabolism in the disease has not been examined.
Local hypoxia, which develops in the pulmonary tissue in the pathogenesis of IPF
and several other chronic lung diseases, has the potential to influence cellular
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metabolism in the diseased lung. Oxygen exposure is a major factor known to
influence cell metabolism throughout the body, however investigation of how
local pulmonary hypoxia influences epithelial cell metabolism is lacking. Other
insults that have potential to influence cell metabolism at the molecular level
have also been defined as drivers of IPF including ROS and growth factors, but
in most cases the connection between their molecular function, their impact on
epithelial cell metabolism, and the influence of altered cellular metabolism on
lung homeostasis has not been made. Contributing to this deficit is a general lack
of understanding regarding the normal metabolic function of individual cell types
in the healthy lung.
The body of work that follows examines the overall hypothesis that
conditions associated with hypoxia-related lung disease alter the normal
metabolism of ATII cells. We hypothesized that ATII cells are normally highly
metabolic and dependent on oxidative mitochondrial metabolism to supply ATP
for their many energy-demanding functions, and that under hypoxic conditions
ATII cell mitochondrial function is suppressed while glycolysis is enhanced. To
further extend this work we focus on the hypoxia-related disease IPF and
examine metabolism of ATII isolated directly from patient samples.
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The work presented herein serves the following aims:
Specific Aim 1: Establish a metabolic phenotype for primary and
model ATII cells.
Specific Aim 2:

Measure the impact of hypoxia on ATII cell
metabolism.

Specific Aim 3: Examine the utilization of lactate as substrate for
ATII cell metabolism.
Specific Aim 4: Examine metabolic function of ATII cells isolated
from human IPF lung tissue.

Investigation of these aims involved use of ATII model cell lines and
primary ATII cells isolated from mouse and human patient tissue samples.
Metabolic function was assessed in vitro via metabolic flux assay to measure
oxygen consumption and acid generation in response to a variety of experimental
conditions including hypoxia, varied metabolic substrate availability, and
exposure to mitochondrial inhibitors. Observations regarding metabolism at the
function level were correlated with evaluations of gene and protein expression.
This body of work provides significant insight into the metabolic function of
ATII cells. We define the metabolic phenotype of well-oxygenated ATII cells and
show that ATII cells are capable of importing and utilizing lactate as substrate for
mitochondrial ATP production, building on previous observations that lactate is
taken up and oxidized in the lung and indicating a specific role for ATII in lung
lactate homeostasis. We also define the metabolic strategy adopted by ATII in
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response to low oxygen conditions, demonstrating that ATII cells are remarkably
resistant to hypoxia and do not enhance glycolytic function in response, adapting
instead through down-regulated ATP demand. Hypoxia impacts mitochondrial
function in ATII cells, reducing mitochondrial oxidization regardless of substrate.
Finally, we connect these observations to the hypoxia-related lung disease
IPF, in which we show that disrupted lactate homeostasis plays a role in the
fibrotic process. ATII derived from human patient IPF lung tissue are less
metabolic overall and relative reliance on glycolysis is enhanced, indicating that
the ability of ATII to rapidly import and utilize lactate in the lung is impaired in IPF
and may thus contribute to lactic acid build-up in this disease. We provide a
hypothetical model of metabolic cooperation between ATII cells and neighboring
cell types based on our findings, and suggest how altered ATII metabolism may
contribute to lactic acid build-up in distal pulmonary tissue. In summary, the work
presented here builds significantly on the current understanding of cellular
metabolism in the lung, the metabolic response to hypoxia, and how ATII cell
changes may contribute to hypoxia-related human diseases.
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CHAPTER 2. ATII CELLS HAVE AN OXIDATIVE,
HIGHLY METABOLIC PHENOTYPE

2.1 Introduction
Due to their physical location, the cells that line alveoli in developed
mammalian lungs are normally exposed to a uniquely well-oxygenated
environment of approximately 13% O2 in non-diseased lungs (an approximate
pO2 of 100 mm Hg) as compared to about 5% (pO2 of approximately 40 mm Hg)
in peripheral blood (38). The mesh of pulmonary capillaries that cover each
individual alveolus moves the entire cardiac output through the lung tissue for
gas exchange, making the alveolar epithelium the only tissue apart from the
heart itself that receives the full volume of blood (and the metabolic substrates it
carries) on every single complete pass through the body.
ATII cells make up about 50% of the alveolar epithelial layer by cell
number. They are the primary producers of pulmonary surfactant and also have
important roles in ion and fluid transport (6-8) and innate immunity (105).
Maintenance of surfactant homeostasis, which is essential for normal lung
function, requires considerable metabolic investment by ATII cells for lipid and
protein synthesis, packaging, secretion, and recycling (4). Fluid transport is per
performed via the action of ATPase ion pumps which have been estimated to
require upwards of 15% of ATII energy supply (23), and the main innate immunity

functions of ATII cells depend upon surfactant protein production and secretion.
ATII cells also serve as progenitor cells capable of repopulating ATI cells
following physical damage or stress (9) and can rapidly repair epithelial wounding
through cell replication and differentiation, cellular processes that require cellular
energy in the form of ATP. Due to their many energy-consuming functions that
are absolutely critical to support normal lung function, ATII cells are predicted to
have a constant high demand for ATP. However, despite their unique position in
the body and the necessity for ATII cells to maintain bioenergetic homeostasis in
order for the lung to function properly, ATII cellular metabolism has not been
thoroughly studied.
Historic studies of whole-lung metabolism demonstrated that the lung
consumes oxygen, indicating mitochondrial respiration and ATP production.
However, the lung was also shown to generate lactate under ambient oxygen
conditions, indicating a degree of glycolytic glucose processing despite abundant
available oxygen (21). These and other early studies elucidated whole-lung
metabolism, but were limited in that they could not address the metabolic
function of specific cell types in the lung. While glycolytic generation of lactic acid
was initially considered to be a response to oxygen limitation, it is now
understood that most cells generate some lactate without the pressure of oxygen
limitation. The degree to which this occurs varies considerably by cell type, with
some cells largely reliant on anaerobic metabolism of glucose to lactate to
generate ATP and others primarily dependent on mitochondrial electron
transport. Simultaneous real-time assessment of oxygen consumption and
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lactate generation provides insight into the degree to which a specific cell type
relies on anaerobic glycolysis versus mitochondrial function. These assessments
have not been previously performed in primary ATII cells or using the
predominant model for ATII cell biology, the MLE-15 cell line.
Part of the difficulty in studying ATII cell metabolism and ATII biology in
general is the challenge of isolating a pure population of ATII from the lung,
which is composed of an enormous variety of cell types, some of which do not
have reliable cell-specific surface markers for use in cell isolation. Furthermore,
primary ATII cells in culture rapidly differentiate into ATI cells, which
phenotypically are very different from ATII cells in terms of both cell morphology
and cell function. While there are multiple cell lines that have historically been
utilized to model ATII cells in vitro including the human tumor-derived A549 and
the MLE-12 and MLE-15 immortalized mouse lung epithelial lines, the utility of
these cells in faithfully modeling ATII cellular metabolism is unknown. Here, we
utilize modern cell-sorting techniques to isolate ATII cells from mouse lung and
perform comparisons of basal, maximal, and overall relative oxidative and
glycolytic function between primary cells and cultures of MLE-15, demonstrating
for the first time that the MLE-15 line recapitulates the relative reliance on
glycolysis versus oxidative function.
Confirming historical findings and predictions based on cell function, we
find that ATII cells rapidly consume oxygen and extrude lactic acid under ambient
O2 conditions, indicating a highly metabolic phenotype. Approximately 50% of
oxygen consumed is dedicated to mitochondrial ATP production. Almost all
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extracellular acidification by MLE-15 can be accounted for by lactic acid
production, implicating glycolytic output as the main driver of extracellular pH
change by ATII. We quantify significant spare respiratory and glycolytic capacity,
reserves of potential energy production above basal levels in culture. Overall we
conclude that ATII cells are highly metabolic and oxidative under ambient O2,
and we provide a platform from which to study the impacts of modulators of ATII
cellular metabolism.

2.2 Results
2.2.1 ATII cells consume oxygen rapidly to fuel mitochondrial ATP production.
Aerobic, mitochondrial energy production requires oxygen as an ultimate
electron acceptor at the end of the electron transport chain. Cells that depend
heavily on mitochondria to generate ATP consume oxygen at rapid rates, while
oxygen consumption occurs more slowly in cell types that are more dependent
on anaerobic glycolysis to generate ATP. In order to assess the aerobic function
of ATII cells, extracellular flux analysis was performed to determine the oxygen
consumption rate (OCR) of cells in culture. MLE-15 cells consumed oxygen at a
rate of 12.7 ± 1.7 pmole O2/min/μg protein. Primary mouse ATII cells consumed
oxygen at a rate of 25.6± 1.4 pmol O2/min/μg protein (Figure 2.1).
Oxygen may be consumed by cells to fuel mitochondrial ATP production,
but there are also other functions that can contribute to total cellular oxygen
consumption. Other processes that consume oxygen include proton leakage
across the inner mitochondrial membrane and non-mitochondrial oxygen
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consumption, which includes reactive oxygen species generation and cell surface
oxygen consumption (106). The degree to which oxygen consumption is
dedicated to mitochondrial ATP production can be determined by inhibiting
mitochondrial ATP-synthase, which effectively blocks ATP production. This leads
to a reduction in OCR from basal rates corresponding to the fraction that is
coupled to ATP generation. Coupling of O2 consumption to ATP synthesis was
measured using MLE-15 cell cultures as a model for ATII. Inhibition of ATPsynthase via in-assay injection of the pharmacological inhibitor oligomycin A
resulted in a 50% decrease in OCR from basal measurements (Figure 2.2).
Therefore, approximately half of oxygen consumed by ATII cells is used as an
electron acceptor facilitating ATP production.

2.2.2 ATII cells generate extracellular lactic acid.
Extracellular lactic acid is produced as a byproduct of anaerobic
glycolysis, wherein pyruvate is converted to lactic acid and extruded from the cell
as waste rather than being utilized by mitochondria to generate reducing
equivalents for oxidative ATP generation. Efflux of lactic acid results in
acidification of the extracellular milieu, which can be measured over time as a
progressive drop in pH, and this value indicates the rate at which cells in culture
perform anaerobic glycolysis. Primary mouse ATII cells produced extracellular
protons at a rate of 48.8 +/- 3.4 pmole H+/minute/ug protein, while proton
production rate (PPR) for MLE-15 cells was 25.5 +/- 4.4 pmole H+/minute/ug
protein (Figure 2.3).
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Figure 2.1: MLE-15 and primary ATII cells rapidly respire oxygen. OCR was
measured for MLE-15 cells and primary mouse ATII cells using an XF24 Extracellular
Flux Analyzer. For MLE-15 cultures, samples were assayed minimally in quadruplicate
and plates run in triplicate. For primary cultures, a total of six individually-cultured wells
were analyzed. MLE-15 and ATII were not compared statistically. Values are normalized
to total protein of wells cultured in parallel. Error bars represent ± SE.
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Figure 2.2: Approximately half of oxygen consumption by ATII cells is coupled to
mitochondrial ATP production. The proportion of oxygen consumption dedicated to
generation of ATP via oxidative phosphorylation was determined in MLE-15 cultures by
measuring OCR before and after addition of oligomycin A, an inhibitor of ATP synthase,
to assay media. For MLE-15 cultures, samples were assayed minimally in quadruplicate
for each condition and plates run in triplicate. * indicates significant difference (p < 0.05)
from basal measurements based on paired Student’s T-Test. Values represent the
percent decrease from basal values following inhibitor injection. Error bars represent ±
SE.
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Figure 2.3: ATII cells have glycolytic function under ambient O2. PPR was
measured as an indicator of glycolysis in MLE-15 and primary ATII cells. Samples were
assayed minimally in quadruplicate for each condition and plates run in triplicate. Error
bars represent ± SE. MLE-15 and ATII were not compared statistically.

67

2.2.3 ATII cells maintain spare respiratory and spare glycolytic capacities
The highest possible rates of mitochondrial function for intact cells can be
measured by adding an ionophore compound, such as FCCP. The effect of this
is rapid dissipation of the proton gradient across the mitochondrial inner
membrane, forcing electron transport to be performed as quickly as possible in a
futile attempt to re-establish the gradient necessary for ATP production. The
difference between basal and uncoupled OCR measurements indicates the
spare (or reserve) respiratory capacity of the cell, or the ability to perform
respiration above basal level. To measure this maximal rate for ATII cells, FCCP
was added to assay wells following basal measurements. OCR measurements
following addition of FCCP indicated that uncoupled respiration rates for MLE-15
cultures was 175% of basal OCR. Uncoupled respiration in primary mouse ATII
cells was approximately 150% of basal OCR (Figure 2.4A), demonstrating a
significant reserve of potential mitochondrial functional capacity in both cell types.
An analogous situation exists for glycolytic function, in that inhibition of
ATP synthesis from oxidative phosphorylation results in enhanced glycolytic
output due to the cells’ attempt to compensate for loss of mitochondrial ATP
production. Addition of FCCP to assay wells thus stimulates enhanced PPR
(spare glycolytic capacity) in parallel to enhanced OCR (spare respiratory
capacity). Upon addition of FCCP to assay media, PPR increased to 133% of
basal rates for primary ATII and 208% basal rates for MLE-15 (Figure 2.4B). This
demonstrates that both cell types are operating at sub-maximal rates of
anaerobic glycolysis.
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2.2.4 MLE-15 cells recapitulate ATII relative reliance on mitochondrial
respiration.
In terms of normalized OCR and PPR values, MLE-15 cells demonstrated
lower function overall than primary mouse ATII cells. While these values alone
are informative, it is the ratio of glycolytic and oxidative metabolic function that
indicates the degree to which a cell type relies on either pathway and provides an
indication of the metabolic phenotype. There was no statistical difference in the
PPR/OCR for primary ATII cells and MLE-15, with values of 1.90 +/- 0.04 moles
H+/moles O2 and 2.13 +/- 0.29 moles H+/moles O2, respectively (Figure 2.5). The
similarity of these values shows that, while MLE-15 cells are less metabolic than
primary ATII cells, they recapitulate ATII metabolic function in terms of relative
reliance on different metabolic pathways.
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Figure 2.4: ATII cells have significant mitochondrial and glycolytic reserve
capacity. To assess reserve capacity, OCR (A) and PPR (B) were measured in cultures
of MLE-15 and primary ATII cells before and after addition of FCCP to assay media. For
MLE-15, samples were assayed minimally in quadruplicate for each condition and plates
run in triplicate. For primary cultures, a total of 6 single-well experiments for each
condition. * indicates significant difference (p < 0.05) from basal measurements, based
on Student’s T-Test. Values represent the percent decrease from basal values following
inhibitor injection. Error bars represent ± SE.
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Figure 2.5: MLE-15 and primary ATII show similar relative reliance on oxidative
versus glycolytic function. Basal PPR and basal OCR measurements were used to
generate a PPR/OCR ratio for in MLE-15 and primary ATII cells. For MLE-15, samples
were assayed minimally in quadruplicate for each condition and plates run in triplicate.
For primary cultures, a total of six individual cultures were assessed. Error bars
represent ± SE.
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2.3 Discussion
Through these studies, a metabolic phenotype has been defined for
mouse ATII cells. MLE-15 and primary ATII cells rely heavily on oxidative
phosphorylation to supply ATP, with MLE-15 consuming oxygen at basal rates in
range of values reported for primary bovine aortic endothelial cells (3) and
primary ATII respiring at rates nearly twice as rapid. Approximately 50% of
oxygen consumption is coupled to mitochondrial ATP production. Primary ATII
and MLE-15 also produced extracellular acid. As in the case of OCR, PPR
measurements were approximately twice as high in primary ATII cells compared
to MLE-15 cells. The transformed nature of the MLE-15 cell line, as well as the
fact that MLE-15 stocks had been maintained in culture for many passages while
primary ATII were used within days of the isolation and purification procedures,
may account for these differences. Regardless, the relative reliance on oxidative
versus glycolytic metabolism (as reflected by the ratio of basal proton production
to O2 consumption) is identical between cell type, indicating similar metabolic
strategy for serving cell energy demand. Furthermore, this supports the use of
MLE-15 cells as faithful models for primary ATII cells in terms of basal
metabolism and metabolic response to stimuli.
Mouse ATII cells in culture demonstrated both spare respiratory capacity
and spare glycolytic capacity. Maximal uncoupled respiratory capacity for MLE15 cells is approximately 175% over basal metabolism, also within range of that
previously reported for endothelial cells (just over 200% basal) but considerably
lower than the 300% over basal reported for cardiomyocytes (3, 35). Primary ATII
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cells maintain slightly less spare respiratory capacity (approximately 150% of
basal), indicating that the primary cells were functioning closer to their maximal
mitochondrial function at time of measurement. Uncoupling of respiration lead to
an increase in lactic acid generation to approximately 200% of basal levels in
MLE-15 and 140% of basal levels in primary ATII cells, indicating a similar
degree of spare capacity to undergo glycolysis as for mitochondrial spare
capacity for each cell type. In general, these data demonstrate that both cell
types operate in culture at sub-maximal metabolic function, and supports the
basal findings indicating that MLE-15 in culture are less metabolically active,
potentially due to many passages in culture.
To gain a better understanding of the metabolic milieu of the alveolar
epithelium, it is of chief interest to understand the metabolic function of other
cells types that compose the alveolus and neighbor ATII cells. This degree of
metabolic characterization has not been performed specifically for other alveolar
cell types. It is likely that ATI cells have lower metabolic function than ATII cells,
as they do not serve many of the energy-consuming functions that ATII cells
fulfill. However, ATI cells do contain mitochondria, and may consume oxygen to
fuel ATP production. Metabolic flux analysis has not been performed on
fibroblasts derived from pulmonary tissue; however, measurements of Normal
Human Dermal Fibroblasts (NDHF) showed lower metabolic function compared
to mouse ATII cells. NHDF cells measured on the XF24 platform demonstrated
OCR and ECAR values of approximately 100 pmole/min and 20 mpH/min, per
50,000 cells seeded into plates 16 or more hours prior to assay (107). This OCR
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value is below the 350 pmole/min raw OCR values obtained for primary ATII cells
at an approximate density of 75,000 cells/well. This concurs with prior
investigation showing lower rates of substrate oxidization by fibroblasts
compared to ATII (22).
The work presented here assessed metabolism in the presence of glucose
and supplemented with glutamine as the sole available substrates for
mitochondrial metabolism. However, studies of whole lung metabolism and
limited investigation of fetal ATII cells suggest that other substrates may be
oxidized, even preferentially, by ATII cells in the lung under physiological
conditions. Several investigations of whole lung metabolism using the isolated
perfused rat lung model reported high rates of lactate uptake and oxidation
simultaneous with lactate production (17, 108). Lactate was also reported to be
incorporated into lung lipids when provided in the perfusate in this model; as ATII
cells are the primary producers of lipid in the lung to generate pulmonary
surfactant, this likewise indicates that ATII cells may utilize lactate in addition to
glucose under physiological conditions.
Variation in experimental protocols makes it difficult to compare these
findings in ATII cells with flux data from other investigators using other cell types.
Plating density, normalization strategy, proliferative capacity of the cell type, and
assay timing vary widely between investigators and have major influence in how
data is interpreted and compared. In this work, acidification is converted to PPR
based on empirically calculated media buffering capacity, because even
relatively minor alterations in assay media formulation can affect ECAR readings
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and the media formulations differ based on the substrate or whether fetal bovine
serum (FBS) has been added to the assay media. However, the majority of
publications report ECAR values, which do not account for buffering capacity of
different assay media formulations, and this makes comparison across studies
difficult. Nonetheless, rough comparison of basal and maximal OCR values
reported in publications or approximated from figures suggests that ATII cells are
less metabolic than skeletal and heart muscle, but are otherwise in the upper
echelon of cell phenotypes in terms of oxidative metabolic function (Table 1). On
the other hand, primary ATII cells in culture demonstrated relatively lower spare
respiratory capacity compared to other cell types. This may in part be due to the
fact that they produce surfactant in culture; indeed, specific growth factors are
added to primary ATII cell culture media that stimulate surfactant production in
order to maintain the ATII cell phenotype and prevent differentiation. Thus, at the
time of a metabolic flux measurement, the cells were actively performing at least
one of their characteristic, highly energy-consuming functions and may require
more of their total mitochondrial capacity to accomplish this. This would also help
explain the different spare respiratory capacities of primary ATII and MLE-15
cells, which produce surfactant to a lesser degree.
Overall, we conclude ATII cells are highly metabolic in culture under
ambient oxygen conditions, and are to a large degree dependent on
mitochondrial ATP synthesis. This work quantifies for the first time the metabolic
phenotype in terms of oxygen uptake and glycolytic output, as established by the
PPR/OCR ratio, as well as demonstrating reserve mitochondrial and glycolytic
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function. MLE-15 cells, while less metabolic overall, recapitulate the relative rates
of lactic acid production and oxygen consumption observed in primary ATII cells,
supporting their use as a model for further metabolic study.
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Table 1: Comparison of mouse ATII OCR values to other metabolic cell types
based on previously reported data. All data are previously reported or approximated
from published reports; all data was obtained using the Seahorse Biosciences XF
instrumentation.

CELL TYPE

Approximate
cell number

Approximate OCR
(pmol O2/min)

Approximate
reserve (% basal)

Reference

ATII Cells
(mouse primary)

80,000

350

150%

Lottes et al,
2014 (37)

Primary Dermal
Fibroblasts
(human)

100,000

240

230%

Moruzzi et al,
2014 (109)

Aortic
Endothelial Cells
(Bovine)

60,000

150

220%

Hill et al,
2010 (110)

Cardiomyocytes
(neonatal
mouse)

50,000

400

400%

Sridharan et al,
2008 (111)

Neuron,
Hippocampal
(mouse)

50,000

250

200-300%

Yao et al,
2011 (112)

Muscle C2C12
Myoblasts
(mouse)

10,000

250

200%

Nicholls et al,
2010 (113)
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CHAPTER 3. CHRONIC HYPOXIA INDUCES
METABOLIC ADAPTATION BY ATII CELLS

3.1 Introduction
In the pulmonary epithelium, ATII cells are normally exposed to relatively
high levels of oxygen compared to the vast majority of cells in the body. In the
healthy developed lung, the cells of the alveoli (including ATII cells) normally
experience a well-oxygenated environment composed of approximately 13%
oxygen (38). However, a number of diseases result in altered oxygen
homeostasis in the pulmonary parenchyma and subject the alveolar epithelium to
decreased oxygen availability. Conditions associated with development of
pulmonary hypoxia include COPD, IPF, lung cancers, and edema (114).
Additionally, the fetal lung develops normally in conditions of low oxygen in utero
that would be considered “hypoxic” in the adult lung (115); indeed, low-oxygen
conditions and hypoxia-associated signaling appear to play a critical role in
normal lung development (116, 117). Determining the mechanisms through
which the cells of the lung respond and adapt to decreased oxygen availability
therefore holds significance for understanding both pulmonary health and
disease.

Metabolic changes are critical for facilitating cell survival in response to
hypoxia. In general, decreased oxygen tension results in a shift away from
mitochondrial ATP production to enhanced glycolytic ATP production in order to
maintain bioenergetic homeostasis. However, this response varies depending on
cellular energy demand and function. While many down-stream pathways
including AMP-activated protein kinase, mTOR, and others are involved in
mediating metabolic change (45), oxygen-sensing and initiation of the signaling
cascade that leads to adaptation is performed by members of the HIF family of
oxygen-sensitive transcription factors. HIFs regulate expression of target genes
in the response to hypoxia, many of which are involved in cellular metabolism.
The three HIF isoforms regulate overlapping, but distinct, sets of target genes,
and their expression varies depending on cell type; while most cells in the body
express HIF1, HIF2 and HIF3 expression is isolated to specific cell populations in
different tissues.
In the lung, HIF isoforms are critical components in alveolar development
(41) and pulmonary surfactant production (117). ATII cells in particular
demonstrate a unique pattern of HIF expression. While like most cells in the body
they expression HIF1, they also robustly express HIF2. Furthermore, while both
isoforms are stabilized immediately in short-term hypoxia, longer exposure
(greater than 8 hours) leads to a decline in HIF1 expression while HIF2 remains
constant. The implication of a HIF2- versus HIF1-mediated response has yet to
be determined; however, HIF2 expression specifically is critical for fetal
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development of the lung structure and surfactant system, which occurs under low
oxygen conditions.
Previous study of alveolar cell adaptation has focused predominantly on
short-term exposures to hypoxia. Some elements of the response measured in
mixed AEC and/or purified ATII cell populations have been identified including
pro-angiogenic signaling, generation of reactive oxygen species and activation of
AMPK (38, 118), up-regulation of glucose transporters and their localization to
the cell membrane (52), and internalization and inactivation of Na+/K+-ATPase
channels (24, 38). Some of these processes are expected to result in a
decreased cellular ATP demand and, potentially, a shift to enhanced glycolytic
glucose metabolism. However, the impacts of longer-term hypoxia are largely
unknown. AECs exposed for 20 hours have been shown to have similar ATP
levels to those cultured at 21% O2 (52) and cell survival does not appear to be
affected (53), but the mechanisms that mediate this remarkable resistant
phenotype are not characterized and the enduring functional metabolic changes
are unknown.
The work that follows characterizes the response of ATII cells to long-term
(20 hour) hypoxia (1.5% O2) at the level of metabolic function and investigates
transcriptional-level change in genes associated with glucose metabolism.
Furthermore, metabolic comparison is drawn between primary ATII cells derived
from mouse lung and cultures of a standard ATII-like cell line, MLE-15, to assess
their usefulness in modeling response to metabolic stressors.
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3.2 Results
3.2.1 ATII cells maintain ATP homeostasis during long-term hypoxia.
ATP was measured in MLE-15 and primary mouse ATII cells exposed to
20 hours’ hypoxia (1.5% O2) compared to control cultures incubated in ambient
oxygen to evaluate maintenance of ATP homeostasis. Following the exposure
period, ATP levels in MLE-15 did not differ significantly between ambient oxygen
and hypoxic culture conditions (Figure 3.1). Primary ATII cells maintained ATP at
near-ambient levels, demonstrating a minimal (albeit significant) decrease in
ATP. This demonstrates that that both MLE-15 and primary ATII cells maintain
energy balance after 20-hour exposure to hypoxia.
An additional set of MLE-15 cultures was exposed in parallel to the prolylhydroxylase inhibitor DMOG, which stabilizes HIF transcription factors in ATII
cells under ambient conditions (49). In this manner, pharmacological prolylhydroxylase inhibition is used to mimic the HIF-driven effects of hypoxia. Similar
to observations of hypoxic MLE-15, 20 hours of exposure to 250 µM DMOG did
not significantly change cellular ATP concentration.

3.2.2 Hypoxia suppresses oxidative metabolism in ATII cells.
In both MLE-15 and primary mouse ATII cells, 20-hour hypoxic exposure
decreased oxygen consumption. MLE-15 and primary ATII cell basal OCR was
decreased to 55% and 50% of rates observed for cells under ambient oxygen
conditions, respectively (Figure 3.2). DMOG treatment also suppressed OCR in
MLE-15.
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MLE-15 and primary ATII cells maintained spare respiratory capacity
following exposure to hypoxia or PHI (Figure 3.3). In terms of percentage above
respective basal rates, reserve capacity was similar between treated cultures and
those exposed to ambient O2 conditions (approximately 175% for MLE-15 and
150% for primary ATII). Although similar in terms of percentage above basal
OCR, due to the lower basal function in hypoxia- and PHI-treated cells absolute
OCR maximal respiratory function was reduced by approximately 50% for both
cell types. This ultimately demonstrates a similar degree of suppression of both
basal and maximal oxygen consumption in response to hypoxia.
In MLE-15 cells, approximately 50% of oxygen consumed was dedicated
to mitochondrial ATP generation regardless of hypoxia or DMOG exposure, as
ATP synthase inhibition via oligomycin A injection elicited a similar, 50% drop in
OCR for ambient O2, hypoxic, and DMOG-exposed cells (Figure 3.4).

82

ATP (as % Ambient Control)

120

*

100
80
60
40
20
0
MLE-15,
Hypoxia

MLE-15,
DMOG

Primary ATII,
Hypoxia

Figure 3.1: Hypoxia and PHI exposure do not alter steady-state ATP concentration
in ATII cells. ATP was measured in MLE-15 cells (solid) and primary ATII cells
(hatched) exposed for 20 hours to hypoxia (1.5% O2) and compared to parallel control
cultures exposed to ambient (21% O2), as described in Methods. An additional set of
MLE-15 cultures was exposed to the pharmacological hypoxia mimic DMOG. Samples
were assayed in triplicate per plate using luminescent assay. Plates were run in
quadruplicate for MLE-15, triplicate for primary ATII. * indicates p < 0.05 versus paired
ambient culture control, assed via paired Student’s T-Test.
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Figure 3.2: Hypoxia and PHI suppress cellular respiration. OCR was measured for
MLE-15 cells and primary ATII cells cultured in ambient O2 (21% O2) or hypoxia (1.5%
O2). An additional set of MLE-15 cultures was exposed to PHI (250 micromolar DMOG).
* indicates significant difference (p<0.05) between treatment group basal OCR and
ambient control basal OCR based on ANOVA. Error bars represent ± SE.
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Figure 3.3: ATII cells maintain mitochondrial reserve capacity in hypoxia. Following
the addition of FCCP to assay wells to stimulate maximal mitochondrial respiration, OCR
was measured for MLE-15 cells and primary ATII cells cultured in 21% O2 or hypoxia
(1.5% O2). An additional set of MLE-15 cultures was exposed to PHI (250 µM DMOG)
under ambient conditions. No significance difference was detected between treatment
conditions and respective ambient controls for either cell type based on ANOVA. Error
bars represent ± SE.
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Figure 3.4: Hypoxia and PHI suppress basal do not affect coupling of oxygen
consumption to mitochondrial ATP generation. The proportion of oxygen
consumption dedicated to generation of ATP via oxidative phosphorylation was
determined by measuring OCR before and after addition of oligomycin A, an inhibitor of
ATP synthase, to assay media. OCR response to oligomycin A was measured in MLE15 cultured in ambient O2 (●), hypoxia () and DMOG (). For MLE-15 cultures, samples
were assayed minimally in quadruplicate for each condition and plates run in triplicate.
Error bars represent ± SE.
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3.2.3 Hypoxia does not enhance glycolytic function in ATII cells.
Acid generation by primary mouse ATII and MLE-15 cells exposed to
hypoxia was measured as an indicator of glycolytic metabolic function. PPR
values did not differ significantly from basal ambient O2 values for MLE-15, while
primary ATII cell acid generation appeared to decrease from ambient O2 values
(Figure 3.5).
Lactate generation was measured using colorimetric assay to confirm
findings from metabolic flux analysis and to determine whether media
acidification could be accounted for by lactic acid generation. Media from MLE-15
cultures incubated in ambient oxygen or hypoxia was assayed for lactate
concentration at several time points following 20-hour exposure. No significant
difference was observed in the rate of lactate generation in terms of extracellular
lactate concentration between ambient and hypoxic cultures, confirming
extracellular flux analysis findings (Figure 3.6A). Similarly, there was no
difference in intracellular lactate concentration (Figure 3.6B). Notably, the
observed rate of extracellular lactate generation based on media concentration
measurements over time was essentially similar to the rate of proton production
as determined by flux analysis, indicating that acidification in both ambient
oxygen and hypoxia is predominantly due to generation of lactic acid. Thus, lactic
acid generation is the major determinant of extracellular pH by MLE-15 cells
under ambient and hypoxic conditions.
Following basal measurements, maximal glycolytic rates were measured
in cultures following addition of FCCP to assay media (Figure 3.7). MLE-15
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underwent an increase in glycolysis following FCCP injection to approximately
200% of basal measurements in ambient oxygen, hypoxia and PHI. This
indicates that the capacity to perform glycolysis was not affected by treatment. In
primary ATII cells, FCCP stimulated PPR to a similar rate in both ambient O2 and
hypoxic cultures, although the increased PPR in these cells was 130% percent of
basal primary cell rates.

3.2.4 Hypoxia enhances ATII cell relative reliance on glycolytic metabolism.
The relative reliance of cells on glycolytic versus oxidative means of
energy production can be assessed based on the ratio of protons produced and
oxygen consumed, or the PPR/OCR ratio. In response to hypoxic exposure,
MLE-15 and primary ATII cells adopted an increased reliance on glycolysis as
demonstrated by an increase in the PPR/OCR ratio for both cell types (Figure
3.8). However, as rates of glycolysis did not change in MLE-15 and appeared to
decrease in response to hypoxia in mouse primary ATII, this “shift” to glycolysis
was the effect of decreased OCR (and not increased PPR).
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Figure 3.5: Hypoxia and PHI do not increase extracellular proton production. PPR
was measured as an indicator of glycolysis in MLE-15 (dark) and primary ATII cells
(light) exposed to hypoxia compared to ambient controls. An additional set of MLE-15
cultures was exposed to PHI (DMOG). For MLE-15, samples were assayed minimally in
quadruplicate for each condition and plates run in triplicate. For primary cultures, a total
of six single-well experiments for each condition. * indicates significant difference
(p<0.05) between treatment group and ambient, unexposed control. Error bars represent
± SE.
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Figure 3.6: Hypoxia does not alter cellular lactate generation in MLE-15 cells. (A)
Lactate was measured in media of MLE-15 cultures exposed to ambient O2 (closed
marker) and hypoxia (open marker). Time points indicate time passed after the addition
of fresh media following 20-hour exposure. (B) Intracellular lactate was measured in cell
homogenates immediately following collection of media samples at t=120 minutes in (A).
Experiments were performed in triplicate. Error bars represent ± SE.
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Figure 3.7: Hypoxia and PHI do not impact ATII cell glycolytic reserve. Following
the addition of FCCP to assay wells to stimulate maximal mitochondrial respiration, PPR
was measured for MLE-15 cells (dark bars) and primary ATII cells (light bars) cultured in
ambient O2 (21% O2) or hypoxia (1.5% O2). An additional set of MLE-15 cultures was
exposed to PHI (250 µmolar DMOG). No significance difference was detected between
treatment conditions and respective ambient, unexposed controls for either cell type
based on ANOVA. Error bars represent ± SE.
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3.2.5
Hypoxia induces changes in ATII mRNA expression of genes
associated with glucose metabolism.
Previous work concerning ATII response to low oxygen tension has
demonstrated a role for HIF proteins in directing the hypoxic response at the
level of transcriptional change. Thus, to determine changes in gene expression
occurring in long-term hypoxia, mRNA harvested from ambient- and hypoxiacultured MLE-15 was subjected to a glucose metabolism-focused qPCR array.
Many genes associated with glycolysis were collectively up-regulated by hypoxia
(Table 2), including those that directly produce glycolytically-derived ATP
(phosphoglycerate kinase, Pgk1) and those serving as master regulatory
enzymes for the glycolytic pathway (phosphofructokinase, PfkI). Enzymes
responsible for phosphorylation (hexokinase 2, Hk2) and isomerization
(phosphoglucomutase, Pgm2) of glucose, required for substrate entry into either
glycolysis or glycogenesis, were up-regulated. Multiple other glycogenic genes
were up-regulated as well, indicating that hypoxia may enhance the ability of
MLE-15 to generate glycogen from glucose. No significant changes to TCA cycle
enzymes or other pathways included in the array were observed, except for
pyruvate dehydrogenase (Pdk1), which negatively regulates entry of pyruvate
into mitochondrial metabolism and instead favors lactate generation via
anaerobic reduction.

3.2.6 Hypoxia alters ATII metabolism to favor glycogen storage.
Based on the observation that hypoxia enhanced expression of metabolic
enzymes associated with glycogen production, glycogen storage was assessed
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in MLE-15 under hypoxic versus ambient oxygen conditions (Figure 3.8).

In

MLE-15 cultured at 21% (ambient) O2, low levels of glycogen were observed.
However, cultures exposed to hypoxia for 48 hours increased intracellular
glycogen stores significantly.

Exposure to PHI also significantly enhanced

glycogen content of MLE-15 cultures.
To determine the effect of re-entry into ambient oxygen on stored
glycogen, separate MLE-15 cultures were exposed to hypoxia for 48 hours,
followed by incubation at 21% O2 for an additional 24-hour period. In these cells,
glycogen content returned to low near-ambient levels, suggesting that stored
glycogen was mobilized and metabolized after oxygen levels were returned to
21%.
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Table 2: Hypoxia-dependent differential gene expression in MLE-15 cells. Focused
qPCR array was performed to assess changes in MLE-15 expression of genes
associated with glucose metabolism in response to hypoxia. 3 cDNA were analyzed per
condition. All genes meeting criteria of >2.0-fold change in gene expression and P < 0.05
(prior to rounding) are shown. Expression of all genes was increased after exposure to
hypoxia vs. ambient O2. † indicates expression changes validated via targeted qPCR for
selected genes. TCA, tricarboxylic acid.
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Aldoa
Eno1
Gbe1
Gpi1
Gys1

Hk2

Pdk1

Pfkl
Pgk1

Pgm2

Tpi1

Enolase 1, α-nonneuron

Glucan (1,4-α), branching enzyme 1

Glucose phosphate isomerase 1

Glycogen synthase 1, muscle

Hexokinase 2

Pyruvate dehydrogenase kinase 1

Phosphofructokinase, liver, B-type

Phosphoglycerate kinase 1

Phosphoglucomutase 2

Triosephosphate isomerase 1

Gene Name

Aldolase A, fructose-bisphosphate

Protein ID

NM_172665

Glycolysis/
TCA cycle

NM_009415

NM_028132

Glycolysis/
glycogen metabolism
Glycolysis

NM_008828

Glycolysis

NM_008826

NM_198308

Glycolysis/
glycogenesis

Glycolysis

NM_030678

NM_008155

NM_028803

NM_023119

NM_007438

Ref. Seq. ID

Glycogenesis

Glycolysis

Glycogenesis

Glycolysis

Glycolysis

Biological Process

2.87

0.05

0.02

0.002

3.55†

4.51

0.02

0.008

3.62

5.02†

0.05

0.04

5.27†
6.88†

0.04

0.001

6.81†
3.91

0.03

0.05

p Value

3.17

3.09

Fold Change
Hypoxia vs. Ambient

0.002

Glycogen
(µg glycogen/µg protein)

*
0.0016

0.0012

0.0008

*
*

0.0004

0
Ambient
Normoxia

Hypoxia

DMOG

Recovery

Figure 3.8: Hypoxia and PHI promote intracellular storage of glycogen, which is
consumed upon recovery in ambient O2. MLE-15 cultures were assayed for
intracellular glycogen content using quantitative fluorimetric detection, as described in
Methods. Samples were assayed in duplicate per assay plate and adjusted for sample
glucose content; assays were run in triplicate. * indicates p<0.05 versus ambient,
unexposed control, determined via ANOVA followed by Tukey post hoc analysis. Error
bars represent ± SE.
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3.3 Discussion
This work characterized the functional-level response of ATII cells to longterm hypoxia exposure in terms of impact on glycolytic and mitochondrial
function, and linked these observations to molecular-level adaptation of glucose
metabolism at the level of transcription. Hypoxia decreases mitochondrial
respiration without enhancing anaerobic glycolysis and lactic acid generation.
Despite this, ATP homeostasis is maintained, indicating that ATII cells primarily
adapt to hypoxia through down-regulation of ATP-consuming processes, rather
than enhanced glycolytic function to compensate for reduced mitochondrial ATP
yield. These results support and extend previous observations that AECs adapt
well to hypoxia in terms of avoiding cell damage and maintaining bioenergetic
homeostasis (52).
Hypoxia suppressed OCR in both MLE-15 and primary ATII cells by
approximately 50%. Previous respirometric measurements for rat ATII exposed
to 2% O2 demonstrated similar suppression in terms of percentage of ambient O2
culture rates (23) using a different method to measure oxygen consumption. In
respirometry studies, exposed rat ATII cells did not demonstrate enhanced
anaerobic glycolytic processing of glucose, as measured by extracellular flux
analysis and confirmed by direct measurement of lactate in culture media over
time. This observation was not anticipated, and strongly suggests that downregulation of ATP consuming processes (rather than enhanced lactic acid
production) is the mechanism through which ATII adapt to reduced mitochondrial
ATP production in hypoxia. This correlates well with clinical observations that
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lactate production from the lung in patients with pulmonary conditions does not
correlate with the degree of hypoxia, but rather with the extent of lung damage
(119). Indeed, these authors proposed that this is the result of robust adaptation
of healthy lung cells to hypoxia, a suggestion that is supported by the work
presented here.
The observation that both basal and maximal respiratory rates are
suppressed by hypoxia suggests that mitochondrial function is directly impacted
to some degree. In other words, if decreased mitochondrial function were an
effect only of reduced ATP demand, FCCP would be expected to stimulate
similar maximal rates under hypoxic and ambient conditions. This, however, was
not the case in these studies, as the addition of FCCP stimulated hypoxic ATII
cell respiration only to the basal levels of cells cultured in ambient oxygen
(approximately half the maximal rates of ATII cells cultured in ambient
conditions). Direct suppression may be an effect of damage to components of the
TCA cycle or electron transport chain, expression changes in mitochondrial
enzymes, substrate limitation, or dynamic changes to the mitochondrial
population via biogenesis and/or mitophagy. No significant changes were
observed in expression of mitochondrial enzymes at the level of transcription,
though this does not rule out protein-level expression changes. In the lung, the
TCA cycle enzyme aconitase has been shown to be particularly sensitive to ROS
generated under extremely hyperoxic conditions (85% O2 and greater); as shortterm hypoxia also generates ROS (38), damage to this or other mitochondrial
components is possible. Substrate limitation to the mitochondria also provides
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possible explanation for suppressed oxygen consumption, as enhanced
expression of PDKs is expected to limit entry of pyruvate into the TCA cycle. The
impact of hypoxia on ATII mitochondrial biogenesis and autophagy is unknown,
and presents a significant direction for future investigation.
Despite suppressed mitochondrial function, glycolysis was not increased
in ATII cells under hypoxia, as would be expected to maintain ATP production at
levels comparable to cells cultured in ambient oxygen conditions. These findings
strongly suggest that energy balance in maintained in hypoxia by reducing ATP
turnover, rather than shifting to enhanced reliance glycolytic production. One
mechanism that ATII cells reduce ATP demand is through down-regulation of
Na+/K+ ATPase ion pump function. Rapidly following the onset of hypoxia, pump
proteins are removed from the cell surface and degraded. However, respirometry
measurements performed by Heerlein and colleagues suggests that the impact
of this response on total ATP conservation is relatively small (23). Other
mechanisms of ATP conservation in hypoxic ATII have yet to be elucidated, but
may include reduced proliferative capacity and/or suppression of surfactant
production, the latter being supported by the observation that surfactant protein
expression is negatively controlled by hypoxia and HIF stabilization (49).
DMOG treatment of cells under ambient conditions resulted in metabolic
responses similar to those observed in response to hypoxia, strongly suggesting
that HIFs drive the observed metabolic adaptations observed here. HIFs are
found ubiquitously throughout mammalian tissues, but ATII cells display a unique
pattern of HIF stabilization in that they strongly express the HIF2 isoform. In the
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lung, HIF2 expression is strictly limited to ATII cells and the vascular endothelium
(120). Furthermore, while HIF1 is stabilized immediately, over time its expression
is reduced, while HIF2 expression remains robust (49, 50). At the 20-hour time
point utilized in these studies, the cellular concentration of stable HIF1α is low,
while HIF2 concentration is high. While the HIF1 isoform has been found to
control transcription of many of the genes coding for glycolytic enzymes, HIF2
targets include genes involved in fatty acid storage, glycogen production, and
anti-oxidant defense. HIF1 has been shown to drive apoptosis in ATII cells (121,
122) while HIF2 promotes anti-apoptotic pathways (123). HIF2 also plays critical
roles in surfactant production (117) and alveolar development in the fetal lung
(41).
Notably, the ATII cell response to PHI differs markedly from previously
observed impacts on cardiomyocytes treated with the same concentration of
DMOG. In cardiomyocytes, DMOG not only suppressed basal OCR, but
completely abolished spare respiratory capacity (which is exceptionally high in
untreated cardiomyocytes). Interestingly, inhibition of HIF1 mostly recovered
spare capacity in these cells, indicating that HIF1 activity specifically suppressed
mitochondrial function. In ATII, spare capacity was largely maintained in DMOGtreated cultures, demonstrating a fundamental difference between the cell types.
This may be one effect of mounting a HIF2-, rather than HIF1-mediated response
in ATII. Limiting HIF1 over longer-term exposure may be a strategy to preserve
mitochondrial function. Given the importance of spare respiratory capacity for
dealing with cell stress and promoting survival defined in neuronal metabolism
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studies (124), uncovering how healthy ATII cells maintain mitochondrial function
in hypoxia (and how this may be disrupted in disease) is an important step in
understanding ATII cell biology. Further investigation will be necessary to
determine how HIF1 versus HIF2 affects mitochondrial capacity.
Gapdh, Hk2, and other glycolysis-associated enzymes were up-regulated
in terms of mRNA expression, confirming previous observations in AEC cultures
(52). This is supported by proteomic work from our lab focused on elucidating the
changes induced by hypoxia to the ATII cell proteome, which indicated that
expression of several enzymes involved in the initial steps of the glycolytic
pathway are up-regulated in hypoxia (37). However, glycolytic rates remained the
same in MLE-15 cells and actually decreased in primary ATII cells under
hypoxia. This report indicates that in unstressed, baseline conditions, the
remaining mitochondrial function supplies sufficient ATP to meet reduced energy
demand without the need to enhance glycolysis.
Previous study of hypoxia has demonstrated up-regulation of cell surface
glucose transporters in AEC (52) and although we did not observe enhanced
GLUT mRNA expression by MLE-15 at 20 hours’ exposure, this has been more
recently demonstrated in ATII cells in short-term (less than 8 hour) exposures.
This highlights a possible key difference in the metabolic function of ATII in shortversus long-term exposure: at the onset of hypoxia, ATP levels drop due to
immediate suppression of mitochondrial function, and the responses previously
observed in association with hypoxia in these cells, including GLUT up-regulation
(52) and phosphorylation of AMPK (24), are effects of the cellular effort to regain
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bioenergetic homeostasis. Indeed, an initial drop in cellular ATP content has
been shown in AEC challenged with anoxia. Based on our findings, these initial
manipulations lead to re-established ATP levels by 20 hours’ exposure. Thus, our
observations represent the potentiated hypoxic response. We expect that the
findings reported here regarding 20-hour exposure represent the conditions to
which ATII are exposed in cases of IPF, COPD, and other chronic lung diseases
associated with chronic hypoxia in distal lung regions.
Findings concerning glycogen storage suggest that in long-term hypoxia,
glucose intake is at least in part dedicated to glycogen production (or other, nonglycolytic functions not assessed here). At 20 hours’ exposure, increased
glucose intake is not connected to increased flux through the anaerobic glycolytic
pathway, as extracellular acidification is not increased in exposed cultures. This
concurs with the conclusion that ATII adapt to hypoxia primarily by downregulating ATP-consuming processes rather than increasing non-oxidative ATP
production. Cultures exposed to hypoxia (1.5% O2) and then allowed to incubate
in ambient O2 conditions showed lower glycogen content near that observed for
cells cultured only under ambient O2, indicating mobilization and metabolism of
glycogen stored during the period of hypoxia. In skeletal muscle, glycogen
storage was shown to occur downstream of hypoxia in a HIF-dependent manner
(125), an effect that is supported in ATII by the observation that stabilization of

HIF via DMOG treatment also induced glycogen storage. In the developing lung,
glycogen storage is a critical component of the development of the surfactant
system and generation of surfactant in preparation for breathing room air, and
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both storage and utilization have been associated with HIF2 signaling (41). In
MLE-15, glycogen storage thus recapitulates the physiology of premature ATII.
The extent to which this occurs in the hypoxic adult lung is unknown.
In summary, this section of work quantifies the impact of hypoxia on ATII
cell metabolic pathway function and capacity. Observations from functional-level
assessment using flux assay and direct metabolite measurement are matched to
transcriptional changes and previously-obtained data concerning the impact of
hypoxia on the ATII proteome. Understanding how healthy human ATII cells
response to hypoxia is clinically important, as a number of diseases associated
with pulmonary hypoxia and in many of these cases the role of hypoxia in the
disease progression is poorly understood.
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CHAPTER 4. LACTATE SERVES AS SUBSTRATE
FOR ATII CELL METABOLISM

4.1 Introduction
While the lung was originally thought to depend on glucose for energy
production, a number of studies of whole lung metabolism demonstrated that
other substrates are taken up into lung tissue from pulmonary circulation and
oxidized. In these studies, lactate in particular was rapidly oxidized by the lung.
Furthermore, lactate oxidation occurred at higher rates than oxidation of other
substrates including glucose. Despite these early observations, lactate utilization
by the lung has received little attention in modern investigation. While a balance
of lactate production and consumption has been shown to be a critical
component of tissue metabolism in heart, skeletal muscle, and most recently
brain tissue, lactate metabolism has not been examined at the cellular and
molecular level in the pulmonary tissue.
Lactic acid is classically considered a cellular waste product. In the
process of anaerobic glycolysis, pyruvate is converted to lactate via the forward,
reductive reaction of LDH and is extruded, with a single proton, from the cell into
the extracellular milieu. A portion of lactate produced by cells of the body is
carried via circulation to the liver, where it is oxidized back to pyruvate and used
to re-generate glucose through the process of gluconeogenesis. However, this

process accounts for less than half of lactate oxidization during rest, and only
25% during exercise. A greater portion of lactate is oxidized by other cells
elsewhere in the body, which can utilize lactate as a metabolic substrate through
oxidization to pyruvate and subsequent use in mitochondrial energy production.
Lactate oxidization for energy production occurs rapidly in cardiac tissue where it
is consumed preferentially over glucose, particularly during exercise. In skeletal
muscle, highly oxidative cells of the slow-twitch red fibers consume lactate
produced by neighboring cells of the fast-twitch white fibers, which are heavily
dependent on anaerobic glycolysis and produce large amounts of lactate (27,
28). Through the complimentary processes of anaerobic lactate production in one
cell type and aerobic lactate oxidation in another, glycolysis and oxidative
metabolism are inextricably linked.
Several previous studies demonstrated that, in addition to glucose, lactate
is oxidized by lung tissue. Wolfe et al (17) used the isolated perfused rate lung
model to demonstrate rapid oxidization of

14

C-labeled lactate by lung tissue. In

this study, lactate oxidation occurred even when glucose was provided
simultaneously and at higher concentrations in the perfusate. Later investigation
by Fox and colleagues examining lactate use in isolated alveolar epithelial cells
from fetal rat lung demonstrated rates of CO2 generation from labeled lactate that
were approximately 20 times the rate of glucose oxidation, the highest rate for
any substrate tested (22). The presence of lactate decreased utilization of
glucose and vice versa, indicating similar pathways of metabolic processing.
Early studies found that lactate was incorporated into lung lipids, indicating a role
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for ATII in lactate oxidization, as ATII cells are the primary synthesizers of lipid
for production of pulmonary surfactant (18). Furthermore, lactate was
preferentially incorporated into the acetyl moiety of synthesized lipids while
glucose primarily composed the glycerol moiety, suggesting that lactate was
processed preferentially by the mitochondria. Despite a strong body of evidence
indicating that lactate is an important substrate in the lung and suggesting in
particular that ATII cells utilize lactate, lactate oxidation has not been examined
in mature ATII cells and has not been linked directly to energy production and
homeostasis.
Lactate consumption for mitochondrial utilization requires, first, cellular
import and second, conversion to pyruvate via the reverse, oxidizing reaction of
LDH. Lactate transport both into and out of cells is mediated by a family of
transport proteins, monocarboxylate transporters (MCTs) that can move lactate
with a single proton down-gradient across cell membranes. There are four MCT
isoforms, MCT1, 2, 3, and 4. All isoforms transport bi-directionally; however,
some isoforms more heavily favor import versus export. MCT4, the lower-affinity
member, is associated with more rapid lactate export and tends to be expressed
in more highly glycolytic cells, including cells of the white muscle cells and brain
astrocytes. MCT1, on the other hand, is associated with import and is found in
cell types known to oxidize lactate for ATP production. MCT1 and MCT4 are
expressed in the developing lung with MCT1 expression localized mainly to the
maturing epithelium (126). Whole lung tissue from adult rat expresses MCT1, 2,
and 4, however localization of expression to specific cell types has yet to be
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examined (34). The importance of MCT-mediated lactate transport to ATII cell
metabolism is unknown.
The ability to oxidize lactate once it is imported requires rapid
mitochondrial activity and a high NAD+/NADH ratio to facilitate reverse activity of
LDH (26). Based on our previous findings, ATII cells are highly metabolic with
rapid rates of mitochondrial activity (37), and due to their physiological location in
the lung epithelium, oxygen is readily available to fuel mitochondrial metabolism
in the healthy lung. Furthermore, intracellular lactate levels are low, favoring
import from a higher external concentration. These important facets of ATII cell
metabolic function inspired the hypothesis that ATII cells import extracellular
lactate and utilize it as substrate for mitochondrial energy production. Using
extracellular flux assay technology to measure cellular metabolism of cells in
culture, we show that primary and model ATII cells can rapidly oxidize lactate for
use as substrate for ATP production. We provide evidence that lactate modulates
glucose utilization in a dose-dependent manner when both substrates are
provided simultaneously. Furthermore, using the addition of an inhibitor of MCT
proteins, we directly demonstrate for the first time the importance of the
transporter in ATII cell metabolism of both lactate and glucose. Additionally,
expression of Mct1 mRNA and protein is shown in ATII cell lysates, specifically
identifying one pulmonary cell population that expresses the transporter.
Cumulatively, this report provides evidence that ATII cells act as a “lactic acid
sink” in the lung, removing lactate and protons from the extracellular milieu for
use in maintaining their own bioenergetic homeostasis.
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Finally, we investigate the effect of hypoxia on ATII cell lactate utilization.
We and others have demonstrated that hypoxic exposure suppressed
mitochondrial metabolism of glucose (23, 37), resulting in a more glycolytic
phenotype. A variety of pulmonary diseases including IPF lead to development of
pulmonary hypoxia and hypoxia-related signaling in the distal lung (73). Because
lactate import and utilization depends ultimately on a high level of mitochondrial
respiration, any condition that impairs mitochondrial function could be expected
to reduce the capacity to consume lactate. Lactic acid build-up has been shown
to occur in IPF lung tissue and contributes directly to the disease process (94),
but the source of the excess lactate is unknown. This work is thus an important
step forward in understanding the ATII functions that may be disrupted in, and
contribute to, disease pathogenesis by developing a thorough understanding of
lactate production, consumption, and balance in the healthy lung.

4.2 Results
4.2.1 Culture in lactate alone induces a highly oxidative ATII cell phenotype.
Compared to cells cultured in glucose, primary ATII and MLE-15 both
showed elevated rates of oxygen consumption when cultured in lactateformulated media (Figure 4.1). For both cell types, culture in lactate increased
OCR by approximately 2-fold over glucose-grown cultures. PPR was low for both
cell types, indicating low lactic acid production, expected due to the lack of
glucose. Thus, in the presence of lactate and absence of glucose, ATII cell
metabolism shifts into a highly oxidative phenotype.
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Lactate utilization as substrate for mitochondrial ATP generation requires
it to first be converted to pyruvate via the reverse, oxidative reaction of LDH.
Thus, inhibition of LDH would be expected to decrease mitochondrial respiration
of cells cultured in lactate by limiting the conversion to pyruvate, and thus the
substrate necessary for mitochondrial NADH production. Inhibition of LDH using
the competitive inhibitor oxamate resulted in a decrease in OCR by cells cultured
in lactate (Figure 4.2) This provides further support for the conclusion that
lactate, via LDH conversion to pyruvate, is utilized by MLE-15 for mitochondrial
reactions. Conversely, LDH inhibition resulted in enhanced OCR in glucosegrown cells, possibly an effect of reducing the amount of pyruvate converted to
lactate and thus increasing the substrate pool for mitochondrial metabolism and
the need to regenerate NAD+.

4.2.2 Rapid respiration by mouse ATII grown in lactate is coupled to
mitochondrial ATP production.
Inhibition of ATP synthase provides a measurement of the degree to
which oxygen consumption is dedicated to ATP production through mitochondrial
respiration. Upon inhibition of ATP-synthase during extracellular flux assay,
oxygen

consumption

by

lactate-cultured

cells

decreased

from

basal

measurements by approximately 60%, indicating that approximately 60% of
oxygen consumption was coupled to mitochondrial ATP production (Figure 4.3).
This response to ATP synthase inhibition was similar to cells cultured in parallel
in glucose, indicating a similar proportion of total basal OCR dedicated to ATP
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synthesis. Considering that lactate-cultured MLE-15 had high basal OCR levels,
this proportion represents approximately twice the amount of oxygen consumed
for ATP synthesis by glucose-grown cells.

4.2.3 Respiration is performed at maximal capacity in mouse ATII cells
cultured in lactate.
Addition of the respiratory chain uncoupling molecule FCCP results in an
increase of oxygen consumption to maximal respiratory rates. FCCP exposure
during metabolic flux assay resulted in OCR values approximately 180% of basal
values for MLE-15 cultured in glucose; however, exposure to FCCP did not
induce a significant increase above basal OCR for cells cultured in lactate
(Figure 4.4). This demonstrates that cells cultured in lactate maintained minimal
spare respiratory capacity, and therefore when lactate alone is available, cells
perform respiration at near-maximum mitochondrial capacity.
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Figure 4.1: Culture in lactate shifts ATII cells into a highly oxidative metabolic
state. OCR and PPR were measured for primary ATII cells (circle markers) and MLE-15
cells (diamond markers) cultured in either 5.5 mM glucose (shaded) or 5.5 mM lactate
(open). For MLE-15 cultures, samples were assayed minimally in triplicate for each
condition and plates run in triplicate. For primary cultures, a total of six single-well
experiments were performed for each condition. * indicates significant difference
(p<0.05) from glucose condition OCR for each cell type; + indicates significance
difference from glucose condition PPR for each cell type. Significance based on
Student’s T-Test. Error bars represent ± SE.
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Figure 4.2: Inhibition of LDH reduces lactate-fueled respiration in MLE-15. OCR
was measured for MLE-15 cells cultured in 5.5 mM glucose or 5.5 mM lactate and
exposed to the LDH inhibitor oxamate. Oxamate was dissolved in assay media to a final
concentration of 20 mM and added to culture wells 1 hour prior to assay; control wells
received normal assay media. Data is represented as percentage of glucose or lactate
controls unexposed to oxamate. n = 5 individually-cultured wells per condition. *
indicates significant difference (p<0.05) from unexposed controls based on Student’s TTest. Error bars represent ± SE.
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ATII cells utilize lactate for mitochondrial ATP production. The

proportion of oxygen consumption dedicated to generation of ATP via oxidative
phosphorylation was determined by measuring OCR before and after addition of
oligomycin A, an inhibitor of ATP synthase, to assay media. OCR response to
oligomycin A was measured in MLE-15 cultured in 5.5 mM glucose or 5.5 mM lactate. 5
independent cultures were measured per condition. Data represent percentage change
from basal OCR measurements following ATP synthase inhibition. Error bars represent
± SE.
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Figure 4.4: Mitochondrial respiration is performed at near-maximal rates in MLE15 cells consuming lactate alone. Following measurements of basal respiration, FCCP
was added to the assay media to measure uncoupled OCR in MLE-15 cells cultured in
5.5 mM glucose or 5.5 mM lactate. n = 5 individually-cultured wells per condition. Data
respresents percentage change from basal OCR values. * indicates significant difference
(p<0.05) from basal OCR for each condition, as determined by ANOVA and Tukey post
hoc analysis. Error bars represent ± SE.
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4.2.4 Lactate availability alters glucose utilization.
To examine the impact of extracellular lactate availability on glucose
metabolism, lactate was provided to MLE-15 in increasing concentrations in
media formulated with 5.5 mM glucose and compared to media with glucose
alone. At concentrations of 2.75 mM lactate and above, PPR was significantly
decreased from the glucose-only condition in a dose-dependent manner (Figure
4.5). Conversely, OCR values did not differ significantly from glucose for any of
the lactate concentrations examined.

4.2.5 Hypoxia suppresses ATII cell lactate respiration.
Following exposure of lactate-grown cultures to 1.5% O2 for 20 hours,
basal OCR of both primary ATII (Figure 4.6A) and MLE-15 cells (Figure 4.6B)
decreased by 50% from ambient O2 values. This degree of hypoxia-induced
mitochondrial suppression is similar to that observed for control cultures grown in
glucose in parallel.
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Figure 4.5: Extracellular lactate concentration regulates glycolytic output. OCR
(dark bars) and PPR (light bars) were measured for MLE-15 cultured in 5.5mM glucose
and increasing concentrations of lactate. Data is represented as % of glucose-only
control. A total of 12 independent cultures were assessed for each condition. * indicates
significant difference (p<0.05) from glucose-only control, as determined via ANOVA
followed by Tukey post hoc analysis. Error bars represent ± SE.

116

OCR (% Ambient Control)

A
120
100
80

*

*

Ambient
Normoxia

60

Hypoxia

40
20
0

Glucose

Lactate
MLE-15

OCR (% Ambient control)

B
120
100

*

80
60

*
Ambient

40

Hypoxia

20
0

Glucose
Lactate
Primary ATII
Figure 4.6: Exposure to hypoxia suppresses respiration of ATII cells cultured in
glucose or lactate to a similar degree. OCR was measured for MLE-15 cells (A) and
primary ATII cells (B) cultured in 5.5 mM glucose or 5.5 mM lactate and incubated in
ambient O2 (21% O2) or hypoxia (1.5% O2) for 20 hours. For MLE-15 cultures, samples
were assayed minimally in triplicate for each condition and plates run in triplicate. For
primary cultures, a total of 6 single-well experiments were performed for each condition.
* indicates significant difference (p<0.05) from ambient O2 OCR for each condition, as
determined via Student’s T-Test. Error bars represent ± SE.
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4.2.6 ATII cell lactate consumption and export are dependent on MCT
function.
MCT proteins control transport of lactate both into and out of cells. Lactate
transport by MCTs can be inhibited pharmacologically using the compound
alpha-4-hydroxycinnamate (CHC), which inhibits all MCT isoforms at the
cytosolic membrane. Addition of CHC to both glucose- and lactate-grown MLE15 cultures during metabolic flux assay resulted in decreased PPR from basal
levels, demonstrating impaired lactic acid export (Figure 4.7A). Addition of CHC
to both glucose- and lactate-grown MLE-affect OCR in glucose-grown cultures;
however, in lactate-grown cultures, addition of CHC decreased OCR (Figure
4.7B) indicating that restricting lactate import reduced mitochondrial function. In
summary, these data indicate that MCT function is necessary for both lactate
export and lactate import and subsequent mitochondrial metabolism in ATII cells.

4.2.7 ATII cells express MCT1 in a non-hypoxia-inducible manner.
Expression of the monocarboxylate transporter isoform MCT1 is
associated with co-import of lactate and protons into cells that oxidize lactate
including cells of the heart and red skeletal muscle fibers. MCT1 protein
expression was confirmed in MLE-15 lysates, with mouse skeletal muscle tissue
lysate as a positive control (Figure 4.8). Mct1 expression was assessed in
lysates from MLE-15 and primary ATII cultures. Both cell types express Mct1
mRNA (cf. Figure 4.9A). Based on Ct values observed in qPCR assays, Mct1
mRNA is expressed by ATII cells at levels in the approximate range of Gapdh.
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MCT1 has been shown to be hypoxia-inducible in some tissues, but not in
others. In lysates from primary ATII and MLE-15 cells exposed to 1.5% O2 for 20
hours, so significant difference in Mct1 mRNA expression was observed (Figure
4.9A). Similarly, MCT1 protein concentration (Figure 4.9B) measured in MLE-15
cell lysates did not change in response to hypoxic exposure. This provides
evidence that MCT1 is not responsive to hypoxia in ATII cells. However, Mct1
mRNA expression was enhanced in MLE-15 cultured under ambient O2 in lactate
compared to those grown in glucose (Figure 4.10). This indicates that expression
of the transporter is responsive to extracellular lactate availability, an observation
that has been made in other tissues (27).

4.2.8 Lactate alone is sufficient to maintain ATP balance but not cell growth.
Culture in lactate in the absence of glucose did not disrupt the ability of
MLE-15 cells to maintain energy balance, as intracellular ATP levels measured
for lactate-grown cultures were statistically similar to those in glucose (Figure
4.11). This was true for culture in lactate under both ambient O2 and hypoxic
conditions.
While ATP level was similar cells cultured in lactate versus glucose, there
was a dramatic different in cell growth. In lactate alone, MLE-15 cells showed
decreased rates of DNA synthesis compared to cells cultured in glucose. DNA
synthesis in the combination of both lactate and glucose did not differ
significantly from glucose-alone demonstrating that it is the absence of glucose,
and not the presence of lactate, that impaired cell growth (Figure 4.12A). These
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results were confirmed by cell counts taken over a period of 5 days, showing
rapid increases in cell number in glucose alone and combined substrate but
minimal increase in lactate alone (Figure 4.12B).
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Figure 4.7: MCT transporter function mediates export and import of lactic acid by
MLE-15 cells. PPR (A) and OCR (B) were measured for MLE-15 cells cultured in either
5.5 mM glucose (shaded) or 5.5 mM lactate (open). Following basal measurements,
CHC was injected into assay wells to a final concentration of 10 mM to inhibit MCT
proteins. n = 9 and 6 individually-cultured wells for glucose and lactate conditions,
respectively. * indicates significant difference (p<0.05) from basal (pre-injection)
measurements, determined using ANOVA followed by Tukey post hoc analysis. A total
of 9 independent cultures were assessed for each condition. Error bars represent ± SE.
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Figure 4.8: ATII cells express monocarboxylate transporter MCT1. MLE-15 cell
lysates (approximately 25 µg total protein) was analyzed for MCT1 protein expression.
Mouse skeletal muscle whole tissue lysate (approximately 12 µg total protein) serves as
positive control for mouse MCT1 protein.
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Figure 4.9: Mct1 expression is not hypoxia-inducible in ATII cells. (A) Expression of
Mct1 RNA was measured in primary ATII cell and MLE-15 cells, cultured in ambient O2
(21%) or hypoxia (1.5% O2) for 20 hours, via qPCR. Fold change was calculated from
delta-delta Ct values using beta-actin for normalization. (B) Expression of MCT1 protein
was measured in MLE-15 lysates from cells cultured in ambient O2 or hypoxia for 20
hours. Band densitometry was performed on blots to semi-quantitatively measure protein
expression. Data represent the ratio of MCT1 band density to beta-actin band density for
normalization. n = 3 lysates from individual cultures per condition. No significant
difference (p < 0.05) was detected between conditions using Student’s T-Test. Error bars
represent ± SE.
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Mct1 expression by MLE-15 is increased by culture in lactate.

Expression of Mct1 RNA was measured in MLE-15 cells, cultured in HITES formulated
with 5.5 mM Glucose or 5.5 mM lactate via qPCR. Fold change was calculated from
ΔΔCt values using beta-actin for normalization. * indicates significant different (p < 0.05)
from glucose-only control, based on Student’s T-Test. Error bars represent ± SE.
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Figure 4.11: Lactate alone is sufficient to maintain MLE-15 cell ATP homeostasis.
ATP was measured in MLE-15 cells cultured in media formulated with 5.5 mM glucose
or 5.5 mM lactate. Samples were assayed in triplicate per plate using luminescent
assay. Samples were assayed in triplicate per plate using luminescent assay. Plates
were run in triplicate. * indicates p < 0.05 versus ambient glucose control. Error bars
represent ± SE.
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Figure 4.12: Lactate alone is not sufficient to maintain cell growth in MLE-15 cells.
(A) MLE-15 cell count in culture was assessed over a growth period of 6 days, or until
cultures reached 100% confluence, for cultures grown in 5.5 mM glucose, 5.5 mM
lactate, or 5.5 mM of both substrates. Data represent total cells per well determined via
hemacytometer count of only cells excluding the vital dye trypan blue. n = 3 individuallycultured wells. * indicates significant different (p < 0.05) from glucose-only control. Error
bars represent ± SEM. (B) EdU incorporation into synthesized DNA was assessed
fluorimetrically, as described in methods. Data represent fluorescent signal from Cy7
normalized to ToPRO3 signal for total DNA. n = 3 individual cultures of MLE-15. *
indicates significant different (p < 0.05) from glucose-only control. Error bars represent ±
SE.
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4.3 Discussion
Early

metabolic

studies

in

the

1970s

and

1980s

conclusively

demonstrated that lactate is oxidized by lung tissue. Lactate oxidization was
implicated as a potentially important process, both for generating cellular ATP
and for providing precursor molecules for lipid synthesis. While these studies
using the whole isolated perfused lung model provided significant insight into
pulmonary metabolism, they were limited in their inability to provide information
concerning the function of specific pulmonary cell types (11), of which there are
many. Despite the ample evidence provided by these early studies that lactate is
a potentially important substrate for lung metabolism, and despite heavy
investigation of lactate consumption in brain and skeletal muscle, lactate
oxidation in the lung has not been revisited using modern techniques. This report
provides evidence that ATII cells import lactate from the extracellular space and
utilize it as substrate for mitochondrial energy production. In this manner, ATII
cells may serve as a “lactate sink” in the pulmonary tissue, consuming lactate
carried in pulmonary circulation and extruded as waste from neighboring cells,
thus preventing lactic acid build-up in the tissue and maintaining a physiological
balance of lactate production and consumption. As lactic acid build-up has
recently been implicated in the pathogenesis of IPF, maintaining this balance
may be a critical, previously unknown role of ATII cells in healthy lung function.
A highly oxidative, minimally glycolytic phenotype was observed in cells
cultured in lactate as compared to those cultured in glucose, resulting in a
dramatic shift in metabolic phenotype. Oxygen consumption by lactate-grown
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cultures occurred at approximately twice the rate of those in glucose. With lactate
provided as metabolic substrate in the absence of glucose, respiration was
performed at maximal rates of mitochondrial function as indicated by the absence
of response to FCCP. The rapid rate of oxygen consumption by ATII cultured in
lactate is dedicated largely to ATP production, as exposure of cultures to the ATP
synthase inhibitor oligomycin A resulted in a decrease of approximately 70%.
This degree of coupling is similar to that observed for cells cultured in glucose in
parallel.
The observation that inhibition of LDH decreased OCR provides additional
support for the conclusion that lactate is used as a precursor substrate for
mitochondrial metabolism, as the lactate-to-pyruvate conversion necessary for
entry into the TCA cycle is accomplished via the reverse reaction of LDH.
Inhibition of this process decreases mitochondrial respiration by limiting available
pyruvate. In glucose-grown cultures, LDH inhibition had the opposite effect,
resulting in enhanced OCR above uninhibited levels. While ATII depend on
mitochondrial metabolism to generate a large proportion of ATP, they do also
simultaneously perform anaerobic metabolism of glucose, as evidenced by basal
PPR rates. LDH inhibition decreases the amount of pyruvate converted to
lactate, instead shuttling pyruvate into the oxidative metabolic pathway, which
likely accounts for the modest increase in OCR in the glucose condition.
The data reported here demonstrate that lactate availability alters glucose
utilization. When provided simultaneously with 5.5 mM glucose, lactate
concentrations of 2.75 mM and higher lead to decreased acid generation. OCR
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values did not change significantly with increasing concentrations of lactate.
These findings demonstrate that glucose metabolism is altered by the presence
of lactate, and supports previous findings from Fisher and Dodia that lactic acid
generation and glucose consumption is reduced when lactate is present (127).
As in that study, we suggest that the observed decrease in PPR is the result of
increased lactate utilization, as lactate competes with glucose as a source of
pyruvate for mitochondrial energy production. However, it is also possible that
decreased PPR is alternatively the result of decreased lactic acid export, due to
change in the extra- to intracellular lactate gradient. Further study will be
necessary to determine the extent to which lactate is utilized as substrate when
glucose is also present; however, this demonstrates that glucose metabolism is
affected by the presence of lactate. Plasma lactate can exceed 20 mM in
extreme cases of hypoxia or hypotension (128), and concentration in IPF lung
are more approximately 2-fold greater than healthy lung (94); thus, modulation of
glucose by extracellular lactate holds important implications for cell function in
pulmonary disease.
For the first time, the importance of MCT proteins in mediating pulmonary
cellular lactate transport is directly demonstrated. Inhibition using a pan-MCT
inhibitor resulted in decreased flux of protons out of cells and into the
extracellular environment, demonstrating the importance of MCT-mediated
lactate export. Furthermore, in lactate-grown cultures, inhibition of MCT reduced
oxygen consumption, demonstrating an effect on mitochondrial metabolism by
limiting lactate transport into the cell. OCR was unaffected in MCT inhibition in
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glucose-grown cells, as expected due to the fact that glucose is imported via its
own set of transport proteins and MCT is not involved in mediating movement of
glucose into the cell. Additionally, we demonstrate expression of the transporter
isoform MCT1 by ATII cells. Expression of this MCT isoform is associated with
lactate import in tissues known to oxidize lactate including cardiac muscle and
skeletal muscle red fibers, and has been previously shown to be expressed in
whole lung tissue. Here, MCT1 mRNA is found in MLE-15 and primary ATII, and
protein expression confirmed in MLE-15, identifying ATII cells as one pulmonary
population that expresses the transporter. This further supports the concept that
ATII cells consume lactate and may serve as a sink for lactate in the lung.
Exposure of rat fetal lung explants to CHC impairs alveolarization (126),
indicating that MCTs play important, though yet undefined, roles in lung
development. In combination with the work presented here, it appears that
lactate transport and metabolism are critical components in proper lung
development.
Use of lactate for mitochondrial metabolism is suppressed by hypoxia, as
evidenced by a drop in OCR by approximately 50% following 20-hour exposure
to 1.5% oxygen. This degree of change in response to hypoxic treatment is
similar to the effect of hypoxia on oxidative metabolism in ATII cultured in
glucose (23, 37). Hypoxia did not alter expression of Mct1, indicating that the
gene is not hypoxia-inducible in these cells. Though Mct1 is up-regulated in
response to hypoxia in adipocytes, in skeletal muscle expression does not
change, as observed here for ATII. As pulmonary hypoxia is associated with
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multiple lung diseases, the impact of hypoxia on the ability of ATII to remove
lactate, together with protons, from the extracellular space may contribute to
lactic acid build-up. Indeed, lactic acid has been shown to increase in lung tissue
in IPF and directly contribute to disease pathogenesis via pH decrease. Based
on our findings, we propose that impaired lactate utilization contributes to the
build-up of lactic acid in the extracellular space that occurs in certain pulmonary
diseases, potentially in addition to enhanced acid generation by ATII or other
cells. Here, only the effect of hypoxia on mitochondrial metabolism of lactate is
investigated; however, we expect that any conditioned that inhibits respiration will
limit lactate consumption.
Despite adopting a very different metabolic profile, cells cultured in lactate
maintained ATP concentration. In fact, a statistically significant increase in ATP
concentration was measured. Cells utilizing lactate in the absence of glucose
cannot undergo glycolysis and thus lose glycolytically-derived ATP, and
increased OCR to maximal levels under these conditions is possibly the result of
compensating for this. While ATP homeostasis was maintained, lactate alone
was insufficient to support cell growth, as measured by increase in cell count
over time and relative rates of EdU incorporation into nascent DNA. This finding
is not surprising, as glycolytic intermediates are required for DNA synthesis.
Intermediate metabolites of glycolysis processed through the pentose phosphate
pathway reactions generate ribose sugars, necessary for nucleotide synthesis.
As lactate oxidation bypasses glycolysis, these products are not formed in the
process of lactate consumption, limiting the availability of substrate for DNA
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synthesis in cells cultured in alone. Culture in combined lactate and glucose did
not inhibit DNA synthesis or increase in cell number, demonstrating that it is the
absence of glucose, and not the presence of lactate, that mediates the effect.
After 5 days of growth, a significant different was seen between glucose and
combined substrate, with the combined condition showing greater cell number.
Rates of EdU incorporation were not significantly different, although this variable
was measured after only one day of culture; significant difference may also be
observed in rate of synthesis given a longer period of growth. While this has not
been examined in further detail, it may be the result of enhanced proliferation,
reduced apoptosis, or both; further study will be necessary to determine how the
presence of lactate influences either or both of these processes.
The capacity of ATII cells to consume lactate from the extracellular space
has important implications for whole lung metabolism. Based on our findings,
ATII cells in the lung may take up lactate produced by neighboring cells in a
situation analogous to white-glycolytic and red-oxidative fiber metabolism in
skeletal muscle tissue. Extracellular oxygen and proton flux has not been
measured for ATI cells and pulmonary fibroblasts; however, in fibrotic lung
disease, activated myofibroblasts generate high levels of lactic acid (94) and
rough comparison of ATII flux measurements to those for normal human dermal
fibroblasts indicate that ATII cells are more oxidative (107). ATII cells may also,
or alternatively, utilize lactate delivered to the alveolus in pulmonary circulation,
similar to the manner in which cardiac tissue consumes circulating lactate.
Multiple investigators have demonstrated lactic acid uptake from pulmonary
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circulation (34), oxidation (17, 18, 129) , and/or incorporation into lung lipids (18).
In this manner, local metabolic cooperation between lung cell phenotypes may
form a key component of normal alveolar tissue homeostasis, providing
metabolic substrate for ATII cell energy and lipid production while also preventing
lactic acid build-up in the healthy lung.
Likewise, dysregulation of local metabolic connection between cell types
may lead to conditions associated with certain diseases. Recent investigation
into pro-fibrotic processes that contribute to myofibroblast activation in idiopathic
pulmonary fibrosis (IPF) have highlighted the importance of lactate balance in the
lung. Kottman et. al. determined that not only is lactate elevated in the lungs of
IPF patients, but lactic acid directly contributes to the process of tissue fibrosis
(94). By lowering the local extracellular pH, lactic acid build-up leads to activation
of latent TGFβ in vitro, added directly to fibroblast culture media in that study.
TGFβ is the primary molecular signal responsible for initiating conversion of
fibroblasts into the myofibroblast phenotype (130), and the study determined that
increased lactic acid leads to enhanced myofibroblast conversion and matrix
deposition. Increased lactate generation was associated with a shift to enhanced
tissue expression of LDH5, the isoform most strongly favoring pyruvate-to-lactate
conversion (and not the reverse). Altered expression was localized roughly to the
epithelium near fibrotic centers, though the cell type(s) responsible have yet to be
specifically identified. While it is now clear that lactic acid build-up is involved in
IPF disease pathogenesis, the cells and molecular processes responsible for
lactic acid build-up in the diseased pulmonary tissue are unknown. Based on our
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findings here, it is rational to conjecture that altered ATII cell mitochondrial
metabolism, and thus reduced ability to remove and consume lactate, is a
contributing factor.
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CHAPTER 5. ATII CELLS IN IPF LUNG ADOPT A
GLYCOLYTIC METABOLIC PHENOTYPE

5.1 Introduction
Idiopathic pulmonary fibrosis is characterized by extensive formation of
fibrous tissue, or scarring, in the pulmonary parenchyma associated with
aberrant,

pathological

deposition

of

extracellular

matrix

by

activated

myofibroblasts. Despite the relatively well-defined role of the fibroblast in the
progression of pulmonary fibrosis and IPF (66, 130), it is in fact the alveolar
epithelium, specifically the ATII cell, that is now thought to be the primary site of
damage that initiates the disease. In the current paradigm, damage to ATII cells
leads to pro-fibrotic signaling from injured and apoptotic cells that stimulates
fibroblast activation and conversion to the myofibroblast phenotype (69).
Myofibroblasts produce excessive amounts of extracellular matrix material, and
epithelial cell-fibroblast signaling results in further damage to the alveolar
epithelium

in

a

feed-forward

mechanism

that

continuously

stimulates

myofibroblasts. Damaged epithelial cells also recruit both innate and adaptive
immune system cell mediators including neutrophils, monocytes, and T cells,
which further enhances the pro-fibrotic environment through cytokine signaling
(92, 93, 131) and production of reactive oxygen species (91). Despite advances
that have placed ATII cells as the central cellular targets of damage in

initiating the disease, the ultimate cause of the damage is unknown. Many
potential sources are currently under investigation including environmental
causes such as smoking and exposure to particulates; mutations in genes
including SPC (59, 60), telomerase (63), and MUC5B (61, 62); gastroesophageal
reflux disease (GERD) and exposure to gastric fluids (132); ER stress and the
unfolded protein response (133); and viral infections (134). Ultimately, in most
cases, generation of ROS is supposed to be at least part of the mechanism of
damage involved in current hypotheses regarding epithelial damage in initiation
of IPF (100, 135).
Altered cellular metabolism has not yet been directly assessed in IPF lung
tissue. However, both the potential initiating insults and the known downstream
pathogenesis events include mechanisms that could cause mitochondrial
damage and alter cellular metabolism in epithelial cells. For instance, history of
cigarette use is associated with development of IPF, and smoking is known to
cause oxidative stress and mitochondrial ROS production and/or direct damage
in a variety of tissues (136-138). Smoke exposure was recently shown
specifically to decrease respiration in ATII cells of exposed mice (139) .
Asbestos, another particulate exposure also associated with IPF, damages
mitochondrial DNA (mtDNA) leading to dysfunction and intrinsic mitochondrial
apoptosis (140, 141).
Beyond endogenous generation of ROS by mitochondria in response to
insult, exposure to exogenous hydrogen peroxide also generates damage in
alveolar epithelial cells, suggesting that ROS production by myofibroblasts and
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immune cells in IPF could alter ATII mitochondrial function. The robust
mitochondrial function of ATII cells and their heavy reliance on oxidative
phosphorylation for ATP generation under normal physiological conditions may
make them a target susceptible to metabolic impairment as an initiating factor
and/or a contributor to downstream pathogenesis in IPF.
TGFβ, a growth factor intimately involved in IPF, may also lead to change
in the metabolic status of ATII. TGFβ is produced by multiple cells in IPF lung
including myofibroblasts and ATII cells themselves, and has through recent
investigation been linked to altered mitochondrial function including aberrant
fission and fusion processes in the mink lung epithelial cell line (34) and
organelle fragmentation in renal epithelial cells (33). TGFβ stimulates ROS
generation via activation of NADPH oxidase 4 (NOX4) and inhibits expression of
antioxidant enzymes (38), and in mink lung epithelial cells leads to cell
senescence associated with enhanced ROS generation and inhibition of electron
transport system complexes (34).
IPF is associated with development of pulmonary hypoxia, yet another
avenue through which ATII cell metabolism may be affected by the disease, as
hypoxia leads to suppression of mitochondrial function in ATII cells. Formation of
fibroblastic foci and scar tissue leads to thickening of the alveolar lining and
reduced gas diffusion. This also affects the oxygen exposure of the alveolar
epithelial cells themselves, which are normally exposed to approximately 13%
oxygen. While there is debate regarding the extent to which the pathological
conditions in the IPF lung subject pulmonary cells to reduced oxygen levels, it
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has been shown that HIF signaling is stabilized and active in the IPF lung tissue.
HIFs are the major inducers of the cellular hypoxic response, and it was
demonstrated that pharmacological stabilization of HIFs using a prolylhydroxylase inhibition at 21% O2 induced similar cellular adaptation as exposure
to extreme hypoxia (1.5% O2). Thus, regardless of whether true hypoxic
conditions occur in the lung tissue in IPF, the noted HIF stabilization is likely to
alter the metabolic function of ATII cells.
It has been recently demonstrated that lactic acid buildup occurs in the
IPF lung. Tissue samples from IPF lung showed remarkably consistent elevation
of lactate concentrations over 2-fold greater with a concurrent drop in tissue pH.
The drop in pH associated with enhanced lactic acid contributes to the profibrotic environment of the IPF lung, in that lactic acid buildup lead to activation of
latent TGFβ and myofibroblast stimulation. The cellular source of the excess
lactic acid is unknown. In the healthy lung, lactate is readily removed from the
extracellular space and oxidized for use in energy production by ATII cells.
However, any suppression of mitochondrial function will reduce the ability of ATII
cells to remove lactate from the extracellular space to fuel their own metabolism.
Reduced lactate consumption by ATII cells, paired with the observed upregulation of lactic acid production from fibroblasts following conversion to
myofibroblasts could disrupt normal lactate balance in the lung leading to
extracellular build-up and tissue acidification that promotes fibrosis. Up-regulation
of the LDH5 isoenzyme has been observed in and around fibroblastic foci of IPF
lung, though the cell type in which LDH5 is up-regulated has not been specifically
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determined. LDH5 favors the forward reaction of LDH that generates lactic acid
from pyruvate, thus favoring a more glycolytic, acid-producing cellular phenotype.
The following work utilizes extracellular flux technology to measure cellular
metabolism of ATII cells isolated from IPF patient lung, providing the first realtime, functional-level assessment of the cellular metabolic phenotype associated
with a specific human pulmonary disease.

While many elements of IPF

pathophysiology have the potential to alter cellular metabolism and recent work
suggests that glycolytic lactic acid production is enhanced in IPF lung,
metabolism of cells isolated from diseased lung tissue have not been previously
measured to assess the functional-level impact of the disease. Furthermore,
there is a distinct need to assess cell function in IPF patient tissues because the
currently available mouse models do not recapitulate many important facets of
the pathological changes that occur in the human IPF lung. We report here that
have low overall metabolic function and favor glycolysis. In further support of a
metabolic shift in IPF ATII we find elevated levels of LDH protein, implicating ATII
as one cell population contributing to the previously observed increase in LDH-M
subunit expression in IPF alveolar lung tissue. Additionally, this work begins to
address the role of TGFβ and the extracellular milieu created by myofibroblasts
in driving metabolic changes by exposing model ATII cells (MLE-15) to activated
TGFβ and myofibroblast-conditioned media and examining the resulting
metabolism in vitro.
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5.2 Results
5.2.1 ATII cells isolated from IPF lung have low overall metabolic function.
To examine mitochondrial metabolism in IPF, extracellular flux analysis
was performed on ATII cells isolated from human IPF patient lung tissue samples
and compared to ATII cells from a normal control sample of non-IPF patient lung,
obtained from distal lung tissue donated from a deceased patient with cause of
death unrelated to lung pathology. ATII isolated from IPF lung demonstrated low,
but significant, OCR values compared to control tissue ATII (Figure 5.1). PPR
(Figure 5.2) values were similar between normal and two of the IPF patient lung
ATII preparations, while one patient showed elevated PPR.
ATII cells from IPF lung responded to FCCP injection with enhanced OCR
and PPR, indicating both reserve respiratory and glycolytic capacities (Figure
5.3A and 5.3B). In terms of percentage increase above basal values, Patient 1
and Patient 3 maintained relatively greater spare capacities than Patient 2, with
respiratory capacity similar to those observed previously for MLE-15. Patient 1
also showed remarkable glycolytic capacity, based on a glycolytic response to
FCCP higher than any previously observed in ATII or MLE-15 cells. Patient 2
maintained respiratory and glycolytic capacity, albeit to a lesser degree than the
others.

5.2.2 ATII cells from IPF lung demonstrate a glycolytic phenotype.
To assess the relative dependence on glycolytic versus oxidative
metabolism in IPF lung-derived ATII, the ratio of PPR to OCR was calculated
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from flux measurements. ATII isolated from all IPF patients showed relative
glycolytic function higher than control lung ATII (Figure 5.4). A549 is an ATII-like
cancer-derived line that is heavily reliant on glycolysis for ATP production (142)
and here is shown as a human “positive control” for reliance on glycolysis. IPF
patients showed PPR/OCR ratios approaching those measured in A549 cultures,
with values greater than those observed here for healthy human control ATII, as
well as those reported previously in this work for MLE-15 and primary mouse
ATII (cf., Figure 2.6). Increased PPR/OCR ratios indicate enhanced glycolytic
relative to oxidative metabolism in IPF-derived ATII.
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Figure 5.1: ATII cells isolated from IPF lung have low respiratory function
compared to normal lung ATII. OCR was measured for primary ATII cells isolated from
human patient lung using an XF Extracellular Flux Analyzer. For each patient, ATII cells
were isolated from a single tissue sample, and samples were assayed minimally in
quadruplicate. A single culture of non-IPF control lung ATII cells was analyzed for
comparison. Values are normalized to total protein of wells cultured in parallel.
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Figure 5.2: Glycolytic function of IPF ATII cells is maintained or elevated
compared to control. PPR was measured for primary ATII cells isolated from human
IPF patient lung. For each patient, ATII cells were isolated from a single tissue sample,
and samples were assayed minimally in quadruplicate. A single culture of control lung
ATII was analyzed. Values are normalized to total protein of wells cultured in parallel.
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Figure 5.3: ATII cells isolated from IPF lung maintain reserve respiratory and
glycolytic capacity. To assess reserve metabolic capacity, OCR (A) and PPR (B) were
measured for primary ATII cells isolated from human IPF patient lung following addition
of FCCP to assay media. For each IPF patient, ATII cells were isolated from a single
tissue sample, and samples were assayed minimally in quadruplicate. A single culture of
control lung ATII cells was analyzed. Data represent percentage increase above basal
measurements following FCCP addition.
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Figure 5.4: ATII from IPF lung rely more heavily on glycolysis than control lung
ATII cells. OCR and PPR data were used to generate a PPR/OCR ratio, indicative of
relative glycolytic versus oxidative metabolism. For each IPF patient, ATII cells were
isolated from a single tissue sample, and samples were assayed minimally in
quadruplicate. A single culture of non-IPF control lung ATII was analyzed. A549 were
assayed minimally in quadruplicate per plate with plates run in triplicate.
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5.2.3 IPF ATII cells express high levels of LDH protein.
LDH is a tetrameric enzyme composed of M and H subunits, and each
isoenzyme is composed of a different ratio of LDH-M to LDH-H. Isoenzymes
containing more LDH-M subunits more strongly favor the conversion of pyrvate to
lactate over the reverse reaction. Of all the isoenzymes, LDH5 (composed of
four LDH-M subunits) most strongly favors lactate production. LDH-M expression
is enhanced in fibroblastic foci in IPF lung tissue, although the cell type
responsible is unknown. To examine LDH expression in IPF ATII and address
their contribution to the observed overexpression in the distal IPF lung, total LDH
and LDH-M subunit protein was measured in lysates from one IPF patient
(Patient 3) and compared to expression in lysates from the glycolytic A549 line
as a human control. Both LDH-M and total LDH expression were increased in
ATII from the IPF patient compared to human A549 (Figure 5.5). However, the
ratio of LDH-M to LDH was comparable between human A549 and the patient
sample, indicating that the altered expression was not specific to the LDH-M
subunit, but rather to LDH in general.
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Figure 5.5: ATII cells from IPF lung express high levels of LDH protein. Total cell
protein lysates from a single culture of A549 and ATII cell derived from human IPF lung
tissue (Patient 3) were analyzed for LDH-M and total LDH via western blot. Expression
was normalized to RNAPII as loading control using band densitometric quantification.
Data represent densitometry readings normalized to RNAPII and expressed as
percentage of normalized expression in A549 lysate.
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Myofibroblasts at fibrotic foci secrete cytokines and growth factors that
alter ATII cell function. One of these factors is TGFβ. The following series of
experiments sought to determine whether secreted factors from in vitro TGFβstimulated myofibroblasts and/or TGFβ alone directly contribute to generating the
metabolic phenotype observed in human ATII cells derived from IPF lung tissue.

5.2.4 Treatment of MLE-15 with myofibroblast-conditioned media or TGFβ
decreases LDH protein expression.
To assess whether factors secreted by TGFβ-stimulated myofibroblasts,
or TGFβ itself, induces enhanced expression of LDH in ATII cells, LDH-M and
total LDH were measured in protein lysates from MLE-15 cells cultured with
TGFβ

versus

control,

and

MLE-15

cells

cultured

in

TGFβ-stimulated

myofibroblast-conditioned media versus control. RNA Polymerase II (RNAPII)
was assessed as a loading control and protein expression was quantified via
band densitometry.
Both LDH-M and total LDH subunit content was decreased in response to
myofibroblast-conditioned media and TGFβ treatments (Figure 5.6A & 5.6B).
Based on densitometric analysis, the degree of decrease was approximately
50% for both proteins, in response to both treatments. No difference was
observed in the ratio of LDH-M to total LDH, indicating that expression of LDH
was suppressed in general, versus specific down-regulation of the LDH-M
subunit.

150

5.2.5 Neither TGFβ-stimulated myofibroblast-conditioned media nor TGFβ
alter MLE-15 cell metabolism.
Oxidative and glycolytic function was measured in MLE-15 cells exposed
to either myofibroblast-conditioned media or active TGFβ to assess their role in
generating the suppressed, glycolytic phenotype of ATII cells from IPF lung.
Following 48-hour exposure, neither treatment altered OCR or PPR values
(Figure 5.7 & 5.8).

5.2.6 TGFβ does not affect the response of MLE-15 to hypoxia.
Hypoxic regions develop in IPF lung. Although we did not observe any
change in oxidative or glycolytic function under ambient oxygen conditions, we
next hypothesized that, due to the observed change in LDH and the multiple
potential influences of TGFβ on mitochondrial function, treatment might alter the
cellular adaption to hypoxia. However, MLE-15 treated with TGFβ experienced a
similar response to hypoxia as control (Figure 5.9). In both treated and control
cultures, 20 hour exposure to hypoxia suppressed OCR by approximately 50%,
with no significant change in PPR. This indicates that 48-hour exposure to TGFβ
did not influence the metabolic adaptation to hypoxia.
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Figure 5.6: Treatment with myofibroblast-conditioned media or TGFβ decreases
LDH expression in MLE-15. MLE-15 cultures were treated with myofibroblastconditioned media (A) or TGFβ (B) for 48 hours. Total cell protein lysates were analyzed
for LDH-M and total LDH via western blot and normalized to RNAPII as loading control
using band densitometric quantification. * indicates significance from respective control,
assessed via Student’s T-Test. Error bars represent ± SE.
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Figure 5.7: Treatment with myofibroblast-conditioned media does not influence
glycolytic or oxidative function in MLE-15. Basal OCR (A) and PPR (B) were
measured in cultures of MLE-15 cells treated with TGFβ-stimulated myofibroblastconditioned media for 48 hours. No significant difference was detected between TGFβstimulated myofibroblast-conditioned media treatment and control via Student’s T-Test.
Error bars represent ± SE.
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Figure 5.8: Treatment with TGFβ does not influence glycolytic or oxidative
function in MLE-15. Basal OCR (A) and PPR (B) were measured in cultures of MLE-15
cells treated with TGFβ for 48 hours. No significant difference was detected between
TGFβ treatment and control using Student’s T-Test. Error bars represent ± SE.
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Figure 5.9: TGFβ treatment does not affect the MLE-15 metabolic response to
hypoxia. OCR (A) and PPR (B) were measured in cultures of MLE-15 cells treated with
TGFβ for a total of 48 hours and hypoxia (1.5% O2) for 20 hours. Values represent
percentage change in basal function compared to cultures grown in ambient O2 (21%) in
parallel. * indicates significant difference from ambient control; no difference was
observed between hypoxic vehicle versus treated cultures, based on Student’s T-Test.
Error bars represent ± SE.
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5.2.7 Exposure of MLE-15 to myofibroblast-conditioned media or TGFβ
induces morphological change.
While no measurable change in metabolism was found following TGFβ
and myofibroblast-media treatments, we noted morphological changes as early
as 24 hours after exposure. ATII and ATII-like cells in culture have cuboidal
morphology and grow in a tightly-connected monolayer with a “cobble-stone”
appearance. At 48 hours, treated cells adopted a less cuboidal, more spread cell
shape (Figure 5.10). These changes are reminiscent of an EMT-like response.
Cells maintained little contact with neighboring cells, unlike the pattern of normal
ATII cells in culture that reflects close connection with neighboring cells. Many
cells showed cytoplasmic extensions. Vehicle- treated MLE-15 and those treated
with unstimulated fibroblast-conditioned media showed similar morphology to
MLE-15 cultured in normal HITES media with no exposure.

5.2.8 Exposure to myofibroblast-conditioned media or TGFβ induces
expression of fibroblast and ATI cell markers in MLE-15.
Based on the observation that TGFβ and conditioned media exposure
induced a change in morphology, lysates from treated and control cells were
examined for changes in fibroblast markers and ATI markers to determine
whether the change in morphology was associated with differentiation into a
fibroblast or ATI cell phenotype (Figure 5.11). A small but statistically significant
up-regulation was observed in expression of the ATI marker Aquaporin 5 (Aqp5)
in response to both treatments. Pro-collagen 1a (Pro-Col1a) mRNA expression
was up-regulated significantly in response to TGFβ treatment, while expression
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of Fibroblast-specific protein (Fps) did not change with either treatment. No
change was observed in expression of the ATII cell marker Thyroid transcription
factor (Ttf).

5.2.9 Exposure of ATII to myofibroblast-conditioned media or TGFβ
specifically enhances Spc mRNA expression.
In addition to fibroblast and ATI markers, surfactant protein expression
was measured in lysates from MLE-15 exposed to conditioned media or TGFβ
versus control. Spc expression is specific to the ATII cell phenotype and Spb is
expressed by lung secretory cells (including ATII). Surfactant expression is of
interest for its value as a marker of the ATII cell phenotype, but also because
genetic mutations in Spc are associated with IPF. In both experiments, Spb
expression was similar between TGFβ-treated cells versus control and
myofibroblast conditioned media-exposed cells versus control. Spc mRNA
expression was several-fold higher than respective controls in both cases (Figure
5.12).
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Figure 5.10: Treatment with TGFβ or myofibroblast media alters MLE-15 cell
morphology. MLE-15 Cultures were exposed to TGFβ versus vehicle or TGFβstimulated myofibroblast-conditioned media for 24 or 48 hours. Images were captured
using a light microscope using the 20X objective. Representative images are shown.
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Figure 5.11: ATI and fibroblast marker gene expression is increased in MLE-15
exposed to myofibroblast-conditioned media or TGFβ. MLE-15 cultures were treated
with myofibroblast-conditioned media (blue bars) or TGFβ (red bars) for 48 hours. cDNA
generated from RNA lysates were analyzed for gene expression via qPCR analysis. Fold
change values are based on ΔΔCt calculations using RPL13 as a housekeeping gene
for normalization. * indicates significant fold change (p<0.05) from respective control
based on analysis using Student’s T-Test. Error bars represent ± SE.
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Figure 5.12: Exposure to myofibroblast-conditioned media or TGFβ increases Spc,
but not Spb gene expression. MLE-15 cultures were treated with myofibroblastconditioned media (blue bars) or TGFβ (red bars) for 48 hours. cDNA generated from
RNA lysates were analyzed for gene expression via qPCR analysis. Fold change values
are based on ΔΔCt calculations using RPL13 as a housekeeping gene for normalization.
* indicates significant fold change (p<0.05) from respective control, assessed via
Student’s T-Test. Error bars represent ± SE.
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5.3 Discussion
The evidence presented here demonstrates that mitochondrial metabolism
is impaired in ATII cells derived from IPF patient lung tissues. Oxidative
metabolic function was low in IPF cells, compared to the higher OCR
measurements of ATII cells from human control lung. Additionally, the remaining
metabolic function was more reliant on anaerobic glycolysis than healthy lung
ATII, as evidenced by an elevated PPR/OCR ratio for all IPF patient samples.
IPF ATII more closely resembled the relative metabolic function of the highly
glycolytic A549 in terms of OCR/PPR ratio (although both OCR and PPR
individually were very low rates compared to those observed in A549 cells).
Altogether, this evidence indicates that ATII cells in IPF lung adopt a glycolytic
phenotype that is less metabolic overall.
The many ATP-requiring functions of ATII cells in the healthy lung result in
a high energy demand that could not be served by the severely impaired
metabolism of IPF ATII. Though ATP content of the cells was not measured here,
without dramatic down-regulation of ATP-consuming processes, the energy
demands normally placed on ATII cells could not be met by the remaining
metabolic function. Many studies indicate that a large portion of surviving ATII
cells in IPF undergo senescence, and the low OCR and PPR levels shown here
potentially reflect this change. ATP-consuming functions that would be limited by
low

metabolism

include

surfactant

production,

ion

pumping

and

fluid

homeostasis, and, notably, progenitor function to repopulate both ATII and ATI
cells in the alveoli. In the healthy lung, ATII cells can regenerate wounded tissue
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through division and differentiation within a matter of hours (143), requiring
cellular energetic investment. However, impaired wound healing and aberrant
ATII progenitor function is a hallmark of IPF. Anomalous ATII cell replication and
differentiation has been demonstrated repeatedly in IPF lung, including both
abnormal hyperplasia as well as suppressed replication. As adequate cellular
metabolism is critical for providing ATP and intermediate compounds for DNA
synthesis and replication, we expect that metabolic suppression may be a factor
in the inability of surviving ATII cells to participate in an appropriate wound
healing process, leading to unresolved epithelial injury.
ATII from IPF lung showed high expression levels of LDH-M subunit
protein and total LDH. Increased LDH-M expression has been recently noted in
IPF tissue, with enhanced expression localized approximately to the region of the
alveolar epithelium at fibroblastic foci (94). Other cells in the region of fibroblastic
foci may also increase expression of LDH-M, particularly activated myofibroblasts
as they have been shown in culture to increase both LDH-M expression and
glycolysis in response to TGFβ. However, the data reported here suggest that
ATII cells also increase expression of LDH in IPF. The potential impacts of
increased cellular LDH include enhanced lactic acid generation. Combined with
decreased mitochondrial function, enhanced LDH likely results in shuttling of
pyruvate preferentially into anaerobic conversion to lactate, leading to the high
PPR/OCR ratio in IPF ATII cells. Reduced mitochondrial metabolism limits the
ability of ATII to consume lactate, and this switch from lactate-consumer to
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lactate-producer may contribute to the build-up of lactic acid and drop in lung
tissue pH that occurs in IPF.
Although treatment with TGFβ did not alter metabolic function in MLE-15
cells cultured in ambient oxygen, it did change LDH expression. Surprisingly, the
change observed was in the opposite direction as anticipated; TGFβ and
myofibroblast media exposure effectively down-regulated LDH-M and total LDH
expression by approximately 50%. The ratio of LDH-M to total LDH was not
changed, indicating that LDH protein expression in general was effected with no
specific change to LDH-M versus LDH-H expression. The healthy lung expresses
primarily LDH3, composed of two subunits each of LDH-M and LDH-H. Thus, this
pattern suggests down regulation of LDH expression without a shift in
isoenzyme. Prior work by others has shown the opposite effect in fibroblasts, in
which up-regulation of LDH-M protein was observed following treatment with
similar concentrations of TGFβ. The nature of the difference in response is
unknown, but may represent a fundamental difference in the metabolic response
of either cell type to TGFβ. Indeed, TGFβ has been shown to produce other
opposing effects in fibroblasts versus ATII cells; for example, treatment leads to
apoptosis resistance in fibroblasts, while in ATII apoptosis is induced by
treatment.
Treatment of MLE-15 cells with myofibroblast-conditioned media and with
active TGFβ both resulted in altered cell morphology at 24 and 48 hours of
exposure. Cells lost cuboidal morphology and close contact with neighboring
cells in favor of a more elongated shape with outward cytoplasmic extensions
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from the cell. Often, cells adopted a spindle-like shape, while a small number of
cells grew larger and more spread out, reminiscent of ATI cell morphology.
Altered cell morphology has been previously described in studies of TGFβ effect
on ATII and AEC, and have been associated with transcriptional and protein
markers of EMT. This concurs with data showing enhanced MLE-15 expression
of fibroblast marker Pre-Col1a mRNA in response to TGFβ treatment, though
more direct markers of EMT such as vimentin and αSMA were not assessed
here. TGFβ has also been implicated in ATII cell differentiation into ATI cells (85).
While we observed significantly enhanced expression of the ATI cell marker
Aquaporin 5, the increase was small. This likely reflects the homogeneity of the
cell population following treatment; both fibroblast-like and ATI-like morphologies
were found in treated cultures, with far less appearing with ATI-like
characteristics.
Up-regulation of select fibroblast and ATI cell characteristics was not
accompanied by down-regulation of ATII markers including Ttf, Spb, or Spc (in
fact, analysis showed a concurrent up-regulation of ATII-cell specific Spc). This
suggests that treated cultures adopted a transitional phenotype rather than full
differentiation at 48 hours. Regardless, our findings provide some support for the
conclusion that ATII cells can undergo EMT in response to TGFβ; however, the
extent to which this occurs, if at all, in vivo is hotly debated. Proponents argue
that TGFβ-induced EMT by ATII Cells contributes to the large pool of fibroblasts
in the lungs of IPF patients, a view supported by multiple in vitro observations like
those reported here. However, in vivo labeling and immunohistochemistry studies
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are conflicting regarding the co-localization of ATII and fibroblast markers. Our
observations may be extended in the future using primary ATII cells, which are
likely to be more sensitive to the effects of TGFβ compared to the immortalized
MLE-15 cell line.
Both treatments also unexpectedly induced up-regulation of SPC mRNA.
This effect was specific, as Spb expression was unchanged, suggesting that upregulation may be related to a downstream function other than enhanced
production of complete surfactant. Spc is specifically expressed in ATII and in
addition to its well-defined role in mediating lipid spreading in the biophysical
function of pulmonary surfactant, mounting evidence suggests that SPC has
innate immunological function as well (144). Spc is associated with suppression
of inflammatory activity through multiple mechanisms including direct binding of
LPS in the extracellular milieu and, in macrophages, inhibiting activation of TollLike Receptors (5). On the other hand, Spc-deficient mice experienced more
severe fibrosis following bleomycin challenge, indicating a potential protective,
anti-fibrotic role for SPC up-regulation in the human IPF lung (145). Of the
genetic mutations associated with IPF, mutations in the human gene encoding
SPC are some of the more commonly found. SPC mutations associated with IPF
lead to protein aggregation, activation of the UPR, and ER stress leading to ATII
cell apoptosis. Thus, enhanced expression of mutated SPC proteins would be
predicted to aggravate ATII cell stress by generating more protein aggregates
within the cell. This effect of TGFβ exposure should be examined at the level of
protein expression to determine whether enhanced SPC protein expression
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occurs, and if enhanced SPC expression is accompanied by an increase in
complete surfactant production. Future experiments will examine the effect of
TGFβ exposure on surfactant protein expression in primary ATII, as MLE-15
express these proteins but do not process, package, and secrete pulmonary
surfactant in the same manner as primary cells.
Given the similarity in response to the two treatments, both in
morphological change in the trends in mRNA expression, it is likely that the
effects are due to a great degree, but not entirely, to active TGFβ. In the
myofibroblast-conditioned media, the presence of TGFβ may be due either to the
presence of remaining TGFβ used originally to stimulate the fibroblasts, or to
secretion of TGFβ by the myofibroblasts. Regardless of the source in these
experiments, TGFβ is an undisputed element of the pro-fibrotic environment in
IPF. Previous study has demonstrated that TGFβ induces hallmarks of EMT in
AEC exposed in vitro (146), although there is still intense debate regarding the
contribution of EMT to the fibroblast population in IPF.
In summary, we demonstrate here that ATII cells isolated from IPF are
metabolically suppressed, showing low oxidative metabolic function with high
rates of glycolysis relative to mitochondrial function. A growing body of literature
has examined various elements of the disease process that have potential to
influence ATII cell metabolism, including ER stress; ROS production by
fibroblasts, immune effectors, and ATII cells themselves; and even direct
mitochondrial DNA damage downstream of TGFβ signaling. However, these
effects have not previously been linked to functional-level metabolic change in
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ATII cells in patient lung tissue. The fact that ATII cells show suppressed
mitochondrial metabolism holds important implications for their function in the
affected lung tissue. This phenotype may contribute to the inability of ATII cells to
appropriately respond to alveolar damage through replication and differentiation
due to decreased ATP supply. Furthermore, impaired mitochondrial metabolism
limits ATII cells’ ability to import lactate and protons from the extracellular space,
an observation reported elsewhere in this work concerning suppression of
mitochondrial respiration in hypoxia. Therefore, reduced capacity to act as a sink
for lactic acid in the lung potentially contributes to the build-up recently observed
in IPF lung tissue. As the associated drop in pH is a direct driver of the disease
pathogenesis through activation of TGFβ in the extracellular milieu, we propose
that reduced lactate consumption by ATII is an important factor in IPF
progression.
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CHAPTER 6. CONCLUSION AND DISCUSSION:
ATII CELL METABOLISM & METABOLIC CONTRIBUTION
TO HYPOXIA-RELATED PULMONARY DISEASE

This body of work has investigated the metabolic phenotype of ATII cells
in health and hypoxia. The work presented here demonstrates that lactate is an
important metabolic substrate for ATII cell energy production, confirming and
extending findings from landmark studies that suggested lactate consumption in
pulmonary tissue. ATII cells import and utilize lactate for use as substrate for
mitochondrial ATP production, pointing to a critical role for ATII metabolism in
maintaining the normal balance of lactic acid in the pulmonary parenchyma by
acting as a sink for lactate and protons. Hypoxia, and likely any insult that
suppresses mitochondrial function, impairs this capability. Finally, these
mechanisms are connected to the disease state of the epithelium in idiopathic
pulmonary fibrosis: mitochondrial metabolism is suppressed in ATII cells isolated
from IPF lung tissue, and their ability to remove lactate from the extracellular
space is reduced. As lactic acid build-up and tissue acidification may be
causative forces in the development of the disease, the findings presented here
hold significance for understanding the early events that contribute to the profibrotic environment that drives IPF progression. In summary, this work suggests

an important role for ATII cell metabolism in IPF and, potentially, other lung
diseases related to pulmonary hypoxia.

6.1 ATII cell metabolic phenotype & adaptation to hypoxia
Based on the work presented here, ATII cells have a highly metabolic,
oxidative cellular phenotype and depend on mitochondrial metabolism and
oxygen consumption to maintain energy balance. We provide evidence that MLE15 cells provide a useful in vitro model for primary ATII cell metabolism. Although
MLE-15 cells appear to be less metabolic overall than primary mouse ATII cells,
relative reliance on oxidative versus glycolytic function was similar between the
cell types. Primary ATII cells operated closer to maximal metabolic capacity than
MLE-15, and there are several reasons that this may be. First, MLE-15 cells are
immortalized and have been cultured in vitro for many passages, while primary
ATII cells were assayed within days of isolation. ATII cells serve many
metabolically-demanding functions in the lung including surfactant production.
While MLE-15 cells express the proteins involved in surfactant production and
packaging, they do so to a lesser degree than primary ATII cells and generally
produce little complete surfactant. We suspect that this leads to a lower energy
demand in MLE-15, as they are not undergoing the same demanding functions
as primary ATII cells. Furthermore, primary ATII cells were plated onto Matrigel
and cultured with the growth factor keratinocyte growth factor (KGF), both of
which are meant to maintain primary ATII cell functions.
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ATII cell respiration is suppressed in hypoxia by decreased energy
demand and direct suppression of mitochondrial function (indicated by the
intermediate level of respiratory capacity). While ATII cells adopt a more
glycolytic phenotype in response to hypoxia, it is likely due to decreased
mitochondrial energy production and not to enhanced anaerobic glycolysis, as
glycolytic output appeared to be similar to ambient conditions in MLE-15 and
modestly decreased in ATII cells by hypoxic exposure.
Despite a lack of enhanced glycolytic output, we observed transcriptionallevel adaption that seemingly would favor enhanced flux through glycolysis, as
expression of several key glycolysis pathway enzymes were enhanced. The
array findings reported here confirm and extend previous reports of expression
change in genes involved in glucose metabolism in response to hypoxia. Several
enzymes involved directly in glycolysis were up-regulated, including Hk2 and
Gapdh. Again, however, lactic acid generation was similar between cells cultured
in ambient and oxygen and hypoxia (1.5% O2). We propose that the observed
pathway re-arrangements are part of the initial response to hypoxia, driven by
HIF1 prior to its decline. Several early (<6 hours’ exposure) responses to hypoxia
in ATII cells have been determined including endocytosis of Na+/K+ ATPase via
AMPK activity (24) and down-regulation of transporter expression, and enhanced
glucose transporter expression and increased glucose influx (52). These studies
show that HIF1 and non-HIF responders drive the initial response to hypoxia.
HIF2 is also stabilized early and probably involved in the early response, but
temporal control of HIF2 target genes has not been examined in short-term
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hypoxia in ATII cells. Due to AMPK and HIF1 activity, the early response to
hypoxia likely does involve enhanced glycolytic flux and lactic acid generation.
Ouiddir and colleagues demonstrated that ATP levels initially do decrease in
AEC exposed hypoxia, and this probably drives an initial increase in glycolysis to
restore ATP levels facilitated by enhanced expression of glycolytic enzymes (52).
However, we demonstrate here that ATP concentrations return to levels
comparable to those in ambient O2 culture by 20 hours of exposure and that the
lasting impact of hypoxia does not involve elevated glycolysis.
Glycogenic enzymes were up-regulated in response to hypoxia, and the
consequence of this was confirmed at the functional level by measuring an
increase in cellular glycogen content. This explains the fate of a portion of
glucose consumed in hypoxia. Previous investigations have shown enhanced
expression of glucose transporters and glucose uptake in hypoxic conditions. Our
results indicate that enhanced glucose consumption serves the process of
glycogen storage, and possibly other pathways of glucose metabolism not
addressed here, rather than enhanced anaerobic lactate production. Glycogen
production and storage is an important step in ATII maturation in the developing
lung, and both storage and utilization of glycogen by ATII in the fetal lung have
been associated with HIF2 signaling (41).
The maintenance of ATII spare respiratory capacity is an important
component of the cell-specific response to hypoxia. MLE-15 cells maintained a
mitochondrial reserve capacity slightly lower than cells in ambient culture in
terms of percentage above basal, and reserve capacity was similar in primary
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ATII under both conditions. Addition of the prolyl-hydroxylase inhibitor DMOG to
MLE-15 elicited a similar response. Thus, in hypoxia and HIF stabilization under
ambient O2 conditions, ATII cells retain mitochondrial capacity above basal
function. The concept of reserve capacity was originally elucidated in neuronal
studies, in which it was shown that neuronal maintenance of mitochondrial
reserve capacity is determinant in the ability of cells to respond to increased ATP
demand without succumbing to stress. The importance of mitochondrial spare
capacity in cells’ ability to handle stress has been implicated in neurological
disorders like Huntington’s Disease in which electron transport chain dysfunction
limits mitochondrial capacity (124), and has also been recently demonstrated to
play a role in photoreceptor cell death induced by oxidative stress. Photoreceptor
cells treated with reagents to induce cell stress lost reserve capacity prior to any
indication of cell death, and the proportional reduction of reserve capacity
correlated with the eventual degree of cell death observed (147). This highlights
the importance of reserve capacity in response to cellular stressors, and
maintenance of mitochondrial reserve may very well contribute to the remarkable
tolerance of ATII cells under hypoxic environments.
The maintenance of some spare mitochondrial reserve by ATII cells
exposed to hypoxia or DMOG is a very different response from that observed in
cardiomyocytes, in which DMOG treatment completely abolished reserve
capacity. While treatment resulted in suppressed basal oxygen consumption in
both cell types, ATII maintained spare respiratory capacity while cardiomyocyte
reserve was completely abolished (111). Maintenance of respiratory capacity in
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particular may influence thus ATII cell resistance to stress in these conditions
and result in exceptional resistance to hypoxia. However, the factors through
which reserve capacity is maintained in ATII where it is lost in other cell types
have not yet been determined.
Experimental knock-down of HIF1 expression in cardiomyocytes exposed
to DMOG restored spare capacity, indicating a key role for HIF1in “clamping”
respiration at basal levels. MLE-15 cells likewise lose expression of HIF1
following 8 hour exposure, and maintain reserve in the absence of HIF1 at 20
hours. In this manner, loss of HIF1 in DMOG-treated cardiomyocytes
recapitulated our observations of 20-hour DMOG treatment in MLE-15. This
provides indirect support for the concept that the natural down-regulation of HIF1
by ATII in long-term hypoxia results in a unique adaptive response driven by
HIF2. HIF2 drives expression of anti-oxidant enzymes, which may help prevent
ROS build-up associated with mitochondrial function under hypoxic conditions,
therefore supporting basal and spare mitochondrial function by preventing
oxidative stress.
Because mitochondrial metabolism could not be stimulated to the levels of
respiration observed in ambient O2 culture, there is direct suppression partially
limiting mitochondrial metabolism. This may reflect a change in mitochondrial
population dynamics. Reduced citrate synthase has been observed in A549 cells
(used as model ATII cells in that study) exposed to 24 hour hypoxia, suggesting
reduced mitochondrial mass (23). This could conceivably result in the
proportional suppression of basal respiration and reserve capacity. Further
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analyses of mitochondrial population dynamics have not been performed in
hypoxia-exposed ATII cells, and this represents a rich avenue for further study,
initially through quantifying mitochondrial number and size, mtDNA content, and
respiratory enzyme content; and secondarily through investigation of drivers of
mitochondrial biogenesis (ie, PGC1α-mediated transcription) and autophagy.
Substrate limitation for mitochondrial respiration could also contribute to
suppression of basal and reserve respiration. Array results detected upregulation of PDK, which reduces pyruvate entry into the TCA cycle via
phosphorylation of pyruvate dehydrogenase. This would serve to limit
mitochondrial substrate availability and promote pyruvate metabolism to lactic
acid by LDH. Substrate limitation due to enhanced PDK may be a mechanism
through

which

mitochondrial

function

is

reduced

in

hypoxia.

Future

pharmacological interference with PDK function under physiologic normoxia and
hypoxia will help to elucidate the role that PDK plays in control of ATII
mitochondrial metabolism under oxygen limitation.
The avoidance of enhanced lactic acid generation, maintenance of spare
respiratory capacity, and overall robust resistance to hypoxic damage observed
in ATII cells here and in previous works may be an effect of mounting a HIF2mediated response and limiting HIF1, which as discussed leads to enhanced
glycolysis and loss of spare respiratory capacity in other cell types. HIF2
expression is localized to a limited number of isolated cell populations in the
body. In the lung, only ATII and vascular endothelial cells express this HIF
isoform, while fibroblasts, macrophage, ATI cells, and cells composing non175

alveolar tissue do not. HIF2 regulates an overlapping but distinct set of genes
related to control of cellular metabolism that seems to be associated with a
storage-and-maintenance phenotype, involving glycogen storage and reduced
lipid consumption in combination with enhanced antioxidant enzyme activity.
Investigation of the consequences of HIF2 on the long-term response of ATII
cells to hypoxia presents an interesting venture for future work. Efforts to knockdown HIF2 expression in MLE-15 utilizing RNA interference techniques are
currently underway, with plans to assess metabolic function via similar flux
assays to those reported here. As HIF2 has been implicated in helping to
mediate the decrease in HIF1 over longer periods of hypoxia, we predict that
HIF2 knock-down cells will maintain HIF1 over time in contrast to the pattern of
expression in wild-type ATII cells. Flux assays using these cells will permit
examination HIF2α’s in reducing mitochondrial respiration without glycolytic
compensation, as well as the potential role in maintaining cellular metabolic
reserve.

Caveats & other considerations
True normoxia for the lung (and therefore, for ATII cells) is not ambient O2
(21%). Rather, normal O2 levels in the healthy mature lung are estimated in the
range of 5-15% (depending on altitude, physical fitness, and the point of
expiration/inspiration cycle, among other factors). Consequentially, in this work
and in essentially all studies of hypoxia reported in the literature to date, control
conditions do not accurately reflect the exposure of cells in vivo. Rather, 21% O2
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represents a mildly hyperoxic condition for ATII cells. Therefore, it is with some
caution that we report here the “normal” phenotype of ATII cells, as well as the
magnitude of change in response to hypoxic exposure. It is possible that ATII cell
metabolism is different under physiologic normoxic conditions for the tissue,
although this value is well above the estimated threshold at which mitochondrial
metabolism is limited by O2 availability. Although HIF stabilization is maximal at
<1% O2, stabilization does occur to some degree over the range of 1-21% in a
graduated manner inversely proportional to oxygen concentration. Thus,
exposure to normoxic conditions that truly mimic the in vivo oxygen exposure
may lead to a different pattern of HIF stabilization and transcriptional control
compared to ambient oxygen exposure. Subtle differences in HIF could
conceivably influence metabolism, and may more robustly promote ATII cellspecific functions that occur in the healthy mammalian lung compared to the
subtly hyperoxic ambient levels. Indeed, though metabolic flux has not yet been
compared between ambient and normoxic oxygen exposures, preliminary
experiments from our lab indicate that culture in 13% O2 results in enhanced
surfactant protein expression in MLE-15 cells, which in standard 21% O2 culture
produce surfactant at lower levels than primary cells. Alternatively, low-level HIF
stabilization and other factors like the balance of stabilized isoforms and the
negative regulation between HIF1 and HIF2 (and potentially HIF3) may prevent
HIF-mediated effects on metabolism in the normoxic range of 8-15% O2. This will
be an extremely important avenue for investigation concerning fundamental ATII
cellular biology.

Experiments comparing metabolic flux of ATII cells across
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graded oxygen concentrations are underway using primary ATII cells and MLE15.
It is important to consider that other sources of extracellular proton
production exist aside from glycolytic lactic acid generation. A major contributor
to media acidification in culture is evolution of CO2 due to respiration. Thus, even
if a cell was solely reliant on mitochondrial respiration (i.e., under experimentally
inhibited glycolysis), some degree of extracellular acidification could still be
observed. Additionally, other acids may be released into the cytosol, contributing
to PPR. Given our unexpected findings regarding the lack of PPR change in
response to hypoxia exposure or PHI, we specifically measured lactate in the
culture media of MLE-15 cells following culture in hypoxia versus ambient oxygen
to determine whether the PPR observed in flux measurements in fact be
attributed to lactic acid generation. Not only was no difference found in lactate
production by MLE-15 cells under the different culture conditions, but also
measured rates of lactate production over time that, when converted to
comparable units, almost exactly matched the PPR data from flux experiments
given that one proton is extruded per molecule of lactate. Using the 2-hour time
point from lactate measurements, the rate of lactate generation is approximately
27 pmol H+/min/µg protein. This correlates extraordinarily well with the
extracellular flux PPR values that ranged from approximately 22-32 pmol
H+/min/µg protein, and provides strong support for conclusions based on PPR
data indicating that lactic acid generation is the primary contributor to
extracellular acidification by MLE-15 cells. Similar lactate measurements were
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not performed using primary ATII cells, and we recognize that it is possible that
primary ATII cells, particularly given their higher observed rate of respiration, may
have other factors in addition to lactic acid generation contributing to PPR.
The fundamental studies reported here rely on mouse primary cells and
the MLE-15 cell line. As with many studies that utilize mouse as a model
organism, there remains uncertainty as to the suitability of mouse as a model for
human cellular metabolism. The lungs in particular represent a critical point of
species-specific differences between mouse and human, in that the respiratory
rates of the organisms are vastly different. In addition, lung development in mice
and humans progresses very differently, with human alveolarization occurring
prior to birth in the relatively low-oxygen conditions of the in utero environment,
while considerable development in mice occurs after birth. Thus, it is conceivable
that the normal, basal rates differ between the species, as well as their response
to hypoxia. The similarity of basal OCR rates in the single population of ATII cells
from the normal human patient to those observed for MLE-15 cells is
encouraging. However, this does indicate that OCR levels in the human primary
ATII were lower than the mouse primary cells. Comparison of the PPR/OCR ratio
provides an indication of relative reliance on glycolytic versus oxidative metabolic
pathways. In terms of PPR/OCR ratio, the normal human ATII culture showed a
ratio of approximately 1, indicating robust reliance on oxidative metabolism. In
mouse primary cells, this ratio was approximately 2, indicating slightly more
glycolytic production. As the human value reported here is based on a single
culture, it is difficult to draw conclusions based on this data alone. Differences in
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instrumentation may also contribute to this difference; analysis of mouse was
performed using the XF24 instrument, while human samples were assayed using
the XF96 platform. Anecdotally a slight increase was observed for OCR readings
in MLE-15 cells assayed on the XF96 compared to the XF24, the effect of which
would be a lower PPR/OCR ratio. Side-by-side comparison of mouse and human
primary cells will resolve this issue for future study; however other species may
better model the human lung and cellular metabolism. Pig lung more closely
represents human in structure and developmental timing, and as a large
mammalian species their respiratory rate is closer to that of humans. Numerous
assessments of body metabolic rate in mammalian species have shown that
basal body metabolic rate is a function of body size, supporting the use of larger
mammals for modeling human metabolism (148). It is expected that planned
extracellular flux analysis of ATII isolated from cryopreserved pig lung tissue
samples will closely mimic measurements in normal human ATII, specifically
supporting the use of pig for modeling fundamental human lung cell metabolism.
The observation that treatment with the PHI compound DMOG elicits
similar results to hypoxia in terms of metabolic flux (and other measured
parameters) suggests that HIF transcriptional control drives the observed effects
of 20-hour hypoxia exposure. PHI has been previously shown by our lab to
stabilize HIFs in MLE-15 cells in a similar manner to hypoxia: HIF1 and HIF2 are
both stabilized early following PHI, whereas beyond 8 hours HIF1 expression
declines while HIF2 remains stable. Using culture conditions similar to these
earlier studies, we observed similar metabolic effects to hypoxia. However, as
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HIF protein was not measured or manipulated directly, this work is limited in its
ability to draw conclusions regarding the role of HIFs in general, as DMOG and
other mechanisms of PHI can have off-target (non-HIF) effects. Also, despite
similar culture conditions, without measuring HIFs directly we cannot conclusively
say that the pattern of stabilization was identical to the prior studies.
Furthermore, while previous work from this lab and others has identified HIF2 as
the major isoform present in ATII cells in chronic (20 hour) hypoxia, it is not
possible from the experiments performed here to determine how HIF1 versus
HIF2 mediates the metabolic effects of long-term hypoxia in ATII cells.
To tease apart the contributions of HIF1 versus HIF2, it will be necessary
to directly manipulate expression of either isoform in ATII cells. Work has been
performed in hepatocytes, with the same goal of isolating the effects of HIF2 on
hypoxia-induced lipid storage, using mice genetically engineered for knockdown
of VHL/HIF1 or VHL/HIF2 (VHL knockdown leads to HIF stabilization regardless
of oxygen exposure). Using a similar scheme, either by RNA interference in ATII
cells or ATII cell isolation from lungs of knockdown mice, ATII cells expressing
only HIF1 or HIF2 can be compared to wild-type. We hypothesize that ATII cells
devoid of HIF2 and expressing only HIF1 would have a robust up-regulation of
glycolytic acid generation in response to hypoxia (or DMOG) and loss of
mitochondrial reserve, contrary to our observations in wild-type ATII but similar to
the effects of hypoxia in other cell types that do not express HIF2. They may also
demonstrate higher levels of apoptosis and cell death, as HIF2 mediates
expression of SOD and other antioxidant enzymes that prevent mitochondrial
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and cell damage. The different roles of HIF1 and HIF2 (and even HIF3) have
recently come under investigation in lung development, during which the different
isoforms appear to play different roles in development of lung structure and the
surfactant system. Building on our findings to date concerning the metabolic
response of ATII cells to hypoxia by identifying distinct roles of HIF isoforms will
greatly inform these developmental studies.

6.2 Lactate shuttling in the alveolar epithelium
Lactate import and oxidization for use as fuel for mitochondrial electron
transport require active mitochondria and rapid respiration, high NAD+/NADH
ratios (which goes hand-in-hand with rapid electron transport), and a gradient of
lactate favoring transport into the cell. Based on observations presented herein
regarding

the

ATII

metabolic

phenotype

and

combined

with

previous

observations of whole lung metabolism, lactate consumption by ATII cells was
investigated in detail. The findings presented here provide support for the
concept of an intercellular lactate shuttle in the lung, analogous to lactate
shuttling that is known to occur between neighboring glycolytic and oxidative cell
types in the brain and skeletal muscle.
By definition, cell-cell lactate shuttles require a cellular lactate source and
lactate sink. This work has provided evidence that ATII cells serve as a lactate
sink in the lung, utilizing extracellular lactate to fuel their own mitochondrial
metabolism. Brooks et al have provided conclusive evidence that lactate is
removed from blood across pulmonary circulation, indicating that blood flow
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through alveolar capillary beds provides a likely source of lactate for ATII
metabolism. Adjacent cells in the alveolar tissues may also provide a nearby
source of lactate that directly feeds ATII. Metabolic flux has not specifically been
measured in pulmonary fibroblasts using in vitro extracellular flux analysis for
comparison. Flux measurements performed using human dermal fibroblasts
indicate that they are less oxidative than mouse ATII cells, however whether this
difference is truly due to cell-specific differences cannot be concluded, as
species-specific

differences

in

cellular

metabolism

may

exist.

Other

measurements using isolated pulmonary fibroblasts showed that they generate
extracellular lactate, and that stimulated pulmonary fibroblasts produce higher
levels (94). ATI cells, which occupy the vast majority of the alveolar epithelial
surface, contain mitochondria based on microscopic assessment but have long
been considered to serve a relatively passive role in the lung, specifically as the
primary site of gas exchange. Their metabolic phenotype is also unknown, but as
terminally differentiated cells with limited ATP-demanding function, individual
cells are most likely not very metabolic compared to individual ATII cells. On the
other hand, given their expansive surface area, they may contribute significantly
to local lactate production. Therefore, it remains to be seen whether neighboring
ATI cells, fibroblasts, or other pulmonary cells provide lactate for ATII cell
consumption. Flux analysis for comparison to ATII measurements and,
eventually, cell type co-culture will be necessary to further define how local
metabolic cooperation between cell types influences lung tissue homeostasis.
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A critical role for MCT-mediated transport in ATII cell metabolism has
been identified in these studies. MCT function mediates both export of lactic acid
produced by anaerobic glycolysis and the import of lactate for conversion to
pyruvate and subsequent use in mitochondrial reactions. MCT1, the isoform
previously associated with import of lactate into oxidative cells of heart and
skeletal muscle, is specifically expressed by ATII cells and is likely responsible
for a significant amount of lactate uptake into pulmonary tissue. MCT1
expression is not affected by hypoxia in ATII at the level of mRNA or protein, a
pattern which is similar to the gene’s expression in muscle but is unlike the
hypoxia-inducible expression observed in adipocytes. However, MCT expression
does appear to be regulated by exposure to extracellular lactate, as culture in
media formulated with lactate leads to increased concentration of MCT1 mRNA.
The ability of lactate to stimulate MCT1 expression has previously been observed
by Brooks and colleagues in other cells that oxidize lactate, and lead them to
coin the term “lactormone” to describe the ability of lactate to regulate
transcriptional responses. The manner in which lactate mediates these changes
has not been investigated directly, but the observation that lactate can generate
ROS suggests a mechanism through which cell responses may be initiated by
lactate ultimately leading to expression changes (27).
Based on this work, we propose that ATII cells consume lactate from the
pulmonary circulation and/or from the extracellular space produced by
neighboring cells to fuel their own mitochondrial ATP production (Figure 6.1A).
Under normal physiological conditions, lactate produced by neighboring glycolytic
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cells (and/or delivered via pulmonary circulation) is removed from the
extracellular space by ATII cells. Lactate is imported via MCT1 transport proteins,
which favor monocarboxylate influx. Lactate is then converted to pyruvate
through the activity of LDH. Reverse activity of LDH reduces NAD+ to NADH and
oxidizes lactate to generate pyruvate. Pyruvate is rapidly used by ATII cell
mitochondria to generate reducing equivalents via TCA cycle reactions, which in
turn fuels electron transfer and oxidative ATP production. In this manner lactate
build-up in the pulmonary tissue is avoided, with lactate instead being used to
fuel ATP generation in ATII cell with high mitochondrial function and ATP
demand.
Based on our findings, lactate serves as a metabolic substrate for
mitochondrial metabolism. Surfactant production requires intermediates of
mitochondrial metabolism to generate acetyl-CoA molecules for de novo lipid
synthesis. Landmark studies that originally investigated the utilization of lactate
by the lung found that, when provided in perfusate using the isolate perfused rate
lung model, labeled lactate was rapidly incorporated into lung lipids. Furthermore,
when lactate and glucose were provided

simultaneously, lactate was

preferentially incorporated into acetyl subunits of lung lipids, while glucose was
incorporated primarily as glycerol moieties. This pattern provides support for
lactate use in mitochondrial metabolism, but importantly demonstrates a specific
role for lactate metabolism in surfactant production.
In accordance with findings presented here and those from previous
studies using labeled lactate, we propose that mitochondrial lactate metabolism
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by healthy ATII cells is an important component of normal surfactant production.
Both lactate and glucose are consistently available to ATII cells in vivo; estimates
from tissue samples have estimated total lactate at approximately 2 mM in
healthy lung. In the local cellular milieu of ATII cells, this may be even higher due
to glycolytic function of neighboring cells. Furthermore, the lung experiences
comparatively low oxygen in utero, but high local lactate concentrations. Given
elevated availability in utero, we expect that lactate serves as a critical substrate
for energy and surfactant lipid production during late lung development.
It is notoriously difficult to maintain production and secretion of surfactant
by ATII cells in vitro. In light of results reported here, this may be an effect of the
substrate that is normally provided in culture; in general, primary ATII cells are
cultured in high-glucose media (>11 mM) that is changed regularly. Extremely
high levels of glucose and low levels of lactate potentially disrupts the normal
surfactant production pathways by limiting lactate metabolism. Based on studies
by Rhoades, Wolfe, and others that followed the fate of carbons from labeled
lactate and showed incorporation into the acetyl moiety of lung lipids, lactate may
be important in generating the lipid component of surfactant. As a transcriptional
regulator or “lactormone” it could also play a role in controlling expression of the
surfactant proteins as well. Studies are currently underway in this laboratory to
assess the effect of lactate supplementation to culture media on surfactant
protein gene expression in model and primary ATII cells, based on the
hypothesis that lactate availability will enhance expression. The concept that
lactate is both a substrate for ATII cell metabolism and a potential transcriptional
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regulator holds significance for both surfactant homeostasis in the mature lung
and regulation of alveolar development and surfactant production in the
developing lung.

Caveats & other considerations
This work has shown that ATII cells can utilize lactate to fuel mitochondrial
metabolism, and the finding that lactate, when provided simultaneously with
glucose, alters glycolytic metabolism in a dose-dependent manner suggests that
lactate is used simultaneously with glucose to fuel respiration. It is clear from
these findings that the availability of lactate alters glucose metabolism, but
despite previous evidence from whole-lung study that strongly supports use of
lactate in place of some glucose for respiration, further study is necessary to
definitively conclude that ATII cells consume lactate in the presence of glucose.
To quantitatively assess the extent to which lactate is utilized when glucose is
also present, it will be necessary to measure uptake of substrates using LC/MS
to quantitate glucose and lactate removal from culture media over time.
Also unknown is the fate of lactate in the cell aside from TCA cycle
metabolism to fuel electron transport. Previous work has indicated that lactate
oxidized by lung tissue is readily incorporated into lung lipids. This suggests that
a large portion of lactate consumed by ATII cells may be diverted from the TCA
cycle and instead incorporated, as acetyl subunits, into surfactant lipid.
Furthermore, when lactate and glucose are provided simultaneously, the acetyl
moiety of lung lipids is almost entirely derived from lactate. Thus it is of interest to
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determine the fate of lactate consumed by ATII, particularly to examine its
incorporation into surfactant lipid. Nuclear Magnetic Resonance (NMR)-based
metabolomic studies of culture media formulated with

14

C-labeled substrates

would be one approach to address these questions.
Intercellular lactate shuttles depend on the presence of both lactate
producers and lactate consumers. While the early studies of lung lactate
consumption measured utilization of lactate taken up from pulmonary circulation,
these investigations, by nature of the whole-lung model, could not assess lactate
shuttling between pulmonary cell types. Accordingly, further development of the
concept of ATII cells as lactate scavengers in the lung will require a thorough
understanding of metabolic function of other, neighboring pulmonary cell types,
including fibroblasts and ATI cells. ATI cell metabolism has not been measured.
Comparison of OCR values from ATII cells in this work to measurements from
human dermal fibroblasts performed by others suggest that fibroblasts are less
oxidative, although differences in species-specific cell metabolism may be a
contributing factor. Future characterization of ATI and fibroblast metabolic
function using XF technology for accurate comparison to our findings will greatly
inform the concept of lactate shuttling in the lung, and of coordinated metabolism
in lung tissue as a whole.
MCT1 protein expression was measured in MLE-15 lysates compared to
mouse skeletal muscle as control. When protein isolated from skeletal muscle
was probed with anti-MCT1 antibody, the resulting blot appeared to have two
bands of very similar size in the appropriate size range for the MCT1 protein.
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However, this second band was not apparent in lysates from MLE-15 cells. The
nature of this discrepancy is unknown, and maybe an effect of alternative posttranslational

modifications,

as

there

are

multiple

phosphorylation

and

ubiquitination sites in the MCT1 protein. Additionally, while MCT1 and MCT2 tend
to be expressed in highly oxidative cell types in mouse and human, species
differences have been noted regarding which isoform (MCT1 or MCT2) is more
abundantly expressed. Here, only MCT1 expression was assessed. MCT2
protein has been found in whole lung protein lysates, and may be expressed
alongside MCT1 in ATII cells, contributing to the import of lactate.
CHC inhibits all MCT isoforms at the cytosolic membrane. Therefore,
while the changes in metabolic flux following CHC addition demonstrate the
importance of MCT to ATII cell metabolism in general, this work does not
differentiate between the different isoforms in terms of contribution to lactate
output and/or input. An MCT1-specific inhibitor has been recently developed, and
could be used to examine flux in response to MCT1 inhibition specifically. We
expect that this form of inhibition would decrease respiration utilizing lactate, as
this would inhibit the isoform strongly associated with lactate import. However, if
other isoforms are also expressed by ATII cells, they may compensate for loss of
MCT1 function, as all MCTs transport lactate bi-directionally to some degree.
The intracellular location of lactate oxidation to pyruvate remains
unknown. While LDH is predominantly located in the cytosol, it has also been
found in peroxisomes and, more recently, in the mitochondria of rapidly respiring
cells. There is ample evidence from studies of lactate shuttling in muscle and
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brain tissue to support the existence of a “mitochondrial lactate oxidation
complex” composed of LDH, MCT, cytochrome oxidase, and supporting
structural proteins at the inner mitochondrial membrane. In this proposed
scenario, lactate is imported into the mitochondria prior to oxidization, after which
the oxidizing environment created by cytochrome c oxidase activity promotes
conversion to pyruvate. Our work on ATII cells cannot differentiate between
cytosolic, peroxisomal, and mitochondrial lactate oxidization, and this remains an
interesting question for future work. Assessing the presence and interaction (via
co-immunoprecipitation) of LDH and MCT proteins in purified mitochondrial
subcellular fractions will determine whether this complex exists in ATII cells as in
oxidative muscle and brain cell types. Additionally, measuring oxygen
consumption of ATII cell mitochondria purified and exposed to lactate as sole
metabolic substrate will demonstrate the ability of mitochondria to utilize lactate
directly. If there is measurable OCR linked to ATP production in mitochondria in
the presence of lactate alone, this would provide strong support for a
mitochondrial mechanism of lactate consumption.

6.3 ATII metabolism in IPF lung
As discussed, many of the initial forms of injury to the epithelium that are
under investigation have potential to alter mitochondrial function in epithelial
cells, often acting ultimately through ROS production. However, prior to this work,
metabolism of ATII cells from IPF lung had not been directly assessed to
determine the functional-level consequences. Only recently was metabolic
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function of IPF fibroblasts explored to determine the consequences of
myofibroblast activation. Based on our findings reported here, IPF ATII cell
oxidative metabolism is suppressed compared to control cells isolated from
normal control patient lung tissue, while glycolytic metabolism is relatively
maintained or enhanced in the disease-conditioned ATII. Strikingly, IPF-derived
ATII maintain reserve capacities, similar to those observed in the MLE-15 healthy
ATII model cells. Though the nature of mitochondrial suppression is not
determined in these studies, given their robust spare respiratory capacity it is
unlikely that suppression of oxidative metabolism is the result of widespread
direct damage to respiratory chain components.
Our comparison of IPF ATII to ATII from control lung bears resemblance
to the metabolic effects of hypoxia on healthy ATII cells in many respects.
Suppression of oxidative metabolism and maintained mitochondrial reserve
capacity are important metabolic consequences of hypoxia detailed elsewhere in
this work. IPF ATII cells showed maintained or elevated glycolytic function
compared to control lung ATII, resulting in a shift to enhanced reliance on
glycolysis. The impact of IPF on the PPR/OCR ratio was greater than the impact
of hypoxia, indicating a more dramatic shift into glycolysis. This was also
accompanied by enhanced expression of LDH, a well-established HIF1 target
gene. Thus, HIF stabilization may play a role in mediating the metabolic changes
observed here. However, it is important to note based on the work of others (94)
that other pulmonary diseases associated with pulmonary hypoxia, such as
COPD, do not appear to be affected by the same metabolic perturbations leading
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to lactic acid build-up and tissue acidification that is observed in IPF. Thus, these
consequences of the disease are potentially unique to IPF and not strictly related
to development of pulmonary hypoxia.
Based on these findings, reduced ATII mitochondrial metabolism
potentially contributes to lactic acid build-up in the IPF lung primarily by loss of
their ability to act as a sink for lactate and protons. Sustained or enhanced
glycolytic output may also contribute directly to increased lactic acid production in
lung tissue. As demonstrated by Kottmann and colleagues, IPF myofibroblasts
generate lactic acid at higher rates than normal fibroblasts (94). Conversely,
based on our studies, IPF ATII cells have suppressed metabolic function. Both
oxidative and glycolytic functions were low in IPF ATII, generating a relatively
more glycolytic but overall less metabolic phenotype. As shown by the response
of cells cultured in lactate to hypoxia, decreased mitochondrial function limits
lactate removal from the extracellular space. Thus, while IPF ATII are not
necessarily producing more acid than healthy ATII, they are removing less
because the demand for substrate is reduced (Figure 6.1B). In this manner,
complimentary metabolic dysfunction in fibroblasts and ATII cells leads to lactic
acid build-up that contributes to pH-mediated TGFβ activation, driving continued
fibrosis and injury (Figure 6.1C).
This work supports the concept that healthy ATII cells can potentially
import and utilize, or “scavenge” excess lactate generated by activated
fibroblasts; indeed, this cell-cell metabolic cooperation may be an element of
normal wound repair in the alveolar epithelium, wherein controlled fibroblast
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activation and myofibroblast differentiation occurs, while ATII proliferation and
differentiation enhances energetic demand. However, metabolically-suppressed
ATII are likely overwhelmed by the lactic acid generated by neighboring
myofibroblasts, leading to acidification. This concept sets the stage for future coculture studies to assess metabolism of healthy and IPF tissue-derived ATII and
fibroblasts.
Signals from activated myofibroblasts may play a role in generating the
suppressed phenotype of ATII cells. We did not observe a metabolic response in
MLE-15 exposed to myofibroblast-conditioned media, but this may be in part due
to the immortalized nature of the MLE-15 cell line. Furthermore, one of the
primary mechanisms proposed through which myofibroblast activity negatively
affects ATII cells at the molecular level is via ROS, which due to antioxidants in
media and instability may be depleted in the conditioned media added to MLE15. This further supports utilizing a co-culture system to examine metabolic
cooperation and dysfunction between fibroblasts and ATII cells from healthy and
IPF lung.

193

Figure 6.1: Hypothetical model of cellular metabolism in the alveoli in healthy and
IPF lung tissue. (A) In healthy lung, lactate produced by neighboring glycolytic cells
and/or delivered via pulmonary circulation is removed from the extracellular space by
ATII cells. Lactate is imported via MCT1 transport proteins, which favor lactate influx
more heavily than other isoforms. Lactate is then converted to pyruvate through the
activity of LDH. Reverse activity of LDH oxidizes lactate to generate pyruvate, which is
rapidly used by ATII mitochondria to generate reducing equivalents via TCA cycle
reactions, which in turn fuels electron transfer and oxidative ATP production. In this
manner lactate build-up in the pulmonary tissue is avoided, with lactate instead being
used to fuel ATP generation in ATII cell with high mitochondrial function and ATP
demand. (B) In disease conditions associated with IPF, mitochondrial respiration is
reduced in response to damage through processes including hypoxia-related signaling,
ER and oxidative stress, or direct mitochondrial damage. This results in a shift toward a
suppressed metabolism in ATII cells that is more glycolytic and less capable of
consuming lactate from the extracellular space. At the same time, myofibroblasts
contribute to acid production in the alveolar epithelium, as demonstrated by Kottmann
and colleagues.

(C) Lowered pH due to lactic acid build-up leads to cleavage and

release of TGFβ from latency binding proteins in the extracellular matrix. Active TGFβ in
the extracellular milieu binds to receptors on the surface of pulmonary fibroblasts.
Receptor binding leads to conversion of fibroblasts into myofibroblasts, the cells
responsible for over-expression of extracellular matrix components and aberrant matrix
deposition characteristic of IPF, as well as direct impacts on ATII.
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Caveats & other considerations
An important consideration in the critical assessment of this work is the
small number of patient samples assessed. ATII isolated from three IPF patients
were measured, and the OCR, PPR, and reserve capacities varied considerably
between patients. Furthermore, only a single non-IPF lung tissue sample was
used as normal control. The variation of ATII cellular metabolism between human
subjects is unknown and, going forward, it will be critical to establish with
confidence a normal metabolic phenotype for human ATII cells. In lieu of control
samples from normal lung which are often difficult to obtain, ATII isolated from
pig may potentially serve as a good control for healthy lung. Pig more closely
resembles human in terms of lung structure, breathing rate, and overall metabolic
rate compared to mouse, and study in the immediate future will characterize ATII
derived from healthy pig lung for comparison to our single human control sample.
It is also important to note that the control sample used was taken from a
deceased patient. While the cause of death was related to seizures and not lung
disease, it is possible that the ATII isolated from this sample were permanently
affected by the period of ischemia between time of death and tissue preservation,
and in that case may not faithfully represent the function of healthy ATII in a living
individual. This highlights the complications of obtaining control samples of
normal tissue from human patients, perhaps one of the biggest barriers to
patient-based lung disease research, and provides further support for finding a
truly suitable model. Future study will determine if pig ATII can serve this
purpose.
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Because fibroblast-ATII cell communication and TGFβ signaling are
through to be primary drivers of continued ATII cell injury and dysfunction in IPF,
we anticipated that treatment with myofibroblast-conditioned media and/or TGFβ
would cause normal MLE-15 cells to adopt the metabolic phenotype observed in
the IPF patient cells, characterized by decreased OCR, sustained or enhanced
PPR, and a resulting increase in PPR/OCR ratio. However, no change in
metabolic function was observed following either treatment. Instead, MLE-15
enhanced expression of fibroblast and ATI cell markers, suggesting partial
differentiation over the 48 hour exposure, without impact to metabolism. It is
possible that this effect is mediated by the immortalized nature of the MLE-15 cell
line, which may result in a markedly different response to the treatments from the
response of a primary ATII cell. This may also be an effect of exposure time; IPF
develops over many years, while cultures in this study were exposed for a total of
48 hours. The gene expression changes and other effects of exposure may long
precede any measureable metabolic changes. Additionally, the changes in
metabolism observed in human IPF patient ATII may be mediated by other cells
in the IPF lung. While the current paradigm in IPF research is focused on
fibroblast-ATII cell interaction, immune cells and secreted factors have also been
shown to play a role and specifically affect ATII cells. Finally, it is also possible
that the source of ATII metabolic dysfunction is related to the original, as yet
unknown, insult that damages the ATII cells and either directly initiates the
disease or leaves the affected ATII cells susceptible to a subsequent stressor (or
“second hit”). As discussed, many of the sources of injury proposed in IPF such
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as smoking and ER stress have potential to influence ATII cell metabolism. The
treatments performed here were intended to mimic elements of downstream
signaling associated with later events in the disease process, without including
the initial injurious stimulus.
Specific induction of Spc gene expression by TGFβ and conditioned
media treatments is a novel observation. The specific effects on Spc without a
concurrent effect on Spb suggests that production of complete surfactant is not
enhanced (although altered composition could also account for this observation).
SPC protein is involved in immune function, specifically in suppressing
macrophage activation by inhibiting TLR-mediated signaling. Additionally, human
SPC mutations are associated with IPF. Our results indicate that TGFβ or other
secreted factors enhance Spc expression in mouse ATII model cells, which, if
recapitulated in patient IPF ATII cells, holds considerable implications for a role in
IPF. Enhanced SPC protein expression in response to fibroblast-generated
stimuli may be a normal response intended to reduce inflammatory responses by
tempering macrophage activation in the lung. Furthermore, enhanced expression
of SPC in response may contribute to IPF in the case of SPC mutations: while
normal levels of mutant SPC protein may be managed by the cell, enhanced
expression could result in rapid protein build-up and aggregation leading to
aggravated ER stress and ROS generation. It will be important to assess
surfactant protein expression in response to these treatments in primary cells
and IPF-derived ATII to better understand the significance of these findings.
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Differences were observed between conditioned media treatment and
TGFβ treatment in terms of the degree of gene expression changes in MLE-15
cells, indicating that TGFβ accounts for some, but not all, of the effects.
Stimulated fibroblasts may themselves produce TGFβ as well as a variety of
other extracellular factors including other cytokines and ROS. Fibroblastgenerated extracellular factors directly influence ATII cells and potentially
mediate the effects on ATII transcription observed here. The role of other factors
in conditioned media, aside from TGFβ, in mediated the effects on transcription
can be investigated by inhibiting TGFβ receptors, activin receptor-like kinase
(ALK). We anticipate that ALK inhibition would abolish the effects of TGFβ
treatment, but that conditioned media would still induce transcriptional effects
(though potentially to a lesser degree than without ALK inhibition).

6.4 Targeting lactic acid production in treatment of IPF
Because lactic acid production contributes directly to the pro-fibrotic
environment that converts and stimulates myofibroblasts, methods to limit lactic
acid production have made an interesting target for therapy to prevent and/or
resolve IPF. Genetic interference with LDHA expression in fibroblasts leads to
decreased LDH activity and lactic acid generation, decreased TGFβ signaling
through downstream Smads, and dramatically decreased expression of αSMA
and other markers of myofibroblast phenotype. Based on these observations,
inhibition of lactic acid generation makes an appealing pharmacological target,
and initial in vitro studies have indicated promise in the use of a naturally-derived
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LDH inhibitor, Gossypol, to inhibit conversion of fibroblasts to myofibroblasts.
While treatment of fibroblasts with TGFβ alone stimulates rapid, robust
differentiation to the myofibroblast phenotype, co-treatment with TGFβ and the
LDH inhibitor Gossypol limited expression of myofibroblast markers, Smad
signaling downstream of TGFβ, compared to cultures treated with TGFβ alone
(149). In vivo experiments using the bleomycin-induced fibrosis mouse model of
IPF have also indicated the potential of Gossypol as a therapeutic treatment, as
treatment of bleomycin-challenged mice with Gossypol via subcutaneous
injection concurrently and for three weeks after bleomyin administration limited
hydroxyproline content of lung tissue, a measure of lung collagen content
indicative of the degree of fibrosis (150).
MCT presents a potential therapeutic target for reducing lactate
overproduction in IPF. In MLE-15, pharmacological inhibition of MCT decreased
lactic acid output and uptake, indicating an important role for MCTs in facilitating
cellular metabolism. Limiting export of lactate may lead to metabolic impairment
of glycolytic cells dependent on anaerobic metabolism. Accordingly, MCT is
gaining attention as a target in the treatment of cancer (151). CHC inhibition of
MCT has been evaluated as a therapy for treating gliomas, highly aggressive
tumors of the central nervous system. In vitro findings showed that CHC
treatment resulted in cell death in a highly glycolytic glioblastoma cell line, while
treatment induced limited growth in a more oxidative line but did not affect cell
viability (152). Low concentrations of CHC limited glucose uptake and acid
generation by the highly glycolytic glioblastoma cells without impacting metabolic
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function in more oxidative cells. In mice with glioblastoma, 40 mM CHC delivered
to the brain via osmotic pump resulted in tumor necrosis with a portion of
subjects achieving complete remission (153).
In IPF, lactic acid concentrates in the lung tissue. Although the cell type
responsible for generating increased lactic is still under investigation, in vitro
studies show that TGFβ-stimulated myofibroblasts produce elevated lactic acid
compared to normal fibroblasts (94). It is unlikely that enhanced lactic acid is due
to output by ATII, as ATII cells isolated from IPF lung assessed in this work had
low metabolic function in general and did not produce more lactic acid than those
from healthy lung. Therefore, given their already low metabolic function, ATII
cells in IPF lung may not be significantly affected by MCT inhibition. On the other
hand, myofibroblasts rapidly generate lactic acid. MCT function has not yet been
studied in fibroblasts, but whole lung tissue robustly expresses the MCT1, 2, and
4 isoforms, and given their widespread expression throughout the body, it is
highly likely that fibroblasts and myofibroblasts depend on MCTs for lactate
export. Relatively low doses of CHC may be sufficient to limit metabolism and
lactic acid output by myofibroblasts, and thus prevent pH-mediated TGFβ
activation without altering metabolism of other, less glycolytic cells in the lung,
including ATII.
In studies of CHC applied via infusion cannula to treat glioblastoma brain
tumors in mice, treatment with relatively high doses did not lead to adverse
neurological outcomes in control animals without tumors, and only slightly altered
metabolite profiles of tissue near the site of application (153). The general lack of
203

metabolic impairment in normal brain cells surrounding glycolytic glioma is
pertinent to the use of CHC in lung because, like ATII cells, neurons import and
utilize as substrate lactate that is exported from nearby cells. Given the
observation that high-dose CHC does not appreciably affect the neuron-astrocyte
intercellular lactate shuttle or other off-target metabolic function in brain tissue
suggests that it may be safely tested in the lung. Further investigation of the
importance of lactate for normal ATII metabolism, as well as in vitro assessment
of CHC treatment on normal fibroblasts and stimulated myofibroblasts will be
necessary before CHC treatment is considered in mouse models of IPF.
However, successful inhibition of fibrosis in the bleomycin mouse model with
treatment of LDH-inhibitor Gossypol shows that preventing lactic acid build-up
through metabolic manipulation is a feasible treatment strategy. Thus, MCT
inhibition represents a potential target for reducing fibrosis by limiting lactic acid
build-up, and general safety and efficacy have been demonstrated in previous
mouse studies in other tissues.
Limiting lactic acid build-up represents a therapeutic possibility for limiting
TGFβ signaling in IPF lung by preventing its activation due to pH change. Other
mechanisms to directly inhibit TGFβ signaling are currently under heavy
investigation in IPF treatment research, including administration of antibodies
directed against TGFβ to block receptor binding, and thus prevent the profibrotic, injurious downstream effects. Whereas these strategies are primarily
intended to limit the effects of the cytokine once it has been activated, prevention
of lactic acid build-up represents a different, complimentary strategy to limit
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pathological TGFβ activation. Strategies to regulate lactic acid metabolism such
as LDH or MCT inhibition may provide and additional level to therapy directed at
controlling TGFβ-mediated damage when applied in combination with antibodybased treatment to scavenge active TGFβ or pharmacological inhibition of
downstream pathways. Moving forward, our work encourages evaluation of
metabolic manipulation as a viable option for combination therapy in the
treatment of IPF.

6.5 Beyond IPF: A role for lactic acid in bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) is a lung disease associated with
preterm birth and one of the most common chronic lung diseases in children with
5,000-10,000 cases occurring in the US each year. The disease is characterized
by poor alveolarization of the lung, including abnormally large alveoli and
reduced number of alveoli. Clinically, there is distinction between what is referred
to as “classic” versus “new” BPD. The original form of BPD that resulted from
oxygen toxicity, high pressure and volume associated with mechanical ventilation
was characterized by epithelial cell metaplasia, bronchial fibrosis, and vascular
smooth muscle hypertrophy (154). With the use of steroids and administration of
pulmonary surfactant, the “new” form of the disease is characterized primarily by
impaired alveolarization. The molecular mechanisms are largely unknown, but
recent hypotheses have focused on the role of oxygen toxicity.
Exposure of the premature lung to high levels of oxygen received during
therapy certainly has potential to influence pulmonary cellular metabolism.
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Hyperoxia has been shown repeatedly to stimulate ATII cell death via necrosis
and/or apoptosis (155), in which mitochondrial production of ROS plays a critical
role. More subtle changes have also been demonstrated in hyperoxia-exposed
alveolar epithelial cells including mitochondrial swelling and ultrastuctural
changes, and alterations in LDH activity (156). At the molecular level, hyperoxia
induces changes in expression and activity of metabolic enzymes including those
associated with glycolytic flux (157). Aconitase, an enzyme involved in the TCA
cycle and necessary for mitochondrial metabolism, has been shown in vitro and
through in vivo studies of adult rat lung to be a molecular target of hyperoxiainduced damage (158, 159). In a primate model of BPD, lung aconitase activity
negative correlated with inspired oxygen tension and exposure to 100% oxygen
resulted in near-complete inhibition of enzyme activity (160). These findings
show that mitochondrial dysfunction occurs in the pulmonary tissue as an effect
of hyperoxia, and strongly suggest that metabolic changes contribute to or even
underlie the impact of hyperoxia on the developing lung in BPD. Indeed, a more
recent study of hyperoxia exposure in neonatal mice demonstrated impaired
respiration, ATP production, and mitochondrial complex I activity in exposed
mice; likewise, exposure of neonatal mice to a complex I inhibitor via
subcutaneous injection recapitulated the effects of hyperoxia on pulmonary
development (161). Importantly, this work indicated a critical role for
mitochondrial

respiration

in

normal

lung

mitochondrial dysfunction as a driver of BPD.
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While the progressive, extensive fibrosis that characterizes IPF does not
occur in BPD, relatively recent developments in BDP research have identified
critical similarities to fibrotic lung disease (162), including the observation that
TGFβ signaling is a central driver of both diseases. In IPF, TGF beta is the
critical growth factor that initiates conversion of fibroblasts into the myofibroblast
phenotype and stimulates overproduction of extracellular matrix components,
leading to the fibrotic scarring that characterizes the disease. TGFβ signaling is
required for normal development and injury repair (163); however, advances
have recently demonstrated that increased levels of TGFβ interferes with
alveolarization during lung development, a characteristic of BPD. Overexpression
of active TGFβ in newborn mice and rats during the alveolarization period that,
unlike humans, continues after birth, results in alveolar hypoplasia that closely
resembles the pattern of disrupted development in BPD (164, 165). High
therapeutic oxygen treatment is a common determinant of BPD in preterm
infants, and hyperoxic exposure in neonatal rats and mice is a common model
used in BPD studies. Hyperoxia is also thought to alter normal TGFβ signaling in
the exposed developing lung. Treatment of neonatal rats with hyperoxia
enhances Smad3 and Smad7 phosphorylation downstream of TGFβ signaling
and increases αSMA and calponin expression (166), all of which are effects
observed in IPF lung as a result of TGFβ activation. Similarly, in neonatal mice
treated with hyperoxia, specific TGFβ receptors were up-regulated, Smad
phosphorylation downstream of TGFβ signaling was enhanced, and expression
of TGFβ-responsive genes were increased (167). Enhanced TGFβ signaling
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correlated with decreased BMP pathway signaling, the balance of which is critical
for normal lung branching morphogenesis (168).
In humans, a study of preterm infants found that levels of active TGFβ
were elevated in endotracheal aspirates from very low birth weight premature
infants, the patient category at most high risk for developing BPD (169).
Collectively, these findings provide evidence that dysregulated TGFβ signaling
during the period of alveogenesis is involved in BPD pathogenesis, but the
factors that enhance TGFβ signaling in cases of BPD are unknown.
The work presented in this dissertation demonstrates that healthy, highly
oxidative ATII cells consume lactate from the extracellular space for use in
mitochondrial ATP generation. Prior studies demonstrated that lactate was
rapidly oxidized by the prenatal lung and ATII cells derived from prenatal lung at
rates of oxidation over 20-times those of glucose (108) Together, this points to
lactate as a preferred metabolic substrate in the fetal lung and suggests that
lactate is constantly imported into ATII cells during development to supply energy
for expansion, differentiation, and alveogenesis. Investigation of MCTs in fetal
lung showed MCT1 localization specifically in premature ATII cells, further
supporting the idea that lactate provides an important substrate during
development. The data presented here also demonstrate that pharmacological
inhibition of mitochondrial ATP production (via FCCP or oligomycin A) in ATII
cells leads to compensatory increase in glycolysis and extracellular acidification.
In BPD, hyperoxia-mediated mitochondrial suppression may stimulate a similar
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shift to enhanced lactic acid generation in an effort to compensate for loss of
oxidative ATP generation from damaged mitochondria.
In this scenario, in a manner that mirrors acid-mediated activation in IPF to
some degree, lactic acid build-up in BPD lung tissue may lead to enhanced
TGFβ activation and downstream signaling that interrupts normal alveolar
development. Lactic acid concentration has not been assessed in BPD lung
tissue or BALF, and metabolism has not been specifically measured in BPD lung
cells or tissue as it has for IPF lung here and in other studies. Based on this new
body of knowledge regarding the role of the balance of lactate consumption and
production by ATII cells in health and disease, lactic acid overproduction
represents both a potential contributor to pathogenesis and a novel target for
therapy in prevention of BPD.
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6.6 Final Comments
Over a century before the conception of the studies presented in this
dissertation, pioneers in pulmonary physiology Bohr and Henriques made the
following insightful observation regarding the function and metabolism of the lung
as an organ:
…the lung is not only the place of excretion of
carbonic acid…and the absorption of oxygen. This
organ is also at the same time, to a variable degree,
the place of the reverse phenomenon; that is to say, a
process in which oxygen is consumed and carbonic
acid formed. From: Datta and Stubbs, p.85 (11)
-

C. Bohr & V. Henriques

The work presented herein has contributed to this early understanding by
elucidating the functions of oxidative and glycolytic metabolism at the cellular
level under conditions of health, hypoxia, and the disease IPF. Despite a flurry of
investigation in the 1970s and 1980s that shed some light on the complex
metabolic functions of the lung as a whole organ, limitations in the ability to
assess metabolism at the cellular and molecular level of the lung hindered further
understanding. Now, the studies presented here add dimension to our
comprehension of metabolism in the critical ATII cells, as well as insight into how
metabolic cooperation between pulmonary cell types may maintain metabolic
homeostasis in the distal lung. Importantly, this report urges that lactate must be
considered as more than simply a metabolic waste product in the lung; it is a
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pertinent substrate for fueling ATP production, and potentially a signaling
molecule to influence cell function at the level of transcription.
This work also represents a fundamental step in IPF research, performing
the first metabolic analyses of cells isolated from human IPF patient lung tissue.
As understanding of the pathobiology of IPF steadily grows, the realization that
current models are, in many ways, insufficient grows as well, emphasizing the
need to assess molecular pathology using patient tissue directly.
The models created from this body of work provide a foundation for
exciting future studies. Cellular metabolism plays a role in IPF, and although the
contribution of individual cell metabolism is just beginning to be elucidated, the
work presented here indicates that future study focused on the metabolic
cooperation of multiple pulmonary cell types in progression of IPF (and
potentially other hypoxia-related pulmonary diseases) will be a major step, both
in understanding the disease pathobiology and in developing therapies by
targeting the metabolic contributions to lung dysfunction.
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MATERIALS AND METHODS

Cell Isolation & Culture
The ATII model cell line mouse lung epithelial-15 (170) was provided as a
generous gift from Dr. Jeffrey Whitsett (Children’s Hospital Medical Center,
Cincinnati, OH). MLE-15 is a line of cells derived from mouse pulmonary tumors.
Cells were immortalized via the simian virus large tumor antigen under control of
the surfactant protein-C promoter from the human SPC gene. This cell line
recapitulates many of the defining characteristics of primary ATII cells including
morphological features and expression of surfactant protein (49). MLE-15 stock
cultures were maintained in a humidified incubator under ambient air (21% O2)
and 5% CO2 at 37°C. Stock and experimental cultures were grown in HITES
medium (RPMI 1640 with 10 μg/ml insulin, 10 μg/ml transferrin, 30 nM sodium
selenite, 10 nM hydrocortisone, 10 nM β-estradiol) supplemented with 2mM
Glutamax and 2% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA).
All media and supplements were obtained from Invitrogen (Carlsbad, CA, USA)
unless otherwise indicated.
Primary mouse ATII cells were isolated from a female C57B/6 mouse,
approximately 6 weeks old. Animal was anaesthetized via intraperitoneal
injection of tribromoethanol solution (125 mg/Kg; 15 µL of 2.5% Avertin per gram
of body weight) and exsanguinated. Lungs were then perfused via injection of 10
mL of saline solution into the right atrium. The trachea was cannulated and lung
filled with 3 mLs of dispase (Thermo Fisher Scientific, Waltham, MA) followed by
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0.5 mL low melt agarose. Ice was applied directly to the chest cavity to solidify
agarose, after which the lungs were removed. Lung tissue was incubated with
dispase and DNase 1 (Sigma) and the resulting cell suspensions treated with red
blood cell lysing buffer (Sigma) and filtered (100 to 40 to 20 µm gauze).
Remaining cells were collected via centrifugation, resuspended, and incubated
on plates pre-coated with Donkey serum (BD Biosciences, San Jose, CA). ATII
cells were panned from plates and cultured in small airway epithelial cell (SAEC)
media (Lonza, Walkersville, MD) supplemented with 5% fetal bovine serum. ATII
cell population purity was assessed by modified PAP stain to count cells positive
for lamellar bodies and SPB gene expression was confirmed via qPCR.
Human IPF ATII cells were isolated from cryopreserved IPF lung tissue
taken from lungs donated from IPF patients receiving transplants at the Medical
University of South Carolina (Charleston, SC). Normal control ATII cells were
isolated from the lungs of a 34 year-old male patient, deceased due to seizure.
All human patient ATII cells used in these studies were isolated from
cryopreserved tissue samples. The cryopreservation procedures and validation
of tissue structural maintenance and cell viability has been reported elsewhere
(171). Briefly, portions of diseased distal lung weighing approximately 0.5 grams
were vacuum-expanded several times in cryopreservation medium to fully
perfuse tissue. Perfused tissues were immediately frozen in liquid nitrogen and
transferred to -80 degree Celsius for storage. To obtain viable cells from tissue,
frozen vials of tissue were thawed in a 37 degree Celsius water bath, then
minced into small portions using sterile forceps and scalpel. Tissue was then
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transferred immediately into a dissociation solution composed of 1X dispase, 3
Units/mL elastase, 300 U/mL collagenase. 0.3 mg/mL DNase, 10 mM HEPES
buffer, and antibiotic-antimycotic; placed into a 37 degree Celsius incubator; and
allowed to incubate with gentle rocking for approximately 1 hour. After incubation,
the suspension was combined with an equal volume of serum-free DMEM
medium supplemented with 40 mM HEPES buffer at pH 7.4 and transferred to a
petri dish. Remaining intact tissue portions were teased apart using sterile curved
forceps, and the dish transferred back into the incubator for 15 minutes. The
resulting suspension was then filtered through a pre-wetted 70 um cell strainer
and serum added to the filtrate to 10%. Suspension was centrifuged for 10
minutes at 200x g to pellet cells.
ATII cells were isolated from pelleted human pulmonary cells using the
MACS magnetic bead cell purification system (Myltenyi Bioscience, San Diego
CA) according to manufacturer’s protocols. Briefly, cells were labeled using
primary antibodies against cell population-specific markers, attached to magnetic
beads such that anti-bound cells are retained when passed over the magnetic
bead sorting column. Three different sortings were performed as follows: first,
cells were incubated with magnetic bead-bound antibody against Annexin V to
remove apoptotic cells. The elution was discarded, and flow-thru from the first
sort was incubated with magnetic bead-bound antibodies against CD35 to label
endothelial cells, CD14 & CD45 to label immune cells, and an “Anti-Fibroblast”
cell-specific antibody. Flow-thru from this sort contained target ATII cells. The
final sort positively selected for ATII cells using magnetic-bead bound antibody
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against CD326 (EpCAM), an ATII cell surface marker. Elution from the positive
sort was plated directly into extracellular flux assay plates. A portion of the elution
suspension was pelleted via centrifugation, resuspended in PBS, transferred to a
glass microscope slide, and allowed to dry overnight for modified Papanicolaou
staining to visualize lamellar bodies. Primary cells were plated and cultured in
SAEC media supplemented with 5% FBS.

In vitro Exposures
For hypoxia experiments, cells were plated at indicated densities and
allowed to attach in an ambient O2 (21% O2) incubator for 1-2 hours. Cultures
were then placed into a Bactron I Anaerobic Environmental Chamber (Sheldon
Manufacturing, Cornelius, OR) with a humidified atmosphere of 1.5% O2/5.0%
CO2 in N2. Exposures were generally performed for 20 hours, with ambient
control cultures kept in a humidified incubator under ambient O2 (21% O2) and
5% CO2. For PHI experiments, 250 µM dimethyloxalyl glycine (DMOG) dissolved
in DMSO was added directly to culture media.
For metabolic substrate experiments, cells were plated in normal HITES
(11.1 mM glucose) media at indicated densities and allowed to attach. Media was
then removed, plates were rinsed gently, and HITES media was replaced with
the appropriate media formulation.
For TGFβ exposure, TGFβ reagent was provided as a generous gift from
Dr. Ryan Kendall (Medical University of South Carolina, Charleston, SC). TGFβ
in 4 mM hydrochloric acid plus 0.1% bovine serum albumin was added directly to
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culture medium after plating to a final concentration of 5 ng/mL. Control cultures
received an equal volume of vehicle only. For conditioned media exposures, cells
were plated originally in HITES media formulated with 7.5 mM glucose. After
attachment in an ambient oxygen incubator (1-2 hours), a volume of fibroblastconditioned media equal to the volume of HITES used for plating was added to
culture wells, resulting in a growth media composed of 1:1 HITES (7.5 mM
glucose) and fibroblast-conditioned media. Conditioned media was a generous
gift from Dr. Stanley Hoffman (Medical University of South Carolina, Charleston
SC). Fibroblasts were cultured in HITES media formulated with 5.5mM glucose
and exposed to either 10ng/mL TGFβ in 4mM hydrochloric acid plus 0.1% bovine
serum albumin or an equal volume of vehicle added directly to media. TGFβstimulated fibroblasts adopted a myofibroblast phenotype, confirmed by the
Hoffman lab via western blot for alpha-Smooth Muscle Actin and Collagen Type
1a in cell lysates. Original media was harvested after 72 hours in culture,
centrifuged to remove cells, and frozen at -80 degrees Celsius prior to use.

Metabolic Flux Analysis
Metabolic

XF analysis allows real-time

measurement of

oxygen

consumption and acid generation by cells in culture. Changes in extracellular pH
and oxygen concentration are measured over time in a small isolated volume of
media, providing measurements of oxidative and glycolytic metabolic function in
vitro (Methods & Materials Figure 1). In many of the experiments performed in
this body of work, assessment of cellular O2 consumption and acid generation of
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near-confluent monolayer cells were assessed using a Seahorse Bioscience
XF24 or XF96 instrument (Seahorse Bioscience, N. Billerica, MA). This
technology also allows compounds to be injected directly into cell culture wells
during flux assay, allowing real-time assessment of metabolic responses.
Optimization of cell densities and inhibitor concentrations were performed prior to
performing the experiments reported herein (see Appendix A). When plating cells
for extracellular flux assays, the cell densities indicated in Table 3 were used to
achieve approximately 90% confluence without cell piling or detachment.
Growth medium was removed prior to assay and replaced with unbuffered
minimal assay medium (Seahorse Bioscience, Billerica, MD) at pH 7.4,
supplemented with 11.1 mM glucose or indicated concentrations of glucose
and/or lactate (as sodium lactate), 2 mM Glutamax, 10 μg/mL insulin, 10 μg/mL
transferrin, and 40 nM sodium selenite. For experiments involving primary cells,
assay media was formulated with 5.5 mM glucose and 5% FBS. Plates were
incubated for 45 minutes to 1 hour in assay media prior to assay.
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Methods & Materials Figure 1: Extracellular flux analysis using Seahorse
Bioscience XF technology. Individual pH and oxygen probes are lowered into each
well of a 24- or 96-well plate containing cells in monolayer culture, trapping a small
volume of media above the cells. Change in media pH and oxygen are measured over
multiple short measurement periods, providing multiple measurements representative of
glycolytic and oxidative cell function. Injection ports allow compounds in solution to be
injected during assay, thus providing real-time information on cellular metabolic
responses. Image courtesy of Seahorse Bioscience Image Gallery (Seahorse
Bioscience, North Billerica, MA).
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Table 3: Mouse cell plating densities used for extracellular flux assays. The
following cell densities were used to achieve approximately 90% confluent cell
monolayers. Due to limited cell number following isolation procedures, human primary
ATII cells were plated into 4 to 6 assay wells at maximal possible densities given yield
for each individual experiment.

Instrument

XF24

Cell Type

Culture Period

Plating Density

MLE-15

20-24 hours

65,000

Primary Mouse
ATII

3-5 days

Approximately
50,000

MLE-15

20-24 hours

16,000

MLE-15

48 hours

8,000

XF96
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For basal oxygen-consumption rate (OCR) and proton production rate
(PPR) determination, O2 concentrations and pH were simultaneously measured
during four 3-minute periods, each followed by a 2-minute mixing period. For
measurements of mitochondrial reserve capacity and ATP coupling parameters,
FCCP (carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone) and Oligomycin A
(Seahorse Bioscience, Billerica, MD) diluted in assay media were injected into
separate wells to final concentrations of 0.5 µM and 1.5 µM, respectively.
Injections are performed to measure the response to inhibitors in real-time after
basal measurements in the absence of inhibitors have been made. Spare
respiratory capacity and glycolytic capacities were calculated as the increase
over basal OCR and PPR readings following FCCP injection. Coupling to ATP
production was calculated as the decrease from basal OCR values following
oligomycin A injection.
For experiments involving MCT inhibition, the pan-MCT inhibitor CHC (as
stock dissolved in DMSO) was diluted in an aliquot of assay media at pH 7.4 and
injected into assay wells following basal measurements to a final concentration of
10 mM CHC. Control wells received an equal volume of DMSO in assay media.
For experiments involving inhibition of LDH, the competitive inhibitor oxamate (as
sodium oxamate) was dissolved in assay media to a final concentration of 20 mM
oxamate and brought to pH 7.4. Exposure was conducted concurrently with
media change, prior to assay. Control cultures received normal assay media
without oxamate. Cultures were incubated in assay media with or without
oxamate for 1 hour prior to assay.
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Raw OCR data was transformed via the “Level (Direct) AKOS” algorithm
(172) using the Seahorse XF24 1.5.0.69 software package. The “Variable
Technique” within the software was used to calculate PPR from measured rates
of extracellular pH change with compensation for media buffering capacity
measured for each media formulation.

ATP, Lactate & Glycogen Assays
ATP content of cultured cells was measured using the CellTitre Glo
Luminescent cell viability assay (Promega, Madison, WI) as per manufacturer’s
instructions. Cells (grown in parallel to metabolic flux assay cultures) were plated
onto 96-well plates at a density of 5x103 cells/well and cultured for 20 hours in
normoxia, hypoxia, or media containing 250 μM DMOG.
Extracellular lactate production was measured using a probe-based assay
(Lactate Colorimetric/Fluorimetric Assay Kit, BioVision, Milpitas, CA) according to
manufacturer’s instructions. Cells were plated onto 6-well plates at densities of
5x105 cells/well and maintained in normoxic or hypoxic conditions for 20 hours.
Cells were then rinsed twice with PBS, media replaced with modified HITES
medium containing 0.5% fetal bovine serum, and culture plates returned to
normoxic or hypoxic conditions. Culture media was sampled at time points 0, 15,
30, 60, and 120 minutes after media was replaced. Media samples were
analyzed via colorimetric assay and cell lysates via fluorimetric assay. Total
protein of cell lysates was determined via BCA assay for normalization.
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Intracellular glycogen content was determined using a fluorimetric probebased assay (Glycogen Assay Kit, BioVision, Milpitas, CA) as per manufacturer’s
instructions. MLE-15 cells were plated onto 6-well plates at densities of 2.5x105
cells/well. Ambient oxygen control cultures were maintained at 21% O2 for 3
days. Hypoxia and DMOG treated cultures were allowed to incubate in ambient
oxygen conditions for 20 hours, after which media was replaced and the cultures
moved into treatment conditions (hypoxic chamber or media containing a final
concentration of 250 μM DMOG, respectively) for 48 h, after which the media
was replaced and the cultures moved into ambient oxygen conditions for 20
hours. Glycogen values were corrected for sample glucose content and
normalized to total cellular protein concentration. Analysis of significance
between ambient control and treatment groups was performed via ANOVA with p
values less than 0.05 being considered significant.

qPCR & Arrays
MLE-15 were seeded on 6-well culture plates at 1.5x105 cells/well. After
20 hours of exposure to experimental conditions, lysates from sample wells were
pooled for each condition for RNA extraction using the RNeasy Mini Kit (QIAGEN
Inc, Valencia, CA), followed by DNaseI digestion. cDNA synthesis was performed
using 2 µg total RNA, a mixture of random 9-mer and oligo-dT priming, and MMuLV reverse transcriptase (reagents from New England Biolabs, Ipswich, MA).
qPCR was performed on a Mastercycler RealPlex2 (Eppendorf, Hamburg,
Germany) using iQ SYBR Green Supermix (BioRad, Hercules, CA). Ct values for
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all genes of interest were normalized to a housekeeping gene for normalization.
For TGFβ and conditioned media treatment experiments, the Ribosomal Protein
L13 (RPL13) was used for normalization; for hypoxia experiments, B-actin was
used. Fold-change values for target genes between groups were calculated
using ΔΔCt analysis to determine expression-fold difference. Significance of
differential expression was assessed via Student’s T-Test of the replicate 2-ΔCt
values for each gene, with p values less than 0.05 considered significant. All
oligonucleotide primers used in qPCR were synthesized by Integrated DNA
Technologies (Coralville, IA) and are listed in Table 4.
Glucose

Metabolism

qPCR

arrays

for

mouse

(PAMM-006Z,

SABiosciences, Valencia, CA) were performed according to manufacturer’s
instructions using 1 µg total cDNA per array plate. Arrays were performed in
triplicate using cDNA created from three individual cultures of MLE-15 for each
condition. Ct values for all genes of interest were normalized to -actin and
hypoxanthine-ribosyl transferase (HPRT) averaged relative expression. Foldchange values for target genes between groups were calculated using ΔΔCt
analysis to determine expression-fold difference. Genes with greater than 2-fold
difference between ambient and hypoxia groups are reported as differentially upor down-regulated in response to hypoxia treatment. Significance of differential
expression was assessed via Student’s T-Test of the replicate 2-ΔCt values for
each gene, with p values less than 0.05 considered significant. Several genes
were selected for independent validation of results; primers used for validation
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were synthesized by Integrated DNA Technologies (Coralville, IA) and are listed
in Table 4.
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Table 4: Oligonucleotide primer sequences used in qPCR analyses. Oligonucleotide
sequences were designed based on murine sequences found at the listed GenBank
accession numbers. Abbreviations: F, forward (sense); R, reverse (antisense).

Organism

Gene Name

GenBank
#

Ribosomal Protein
L13A

NM_00943
8.5

Hypoxanthine-ribosyl
transferase

NM_013556.2

Monocarboxylate
Transporter 1

NM_009196.4

Surfactant Protein B

NM_147779.1

Primer pair sequence (5’ to 3’)
F: GAAGCAGATCTTGAGGTTACGG
R: TATTGGGTTCACACCAGGAGTC
F: AGGCCAGACTTTGTTGGATTTG
R: TTCAACTTGCGCTCATCTTAGG
F: CACACATAACGATACTAGATTTGCG
R: TAGGAGAAGCCAATAGAAATGAAGG
F: TGCCAAGAGTGTGAGGATATTGTCCAC
R: CCAGCTTGTCCAGCAGAGGGTTTG
F: CCGGATTACTCGGCAGGTCCCAG

Mouse

Surfactant Protein C

NM_011359.1
R: ATGCCAGTGGAGCCGATGGAAAAGG
F: GCGCCATGTCTTGTTCTACCTTGC

Thyroid Transcription
Factor

NM_009385.2

Aquaporin 5

NM_009701.4

R: GTCGTCCAGCAGTTTGGTCTTTGTG
F: ACTCACCGTCTTTGGTTCGTCCTC
R: GTGGCAGTCGTTCTGCCTAATTCC
F: ACATCCCTGAAGTCAGCTGCATACAC

Pre-Collagen 1a

NM_007742.3
R: GTCTCCCTTGGGTCCCTCGACTC
F: TAGCTTCCTGGGGAAAAGGACAGATG

Fibroblast Specific
Protein

NM_011311.2

Ribosomal 18s RNA

NR_003286.2

R: CATCTGAGGAGTCTTCACTTCTTCCG
F: ATGAACGAGGAATTCCCAGTAAG
R: TAAACCATCCAATCGGTAGTAGC

Human
F: GGACATCGTCCACATCCTTAACAAGATG
Surfactant Protein B

NM_000542.2
R: ATTGCTGCTCGGAGAGATCCTGTGTGTG
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Western Blotting
For protein harvest from cell cultures, cells were lysed in modified RIPA
lysis buffer (150 mM NaCl, 50 mM Tris pH 8, 1% Triton) plus 0.5% SDS, 1 mM
phenylmethylsulfonyl

fluoride,

and

protease

inhibitor

cocktail

(Sigma).

Quantification of protein samples was performed by Bichinoic Acid assay, using
bovine serum albumin as standard. Protein aliquots were acetone precipitated
and resolubilized in LDS sample buffer (Invitrogen, Grand Island NY). All
separations were run under reducing conditions by adding 5% betamercaptoethanol to lysates added and incubating samples for 5 minutes at
approximately 95 degrees Celsius.
Samples

were

separated

by

SDS-NuPAGE

(polyacrylamide

gel

electrophoresis) Bis-Tris Minigels (Invitrogen) and blotted onto nitrocellulose
membranes using Tris-Glycine buffer (Invitrogen). Blots were blocked for 2 hours
in PBS containing 0.1% Tween 20 and 5% milk, then incubated with primary
antibodies in phosphaste-buffered saline (PBS) containing 0.1% Tween 20 and
0.5% milk for 2-3 hours or overnight in 4 degrees Celsius. The following primary
antibodies were used: polyclonal Goat anti-MCT1 (Santa Cruz, Dallas, TX),
monoclonal Rabbit anti-B Actin (Sigma), polyclonal Rabbit anti-LDH (Santa
Cruz), polyclonal Sheep anti-LDH5 (AbCAM, Cambridge, MA), monoclonal
mouse anti-RNA Polymerase II (Santa Cruz). Donkey anti-goat and donkey antirabbit secondary antibodies (LI-COR, Lincoln, NE) attached to fluorophores of
different emission wavelengths were used to visualize protein bands on a LICOR Odyssey (LI-COR). Semi-quantitative band densitometry and normalization
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was performed using Li-COR Image StudioTM 4.0 according to manufacturer’s
instructions.

Anti-sheep

antibody

conjugated

to

peroxidase

(Jackson

ImmunoResearch Laboratories, West Grove, PA) was developed using the
SuperSignal West Dura Extended Duration Substrate kit luminol and stable
peroxide buffer (Thermo Scientific, Rockford, IL) and visualized on a Fluorchem
8900 Imager (Alpha Innotech Corporation, San Leandro, CA). Alpha Innotetch
Alpha Ease FC software was used for band densitometry of LDH-M blots.

EdU Incorporation
Relative rates of DNA synthesis were determined using EdU nucleotide
analog incorporation followed by Cy-Dye staining as previously described (173).
Cells were exposed to indicated media conditions for a total of 24 hours. EdU
(Sigma) was prepared from a stock concentration of 25 mM dissolved in water
and added to culture wells at hour 12 (for 12-hour total EdU exposure). For
overnight exposure, EdU was added to a final concentration of 2 µM. Cells were
then fixed with 4% PFA, permeabilized with 0.5% Triton X-100, and incubated
with labeling solution containing azide-conjugated Cy7 (Lumiprobe, Hallandale
Beach FL) for 15 minutes at 37 degree Celsius. Each sample well was stained
subsequently with ToPro3 (Invitrogen) nuclear stain for normalization. ToPro3
and Cy-7 were visualized and quantified using the plate array setting on a LiCor
Oddessy Imager (LiCor). Readings from wells containing no cells were
subtracted to account for background. Negative control wells were included that
received only Cy7 or ToPro3.
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Cell Counting
For experiments assessing cell growth and for plating in all other in vitro
experiments, cells were lifted from culture dishes using trypsin (if necessary),
centrifuged to pellet cells and remove trypsin, and resuspended in a known
amount of media or PBS. An aliquot of cell suspension was mixed with the vital
dye trypan blue in a 1:4 dilution and pipetted onto the hemacytometer. Cells
excluding trypan blue were counted. For both calculating plating densities and
measuring growth over time, live (trypan-blue excluding) cells only were
considered.

Modified Papanicolaou staining & ATII cell count
Modified Papanicolaou staining was performed to assess the purity of ATII
cell cultures. Following cell isolation procedures and/or immediately following
assay measurements, cells were smeared onto a cleaned glass microscope slide
and allowed to dry overnight at 4 degree Celsius. Slides were stained with Harris
hematoxyline stain and “blued” via submersion in a 1:40 dilution of saturated
lithium carbonate solution in water. Dehydration was performed via immersion in
ethanol dilutions of 50%, 80%, 95%, and 100%, followed by 1:1 ethanol:xylene
and finally 100% xylene. Slides were allowed to dry, then fixed with permount.
To assess ATII cell population purity, the percentage of cells with
prominent blue inclusions (representing stained lamellar bodies) was determined.
200-400 total cells were counted per slide using a light microscope. For all
included studies, purity was 95% or greater.
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Statistics
Student’s T-test and ANOVA were used where indicated using GraphPad
and the VassarStats ANOVA analysis tool. For all analyses, significance was
defined as p < 0.05. When ANOVA was used and resulted in a significant F-ratio,
Tukey HSD [0.05] post-hoc test was performed to determine significant
differences among groups. All error bars shown represent +/- standard error.
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APPENDIX A. OPTIMIZATION OF EXTRACELLULAR FLUX ASSAY

Prior to experimentation, optimization was performed using the MLE-15
and A549 cell lines concerning cell seeding density and mitochondrial inhibitor
injection concentrations. All optimization was performed using 24-well plates
designed for use on XF24 instruments; for XF96 experiments, densities and
concentrations were scaled proportionally.
To determine optimal seeding densities for XF assay, cells were seeded at
densities of 5, 7.5, and 10*10^5 cells per well. Cultures were allowed to incubate
for approximately 24 hours prior to assay, after which wells were inspected for
confluency. This indicated that greater than 5*104 but less than 7.5*104 cells per
well should be used to obtain approximately 90% confluent monolayers without
cell piling. Ultimately, assays reported here using the XF24 were performed using
seeding densities of 6.5*104 cells per well.
Mitochondrial inhibitors can induce loss of mitochondrial membrane loss if
used at high concentrations. Alternatively, low concentrations induce only partial
response, leading to misinterpretation of data. Thus, for these experiments it was
critical to determine the minimal concentrations of FCCP and oligomycin A
needed to induce maximal response.
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Appendix Figure A.1: Optimization of FCCP concentration for XF assay. After initial
experiments using a wide range of FCCP concentrations indicated optimal concentration
between 0.1 and 0.7 µM, MLE-15 were exposed to final concentrations of 0.3 (group
G4), 0.45 (group G5), 0.6 (group G6), and 0.7 (group G7) µM FCCP as an injection at
point B and the OCR response measured. Group G5 demonstrated the greatest
response, thus 0.45 µM was optimal. This value was rounded to 0.5 µM FCCP for
subsequent experiments.
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Appendix Figure A.2: Optimization of Oligomycin A concentration for XF assay.
MLE-15 were exposed to final concentrations of 0.1 (group G2), 0.75 (group G4), 1.0
(group G5), 1.5 (group G6), and 3.0 (group G7) µM Oligomycin A as an injection at point
B and the OCR response measured. Group G6 demonstrated the greatest response,
thus 1.5 µM was optimal. This concentration was used for all subsequent studies.
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APPENDIX B. GLUTAMAX-FREE CONTROL FOR
METABOLIC ASSAY OF CELLS CULTURED IN LACTATE

Glutamax, the Glutamine-Alanine dipeptide, was added to cell culture and
assay media for all experiments, even those targeted to assessing metabolism of
lactate in the absence of glucose. The rationale for including Glutamax in the
media formulations is based in the function of glutamine in mediation of oxidative
stress, particularly important because some experiments required culture in
hypoxic conditions which induces ROS generation and oxidative stress.
However, the addition of Glutamax provides an additional oxidizable substrate
besides lactate: glutamine can be oxidized directly by the TCA cycle, and alanine
can be converted to lactate and pyruvate and thus can also provide oxidizable
substrate to fuel mitochondrial metabolism.
In order to confirm that extracellular flux measurements were faithfully
representing

the

effect

of

culture

in

lactate

alone,

follow-up

control

measurements were performed in MLE-15 cultures in lactate-formulated media
with and without the addition of 2 mM Glutamax. The absence of Glutamax did
not result in deviation from OCR levels observed in lactate-formulated media
containing Glutamax.

233

Basal OCR
(as % +glutamax control)

120
100

80
60
40
20
0

Lactate media,
with glutamax

Lactate media,
no glutamax

Appendix Figure B.1: OCR in lactate-formulated media is not significantly affected
by the absence of Glutamax. OCR was measured in MLE-15 cultured and assayed in
media containing 5.5 mM lactate and formulated with or without 2 mM Glutamax. 6
individual cultures were measured per condition. No significant difference was measured
between conditioned based on Student’s T-Test. Error bars represent ± SE.
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APPENDIX C. COMPLETE RESULTS FOR PCR ARRAY
Table 5:

Detailed results for glucose metabolism focused qPCR array using

mRNA obtained from MLE-15 cultured in hypoxia versus ambient O2. Focused
qPCR array was performed to assess changes in MLE-15 expression of genes
associated with glucose metabolism in response to hypoxia. Per condition, 3 individual
cDNA were analyzed. All genes assessed are shown; genes with greater than 2-fold
difference between ambient and hypoxia groups and having a p value <0.05 are
represented in bold type.

* AVG ΔCT values are the average normalized values

obtained from three independent arrays for both hypoxia and ambient groups. Downregulation in hypoxia versus ambient is indicated by negative fold-regulation value.
† Expression of this gene was low (average threshold cycle > 30) in either the hypoxia or
ambient sample, but higher in the other sample (cycle < 30). ‡ Expression of this gene
was low (average threshold cycle > 30)in both hypoxia and ambient samples, and the pvalue for the fold-change is either unavailable or > 0.05. § Expression of this gene was
very low or undetected (average threshold cycle is either not determined or greater than
the defined cut-off of 35) in both samples, making this fold-change result erroneous and
uninterpretable. Gene Array: SA Biosciences PCR Array Catalog #PAMM006.
Abbreviations: GOI, gene of interest; HKG, housekeeping gene.

Gene
Symbol

RefSeq ID

* AVG ΔCt
(Ct(GOI) - Ave
Ct(HKG))

2

-ΔΔCt

Fold
Change

p value

Fold Up- or
DownRegulation

Hypoxia

Ambient

Hypoxia

Ambient

Hypoxia/
Ambient

Hypoxia/
Ambient

7.04

7.24

7.6E-03

6.6E-03

1.15

0.967

1.15

6.43

6.72

1.2E-02

9.5E-03

1.22

0.550

1.22

Pdpr

NM_001024
606
NM_198308

Acly

NM_134037

2.23

2.14

2.1E-01

2.3E-01

0.94

0.784

-1.06

Aco1

NM_007386

9.56

9.13

1.3E-03

1.8E-03

0.74

0.531

-1.35 †

Aco2

2.09

2.12

2.4E-01

2.3E-01

1.02

0.976

1.02

10.69

11.47

6.1E-04

3.5E-04

1.73

0.387

1.73 ‡

Aldoa

NM_080633
NM_001081
326
NM_007438

-3.49

-1.86

1.1E+01

3.6E+00

3.09

0.054

3.09

Aldob

NM_144903

11.96

12.39

2.5E-04

1.9E-04

1.34

0.881

1.34 ‡

Aldoc

NM_009657

0.26

2.57

8.4E-01

1.7E-01

4.97

0.082

4.97

Bpgm

NM_007563

6.38

4.83

1.2E-02

3.5E-02

0.34

0.069

-2.93

Cs

NM_026444

2.39

2.13

1.9E-01

2.3E-01

0.84

0.421

-1.19

Dlat

NM_145614

4.13

3.58

5.7E-02

8.4E-02

0.68

0.494

-1.47

Dld

NM_007861

2.64

2.42

1.6E-01

1.9E-01

0.86

0.541

-1.16

Pdp2

Agl
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Table 5--continued
* AVG ΔCt
(Ct(GOI) - Ave
Ct(HKG))

Dlst

NM_030225

3.92

3.27

6.6E-02

1.0E-01

Hypoxia/
Ambient
0.64

0.228

Fold Up- or
DownRegulation
Hypoxia/
Ambient
-1.57

Eno1

NM_023119

-1.43

0.23

2.7E+00

8.5E-01

3.17

0.030

3.17

Eno2

NM_013509

2.22

5.25

2.1E-01

2.6E-02

8.15

0.124

8.15

Eno3

NM_007933

4.56

3.63

4.2E-02

8.1E-02

0.53

0.236

-1.90

Fbp1

NM_019395

11.14

13.47

4.4E-04

8.8E-05

5.00

0.187

5.00 ‡

Fbp2

NM_007994

9.58

9.75

1.3E-03

1.2E-03

1.13

0.892

1.13 ‡

Fh1

NM_010209

2.86

2.75

1.4E-01

1.5E-01

0.92

0.617

-1.08

G6pc

NM_008061

13.53

14.51

8.4E-05

4.3E-05

1.97

N/A

1.97 ‡

G6pc3

NM_175935

4.65

4.99

4.0E-02

3.1E-02

1.27

0.537

1.27

G6pdx

NM_008062

3.69

3.75

7.8E-02

7.5E-02

1.04

0.745

1.04

Galm

NM_176963

7.99

8.17

3.9E-03

3.5E-03

1.13

0.935

1.13

Gapdhs

NM_008085

9.97

10.74

1.0E-03

5.9E-04

1.71

0.258

1.71 ‡

Gbe1

NM_028803

1.41

4.18

3.8E-01

5.5E-02

6.81

0.001

6.81

Gck

NM_010292

13.91

14.99

6.5E-05

3.1E-05

2.12

N/A

2.12 ‡

Gpi1

-1.43

0.54

2.7E+00

6.9E-01

3.91

0.039

3.91

3.29

3.00

1.0E-01

1.2E-01

0.82

0.736

-1.22

Gsk3b

NM_008155
NM_001031
667
NM_019827

7.11

7.42

7.3E-03

5.8E-03

1.24

0.326

1.24

Gys1

NM_030678

1.29

3.69

4.1E-01

7.8E-02

5.27

0.039

5.27

Gys2

NM_145572

13.91

13.82

6.5E-05

6.9E-05

0.94

N/A

-1.06 ‡

H6pd

NM_173371

6.95

6.41

8.1E-03

1.2E-02

0.69

0.762

-1.46

Hk2

2.18

4.97

2.2E-01

3.2E-02

6.88

0.051

6.88

12.83

13.72

1.4E-04

7.4E-05

1.84

0.176

1.84 ‡

Idh1

NM_013820
NM_001033
245
NM_010497

4.18

3.76

5.5E-02

7.4E-02

0.75

0.507

-1.34

Idh2

NM_173011

2.22

2.29

2.1E-01

2.0E-01

1.05

0.824

1.05

Idh3a

NM_029573

3.31

2.52

1.0E-01

1.7E-01

0.58

0.129

-1.73

Idh3b

NM_130884

3.72

3.38

7.6E-02

9.6E-02

0.79

0.772

-1.27

Idh3g

NM_008323

2.65

2.43

1.6E-01

1.9E-01

0.86

0.581

-1.17

Mdh1

NM_008618

1.49

1.46

3.6E-01

3.6E-01

0.98

0.836

-1.02

Mdh1b

NM_029696

13.91

14.59

6.5E-05

4.1E-05

1.60

N/A

1.60 §

Mdh2

NM_008617

1.30

1.00

4.1E-01

5.0E-01

0.81

0.165

-1.23

Ogdh

NM_010956

13.48

14.05

8.7E-05

5.9E-05

1.48

0.441

1.48 ‡

Pck1

NM_011044

13.48

13.98

8.7E-05

6.2E-05

1.41

0.491

1.41 ‡

Pck2

NM_028994

2.92

3.85

1.3E-01

6.9E-02

1.91

0.290

1.91

Pcx

NM_008797

5.31

5.83

2.5E-02

1.8E-02

1.43

0.355

1.43

Pdha1

NM_008810

3.39

3.19

9.6E-02

1.1E-01

0.87

0.593

-1.14

Pdhb

NM_024221

2.80

2.77

1.4E-01

1.5E-01

0.98

0.754

-1.02

Pdk1

NM_172665

2.89

5.21

1.4E-01

2.7E-02

5.02

0.008

5.02

Pdk2

NM_133667

6.88

6.55

8.5E-03

1.1E-02

0.80

0.346

-1.26

Pdk3

NM_145630

3.92

4.91

6.6E-02

3.3E-02

2.00

0.015

2.00

Pdk4

NM_013743

13.48

15.18

8.7E-05

2.7E-05

3.23

N/A

3.23 ‡

Pfkl

NM_008826

6.27

8.12

1.3E-02

3.6E-03

3.62

0.023

3.62

Gene
Symbol

Gsk3a

Hk3

RefSeq ID

Hypoxia

Ambient

2

-ΔΔCt

Hypoxia

Ambient
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Fold
Change

p value

Table 5--continued
Gene
Symbol

RefSeq ID

* AVG ΔCt
(Ct(GOI) - Ave
Ct(HKG))

2

-ΔΔCt

Fold
Change

p value

Fold Up- or
DownRegulation

Pgam2

NM_018870

10.39

10.49

7.4E-04

6.9E-04

Hypoxia/
Ambient
1.07

Pgk1

NM_008828

-2.29

-0.46

4.9E+00

1.4E+00

3.55

Pgk2

NM_031190

13.91

15.51

6.5E-05

2.1E-05

3.04

N/A

3.04 §

Pgm1

NM_025700

5.05

4.99

3.0E-02

3.1E-02

0.96

0.779

-1.04

Pgm2

NM_028132

0.98

3.15

5.1E-01

1.1E-01

4.51

0.020

4.51

Pgm3

NM_028352

5.56

5.21

2.1E-02

2.7E-02

0.79

0.508

-1.27

Phka1

NM_173021

7.29

7.15

6.4E-03

7.1E-03

0.91

0.706

-1.10

Phkb

NM_199446

6.06

6.16

1.5E-02

1.4E-02

1.08

0.703

1.08

Phkg1

NM_011079

11.62

11.35

3.2E-04

3.8E-04

0.83

0.911

-1.20 ‡

Phkg2

NM_026888

5.25

5.53

2.6E-02

2.2E-02

1.21

0.803

1.21

Pklr

NM_013631

13.96

14.41

6.3E-05

4.6E-05

1.37

N/A

1.37 §

Prps1

NM_021463

3.31

2.92

1.0E-01

1.3E-01

0.76

0.348

-1.31

Prps1l1

NM_029294

N/A

15.22

N/A

2.6E-05

N/A

N/A

N/A §

Prps2

NM_026662

5.58

5.30

2.1E-02

2.5E-02

0.82

0.691

-1.21

Pygl

NM_133198

12.53

14.46

1.7E-04

4.4E-05

3.81

0.234

3.81 ‡

Pygm

NM_011224

9.64

10.20

1.3E-03

8.5E-04

1.47

0.537

1.47 ‡

Rbks

NM_153196

9.05

8.33

1.9E-03

3.1E-03

0.61

0.389

-1.65 †

Rpe

NM_025683

4.31

4.42

5.1E-02

4.7E-02

1.08

0.717

1.08

Rpia

NM_009075

5.51

5.29

2.2E-02

2.6E-02

0.86

0.606

-1.16

Sdha

NM_023281

3.75

3.38

7.5E-02

9.6E-02

0.77

0.497

-1.29

Sdhb

NM_023374

3.53

3.06

8.7E-02

1.2E-01

0.72

0.112

-1.39

Sdhc

NM_025321

2.08

2.05

2.4E-01

2.4E-01

0.98

0.826

-1.02

Sdhd

NM_025848

2.39

2.30

1.9E-01

2.0E-01

0.94

0.734

-1.07

Sucla2

NM_011506

4.29

4.11

5.1E-02

5.8E-02

0.88

0.483

-1.14

Suclg1

NM_019879

4.72

3.92

3.8E-02

6.6E-02

0.58

0.063

-1.73

Suclg2

NM_011507

10.56

10.69

6.6E-04

6.1E-04

1.09

0.940

1.09 ‡

Taldo1

NM_011528

3.19

2.45

1.1E-01

1.8E-01

0.60

0.100

-1.67

Tkt

NM_009388

1.32

1.71

4.0E-01

3.1E-01

1.30

0.803

1.30

Tpi1

NM_009415

-1.92

-0.40

3.8E+00

1.3E+00

2.87

0.054

2.87

Ugp2

NM_139297

2.97

3.82

1.3E-01

7.1E-02

1.80

0.150

1.80

Gusb

NM_010368

5.72

4.35

1.9E-02

4.9E-02

0.39

0.083

-2.58

Hprt

NM_013556

2.24

2.51

2.1E-01

1.8E-01

1.20

0.092

1.20

Hsp90a
b1

NM_008302

-0.20

-0.37

1.2E+00

1.3E+00

0.89

0.985

-1.13

Gapdh

NM_008084

-4.96

-3.01

3.1E+01

8.1E+00

3.85

0.163

3.85

Actb

NM_007393

-2.04

-2.13

4.1E+00

4.4E+00

0.94

0.836

-1.07

Hypoxia

Ambient

Hypoxia
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Ambient

0.679

Hypoxia/
Ambient
1.07 ‡

0.002

3.55
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